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In the wake of the PAT (Process Analytical Technology) initiative launched by the American 
FDA early 2003, the Netherlands Vaccine Institute has started the Parametric Release, or 
PaRel project. Together with project partners Siemens Pharma (Zwijndrecht, Belgium) 
and Applikon Biotechnology (Schiedam, The Netherlands) a new approach towards the 
development of modern manufacturing processes for vaccines was investigated. The project 
ran from 2003 until the end of 2007 and its outcomes were used for the writing of this 
thesis. New analytical methods for both the product and the process are introduced for the 
cultivation process step for a whole cell vaccine against whooping cough disease, one of 
the oldest approved biopharmaceutical products. The information from these new methods, 
combined with the long manufacturing history and process knowledge already available 
at the Netherlands Vaccine Institute, have resulted in a science-based rationale for the 
cultivation of Bordetella pertussis bacteria for the preparation of this vaccine. 
Bordetella pertussis and the whole cell vaccine against whooping cough 
disease
Bordetella pertussis is the causative agent of whooping cough disease. It is a gram negative, 
obligate aerobic cocco-bacillus, which means it is shaped as a short rod. It is closely related 
to the other species in the Bordetella genus, B. parapertussis and B. bronchoseptica, which 
are also pathogens. B. pertussis is the only exclusively human pathogen, while the others 
have a broader host range. 
The whole cell vaccine against whooping cough disease consists of inactivated bacteria. 
This means that the production process is straightforward. After cultivation, the cells are 
concentrated using continuous centrifugation and then inactivated at 56 °C. The bulk vaccine 
is then usually adjuvated using aluminium phosphate or aluminium hydroxide and mixed 
with the vaccines against diphteria, tetanus and polio to constitute the DTP-polio vaccines 
that are commonly used for infant vaccination world wide. 
The whole cell pertussis component is currently replaced by an acellular variant in most 
vaccine preparations, because of the adverse effects caused by cellular components of the 
B. pertussis bacterium. These acellular vaccines usually consist of a mixture of several 
virulence factors of B. pertussis: pertussis toxin, pertactin, FHA, or fimbriae (see Fig. 1). 
Several formulations are on the market with one or more of these proteins. These virulence 
factors are all present on the outer membrane of B. pertussis, or, like pertussis toxin, excreted 
into the culture medium. These proteins can induce a protective immune response after 
vaccination, some by themselves (pertussis toxin), others in combination with each other. 
The exact mechanism for induction of protective immunity through vaccination is still 
largely unclear. This means that vaccination with a whole cell vaccine may intrinsically be 
better than vaccination with an acellular vaccine, because it presents the same components to 
the immune system as a natural infection and is therefore able to induce a more “complete” 
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immune response1. For now, the safety concerns in the whole cell vaccine debate have won 
over the efficacy benefits, which means that from 2005 the Netherlands have also adopted 
an acellular vaccine against whooping cough. 
Type III
TCT
Figure 1. Schematic representation of the Bordetella pertussis bacterium. The main virulence factors are shown as 
well as the bvg regulon system that controls the expression of most of these virulence factors. This drawing is taken 
from Locht et al. (2001) Curr Opin. Microbiol. 4:89-892.
PAT for biopharmaceuticals
Being second only to the aviation industry in terms of regulatory burden, the pharmaceutical 
industry is dominated by strict compliance to safety and quality rules, such as those 
prescribed in the Good Manufacturing Practice (GMP) regulatory body. These regulations 
have resulted in an industry, which heavily relies on “quality by testing” instead of “quality 
by design”. In other words, product quality and safety in manufacturing are assured through 
protocols (Standard Operating Procedures or SOP’s) and end-product testing. Process 
changes or optimizations require extensive (clinical) testing and additional paperwork in 
order to comply to regulation. Therefore process improvement is often not pursued and 
many of the established processes are outdated or sub-optimal. 
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In other industries, such as the petrochemical industry, on line monitoring of product 
quality and continuous process optimization strategies are already common. The American 
Food and Drug Administration (FDA) recently recognized the need for the pharmaceutical 
industry to come up to the same level. For this, the FDA launched its Process Analytical 
Technology (PAT) initiative3. In summary, it prescribes quality assurance to become part of 
the process (i.e. quality by design) rather than relying on final product testing at the end of 
manufacturing (quality by testing). This means that processes need to be well characterized 
and the critical attributes of the process, the product and their interaction need to be known. 
In short, when one can not use final product testing as a means of quality assurance, the 
processes themselves need to be able to yield product of consistent high quality, without the 
necessity of final product testing as a fail safe. 
The European Medicines Agency (EMEA) has adopted the PAT principles as well as the 
Japanese authorities. This resulted at the International Conference for Harmonization in 
the writing of three new guidance documents (Q8, Q9 and Q10), which can be considered 
the world standard for this new regulatory concept for product and process quality4. For 
pharmaceutical small molecules with relatively simple production processes, the application 
of PAT is becoming more and more common. For biological products acceptation of the PAT 
concepts has been much slower. This led the FDA to invite biopharmaceutical companies to 
work with them for pilot submissions of biopharmaceutical PAT applications5. 
The PaRel project was aimed at implementation of PAT on the cultivation process step of 
a whole cell vaccine against whooping cough disease. This process step involves the batch 
cultivation of the Bordetella pertussis bacterium. Because the cultivation process step is 
the most complicated and critical step in this production process, it was chosen for the 
development of the tools, equipment and knowledge necessary for full PAT application. 
Compared to a small molecule drug, this vaccine can be considered as relatively undefined 
and complex. This brings new challenges in how to assure product quality during processing. 
The FDA has acknowledged to project partner Siemens, that the approach chosen in the 
PaRel project can lead to approval of a PAT application for a complex biopharmaceutical 
product like a whole cell vaccine.
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Contents of this thesis
Understanding of the cultivation process involves understanding of the interior physiology 
of the cell and how it responds to changes outside the cell, either due to process changes or 
disturbances. Especially in a batch-wise operated bioreactor, this understanding is important, 
because a batch cultivation process typically has continuously changing conditions, wich 
can influence cell physiology. In order to achieve this, a full genome DNA microarray 
analysis was developed for monitoring of mRNA expression profiles or Bordetella pertussis. 
Changes in the environment of a cell usually result in changes inside the cell. A major part 
of these intracellular effects can be identified with a microarray analysis. By measuring the 
gene expression levels during cultivation, the pathways or specific proteins that are affected 
by changes during processing can be identified. In this way, disturbances of specific process 
parameters can be assessed for impact on product quality. Also the reproducibility between 
batches can be investigated and the optimal harvest point can be determined by examining 
the gene expression profile. 
Some genes are more important than others for the efficacy of the vaccine, e.g. to induce 
a protective immune response after administration. In a whole cell vaccine, the outer 
membrane proteins are the targets that are presented to the immune system, therefore the 
outer membrane protein composition is considered to be of critical importance for vaccine 
quality (Fig 1). Identification of the genes that are important for the correct outer membrane 
composition in terms of inducing a protective immune response is the subject of Chapter 2. 
These are mostly genes that are involved in the virulence of Bordetella pertussis, meaning 
that they play a role in the colonization and infection of the human host. 
The virulence genes of the Bordetella genus are regulated by a highly conserved molecular 
switch, called the bvg system (Fig. 1). This means that a single extracellular signal can 
induce the complete physiological switch between the virulent and the non-virulent state6. 
All genes involved are under the control of the same operon system. For some strains these 
virulence genes were already investigated7, 8, but not in terms of optimal outer membrane 
composition for vaccine manufacturing. 
We investigated the genes in the NVI’s vaccine strain B. pertussis 509 and compared 
the genes that are differentially regulated between the virulent and non-virulent state 
with published results from other strains7. Fifty-six marker genes were identified to be 
conservatively regulated between strains. These genes are important for virulence and can 
be expected to be involved in inducing a protective immune response9. Microarray analysis 
of the expression levels of these marker genes of samples taken during processing could then 
be used to investigate the impact of process disturbances or failures on the expected outer 
membrane composition. 
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One of the process parameters that was investigated is the dissolved oxygen concentration 
(Chapter 3). Because B. pertussis is an obligate aerobic organism, the availability of oxygen 
during cultivation is essential. To investigate this, a series of cultivations were oxygen 
limited for 90 minutes. Samples were taken immediately before and after limitation and at 
the end of cultivation for microarray analysis. Oxygen limitation had a strong effect on gene 
expression levels of many genes immediately after the event, including virulence genes. At 
the end of cultivation, however, the oxygen limited cultures could not be distinguished from 
the standard control cultivations. This indicates that oxygen limitation can have an effect on 
vaccine quality, but this effect is reversible. As long as oxygen limitation does not occur at or 
near the end of cultivation it is not a critical factor for the manufacture of the vaccine. 
Using microarrays for the monitoring of the crucial genes allowed for the analysis of the 
critical process attributes for the cultivation of B. pertussis. High expression of the 56 
virulence marker genes is associated with high cellular virulence and thus good expected 
product quality, while low expression levels are associated with poor expected quality. 
Therefore, a weighed average of the expression levels of these virulence marker genes can 
serve as a predictor for the quality of the bacterial suspension at the end of cultivation.  This 
so called product quality score can be used to compare batches or samples of the same batch 
with each other in an objective manner.
The product quality score was used to determine one of the most critical events in any batch 
cultivation: the optimal harvest point (Chapter 4). As biomass accumulates exponentially, 
nutrient concentrations drop exponentially (Fig. 2). Limitation of nutrients can result in 
a range of unwanted effects including cell lysis or the suppression of virulence genes10. 
In order to investigate the optimal harvest point, four identically operated cultivations 
were each sampled at 11 time points for microarray analysis. A continuously changing 
gene expression pattern over time was expected, because of the continuously changing 
extracellular environment in a batch cultivation. However, gene expression proved to 
be relatively constant, which resulted in high product quality scores during most of the 
cultivation. Towards the end of cultivation, the product quality score dropped sharply (Fig. 
2). This coincided with the depletion of the nutrients lactate and glutamate. This pattern 
allowed accurate determination of the optimal harvest point. 
By measuring lactate and glutamate concentrations during cultivation, the bacteria can now 
consistently be harvested before nutrients become limiting, assuring the optimal composition 
of the bacterial outer membrane. 
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Figure 2. Batch profile analysis for the cultivation of B. pertussis (taken from Chapter 4). The left diagram shows the 
average growth curve of four cultivations going up and the average nutrient concentrations (lactate and glutamate) 
going down. A to K mark the points at wich samples for microarray analysis were taken. The right diagram shows 
the relative product quality scores at the sample points A to K. It is clearly shown that the product quality score is 
consistently high for most of the process. Towards the end of the cultivation (points J and K) a sharp drop in the 
score is shown. This corresponds with the depletion of important nutrients (left diagram). 
The definition of PAT states that it is a “system for designing, analyzing and controlling 
manufacturing through timely measurements of critical quality and performance attributes 
of raw and in-process materials and processes, with the goal of ensuring final product 
quality.” With the at line measurement of nutrient concentrations and the supporting 
evidence that this correlates with virulence gene expression and subsequently outer 
membrane composition, the requirements for a PAT application are fulfilled, at least for the 
harvest point determination. For other critical process attributes several sensors are available 
(i.e. for pH or dissolved oxygen). However, these sensors only monitor a single parameter, 
which generates the risk of either missing a critical parameter or having to mount numerous 
probes on the bioreactor system for each individual parameter. To be able to monitor many 
parameters simultaneously, a near infrared (nIR) spectroscopic probe was introduced. This 
probe was placed inside the bioreactor and measured a spectrum between 800 and 2500 nm. 
This region, situated between visible light and far infrared, is sensitive both for chemical 
changes (band vibration overtones) and physical changes (combination bands), such as 
optical density, viscosity, particle size and particle morphology. This makes this technique 
highly suitable for monitoring bacterial cultivation processes as was confirmed by initial 
pilot studies (Chapter 5). 
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To control the manufacturing process through these “timely measurements” (as stated in 
the PAT definition) the on line process data, including nIR, needs to be readily available for 
process control models that feed back into the process. To allow this, project partner Siemens 
developed the SIPAT software. This software gathers all data that is measured online (i.e. 
pH, dissolved oxygen, temperature, nIR, controller outputs, gas flows, etc) and stores them 
in a central database with aligned timestamps. This database is accessible for process models 
that can be run in the integrated Umetrics Simca software. Output from these models flows 
back into the bioreactor control system in order to make adjustments to the process. This 
software allows the use of any process sensor for the monitoring and control of any process 
step. In this case, the development of the SIPAT software allowed the integration of nIR data 
with the other process data, making a true PAT application possible. 
With the PAT initiative came also the concept of process design space. The International 
Conference for Harmonization (ICH) defines the design space as “the multidimensional 
combination and interaction of input variables (e.g., material attributes) and process 
parameters that have been demonstrated to provide assurance of quality”11. This means that 
product quality is no longer assured at specific process settings, but rather a range of settings 
is explored. One of the best ways to explore the process design space is by using Design of 
Experiments (DoE)12. In this way a number of critical process parameters is tested at a range 
of settings using a minimal number of experiments. The main benefit of this approach is 
that the interaction between the critical parameters at different settings is investigated. We 
used this approach to explore the process design space of the cultivation of B. pertussis by 
executing a series of designed experiments in which several critical process parameters were 
varied simultaneously (Chapter 6). 
Based on these experiments, a process model was constructed that describes the design space 
for the cultivation of B. pertussis for the tested ranges of the critical parameters. This process 
model can be executed on line using the SIPAT software, which allows an on line check if 
a new process is running within the tested process design space. Newly gathered data can 
be added to the process model so that it becomes more accurate over time. Ultimately this 
model can be validated so that it assures product quality on line, allowing real time product 
release. 
The work in this thesis demonstrates that although the initial PAT guidance was only intended 
for small molecule drugs, the same principles can also be applied to biopharmaceutical 
products. Biopharmaceutical processes, and especially the cultivation process step, are 
intrinsically more complex than processes for chemical drugs. By applying a sound scientific 
approach for development of process understanding and by using the appropriate sensors 
and monitoring techniques, a biopharmaceutical process can become as stable and capable 
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as any “world class” manufacturing process (see Chapter 7). 
The ultimate benefit of PAT application will be mitigation of risks (failures) during 
manufacturing, flexibility in process optimization and safer and better products. The effort 
taken for building process understanding will be rewarded when scale up, process changes 
or even medium optimizations are more easily implemented throughout the product’s 
manufacturing lifetime. Furthermore, on line monitoring of product quality and subsequent 
adjustment to the optimal trajectory will lead to less failed runs and a more consistent 
product of high quality. Real time quality assurance will lead to shorter cycle times and 
lesser stockpiles. These benefits have made the FDA decide to make PAT application the 
mandatory backbone of future pharmaceutical process development and manufacturing. This 
thesis demonstrates that it can even be applied on a complex and undefined product such 
as a whole cell vaccine, which means it should also be feasible for any (bio)pharmaceutical 
product currently on the market. The PAT initiative can therefore help to increase the safety 
and efficacy of medicines in general while reducing the time to market for new products and 
the operational costs of manufacturing. This is good news, for the regulatory inpectors, the 
manufacturers and the patients. 
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Abstract
Since variation in process time and process output is commonly accepted to be inevitable 
for biological processes, application of Process Analytical Technologies (PAT) on these 
processes is challenging. In this paper the applicability of PAT on the cultivation of Bordetella 
pertussis bacteria as part of the manufacture of a vaccine against whooping cough disease 
is investigated. Scrutinizing and eliminating the most prominent sources of variance make 
the cultivation process step highly reproducible. Furthermore, the use of DNA microarrays 
allows investigation of how disturbances influence cellular physiology and product quality. 
Marker genes for product quality were identified, providing the means to quantitatively 
assess product quality, which is hardly possible using the mandatory animal tests for 
product quality. The tools and results described in this paper, combined with suitable on line 
measurements, can make full PAT application for this process step possible. Ultimately, the 
process can be designed and controlled towards consistent end product quality. 
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Introduction
Production processes of biologicals are generally considered less controllable and more 
susceptible to variation than processes for chemical drugs due to poor process understanding. 
Vaccines are considered to be at the low end of this spectrum. The production of vaccines 
has historically only been considered viable as a low-cost, low-tech industry and this became 
even more difficult after the introduction of GMP in 1980. Despite all the breakthroughs 
in immunological sciences of the past decades, the production processes for vaccines 
are essentially unchanged. Only recently vaccines have attracted the interest of large 
pharmaceutical companies for being potential block-buster candidates1. This means that 
vaccines are more and more becoming high-value biologicals. This generates a drive for 
more robust and efficient manufacturing processes for vaccines.
The US Food and Drug Administration (FDA) has recognized the need for robust and 
efficient manufacturing throughout the pharmaceutical industry. The high regulatory burden 
in this industry prevents continuous process optimization and process adaptations as a means 
for increasing manufacturing efficiency. In order to overcome these regulatory barriers, the 
FDA has launched the Process Analytical Technology (PAT) Initiative in 20032.
PAT is considered by the FDA to be the desired future state of pharmaceutical manufacturing. 
It requires a risk-based approach in which the critical process parameters or attributes are 
assessed for their risk for product quality. Monitoring and control of these parameters can 
assure good process performance and even the quality of the product as it is formed3. This 
requires an on line monitoring and control system that can measure the critical parameters 
during processing and take appropriate action upon any deviation. Although the application 
of PAT in a vaccine manufacturing process may seem challenging, a science-based approach 
has much to win in this industry, since production processes for vaccines are usually highly 
empirical. Before a PAT system can be designed, the process needs to be sufficiently 
understood and the critical process attributes that need to be monitored and preferably be 
controlled on line have to be identified. In this paper these first stages of PAT application are 
investigated for the cultivation process step of a vaccine against whooping cough disease. 
For inactivated or attenuated live vaccines product quality is primarily determined during 
cultivation of the actual pathogen. For a-cellular or subunit vaccines this might be the 
cultivation of the host cells (i.e. CHO cells or E. coli bacteria), which produce the required 
vaccine components. The focus of this work is on a whole-cell vaccine against whooping 
cough disease. This vaccine is based on a heat-inactivated suspension of the pathogen, the 
Bordetella pertussis bacterium. Especially with such an inactivated whole-cell vaccine, the 
cultivation process step is the most relevant process step for PAT application, because in this 
step product quality is mainly determined.
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A whole-cell vaccine might in principal provide a broader immune response then an a-
cellular vaccine, because it inherently contains all necessary components for inducing 
protection. Several studies have indicated that whole-cell vaccines may have a better 
efficacy than a-cellular vaccines4-6, but the side effects after vaccination have resulted in 
a strong decrease of their application. These side effects (i.e. swelling, fever) are mainly 
caused by lipopolysaccharide (LPS). The presence of LPS anchored in the outer membrane is 
relatively constant under normal production conditions7, whereas the expression of the outer-
Figure 1. Schematical representation of the regulatory 
BvgA/S network of B. pertussis. Virulence inducing 
conditions (top half) trigger BvgS to phosphorylate 
BvgA through a phosphorelay pathway. Activated BvgA 
(BvgA*) acts as a transcription factor and binds to the 
promotor sequences (PbvgA, Pvag) of Bvg-activated 
genes to induce transcription. Because BvgA and BvgS 
are Bvg-activated genes as well, a positive feedback loop 
exists that results in high abundance of activated BvgA. 
Activated BvgA also binds to promotor sequences of 
Bvg-repressed genes to inhibit transcription (not shown). 
Virulence repressing conditions (bottom half) result 
in a de-phosphorylation of BvgA to stop the induction 
of Bvg activated genes. Expression of Bvg-repressed 
genes will no longer be inhibited and these genes will 
be subsequently activated (not shown). (Adapted from 
Figure 5 of Scarlato et al10).
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membrane proteins that are important for inducing a protective immune response can vary 
dependending on cultivation conditions8. Optimal outer-membrane protein composition can 
therefore be considered a critical attribute for product quality. More precisely, the expression 
levels of virulence factors are critical for product performance. 
The mechanism through which B. pertussis regulates the expression of virulence factors 
has been extensively studied8-10. Most known virulence factors are under control of a two-
component regulatory system named BvgA/S. This system functions as a molecular switch 
that acts to activate or repress virulence factor expression depending on environmental 
conditions (Figure 1). In order to obtain a high quality product, this switch needs to be in the 
bvg mode, resulting in bacteria that express virulence factors abundantly.
Having defined the properties of the product that are critical for product quality, accurate 
measurement of these properties is the next step for PAT application. This requires much 
more precise information than is provided by the mandatory animal tests that are currently 
used for this vaccine11. DNA microarrays for analysis of gene expression levels and profiles 
are proposed for assessment of product quality at the end of cultivation. mRNA expression 
levels are expected to serve as an indicator for the expression of virulence factors and other 
proteins relevant for prediction of product quality and process performance.
The availability of the full genome sequence of B. pertussis12, created the opportunity to 
design a DNA microarray covering 93% of the B. pertussis open reading frames. Recent 
research has shown that the use of DNA microarrays can accurately determine the virulence 
state of the bacterium13;14. This technique can be applied in several manners. First, the genes 
crucial for virulence, and thus product quality, can be assessed. Second, overall expression 
levels at the end of cultivation can be compared with other batch runs. Good correlation 
between overall mRNA expression levels will indicate comparable end-product quality, 
whereas disturbances in expression levels can be identified and investigated. 
After the desired product is defined and its quality can be accurately assessed, the biggest 
challenge that remains is the reproducible performance of the actual manufacturing process. 
The ability to do this cultivation in a robust and reproducible manner is a prerequisite for 
implementation of PAT, as it demonstrates process understanding and the ability to control 
critical process variance.  Bacterial cultivation has many sources of variance, some of which 
could risk end quality to be out of specifications. Assessment of all relevant sources of 
variance and subsequent assessment of their potential risk for end-product quality, although 
complicated, could be one of the most rewarding exercises in the PAT trajectory, because 
improvement of process reproducibility is of key importance for robust processing. 
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In this paper we demonstrate the first stages of PAT application in the cultivation process of 
B. pertussis bacteria for a vaccine against whooping cough disease. First, the elimination of 
the most obvious causes of variation reduces the variation of the cultivation process. Next 
the use of DNA microarrays for identification of the relevant genes affecting product quality 
is demonstrated. Finally, we show how DNA arrays can be used to check the reproducibility 
of the cultivation with respect to the entire transcriptome and the relevant marker genes.
Materials and methods
Bacterial strain, media and growth conditions
The B. pertussis 509 strain (Netherlands Vaccine Institute, Bilthoven, The Netherlands) used 
in this study was collected in 1963 as a clinical isolate and used as vaccine strain in the 
combined diphtheria, pertussis, tetanus and polio (DPTPolio) vaccine until 2005. 
All bacterial cultures were grown in chemically defined THIJS-medium15, which consists 
of basic medium and supplement. Supplement (1% v/v) was added to the basic medium 
shortly before inoculation. The pH after addition of supplement was 7.1. The preculture 
was inoculated with 10ml B. pertussis 509 working seedlot (cells at OD
590
=1.0±0.05  frozen 
with 10% glycerol, stored at -140 °C) and grown in 500ml shake flasks containing 200ml 
medium at 35°C, on an orbital shaker at 200 RPM. When the starting culture reached 
OD
590
=1.0±0.05, it was used to inoculate either a bioreactor (reproducibility experiments, 
cultivation A through E), or other shake flasks (Bvg-modulation experiments). Start density 
was OD
590
 = 0.050±0.005 for all cultivations. 
Bioreactor cultivations
All bioreactor experiments were carried out in a 7 L in situ sterilizable glass bioreactor 
with a working volume of 4 L. Temperature, dissolved oxygen (DO) concentration, pH and 
stirrer speed were controlled at 37°C, 30%, 7.2 and 450-650 rpm, respectively. Oxygen 
concentration was first controlled with increments of 50 rpm in stirrer speed until 650 rpm 
was reached. After this setpoint was reached, DO was controlled by increasing the fraction 
of oxygen in the headspace. After the bioreactors were filled with 4L THIJS medium and 
reached setpoint temperature and DO=100%, they were inoculated with 200 ml preculture 
at OD
590
=1.0±0.05. Samples were taken at time points indicated in for OD
590
 and at line 
nutrient-concentration measurements. Samples were sterile filtered (0.22 μm) and stored 
at -20 °C for later NMR analyses. Growth data was fitted against a standard asymmetrical 
sigmoid curve (y=a+b/(1+exp(-(x-dln(21/e-1)-c)/d))e) using Tablecurve 2D software (AISN 
Software, USA).
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Nutrient-concentration analysis
Nutrient (lactate and glutamate) concentrations were determined at line using an YSI 2700 
analyzer (Yellow Springs Instruments, Yellow Springs, USA). Supernatants were later 
analyzed by 1H-NMR using a JEOL JNM ECP 400 spectrometer operating at 400 MHz (JEOL, 
Tokyo, Japan) equipped with a JEOL Stacman autosampler for 16 samples. Supernatants 
were analyzed by adding 0.1 ml of D2O containing 3-(trimethylsilyl)[D4]proprionic acid 
sodium salt (TMSP, 0.167 mM) to a 0.9 ml sample. The water signal was suppressed by 
irradiating the signal with standard NMR software. The spectra were referenced using the 
TMSP signal at 0 ppm. Lactate and glutamate concentrations were quantified by integration 
of the relevant signals. NMR was also used to check samples for any waste metabolites. 
Virulence modulation
Virulence was repressed with addition of either 50mM MgSO4 or 20mM niacin to the basic 
medium. The acidity of niacin was compensated using additional NaOH (5M). To maintain 
Na+ concentration at 75mM in all media, the amount of NaCl was adjusted accordingly. 
When the preculture reached OD
590
=1.0±0.05, 10ml suspension was used to inoculate each 
of the 12 experimental shake flasks (4 normal medium, 4 MgSO4 containing medium and 4 
niacin containing medium). Harvest samples were analyzed with DNA microarrays.
Microarray design
Samples were analyzed using a full genome B. pertussis microarray. Based on the complete 
genome sequence of B. pertussis Tohama I12, a set of 3582 70-mer oligonucleotides was 
developed at Operon (Cologne, Germany), covering 93% of all open reading frames. 
Oligonucleotide pellets were dissolved in 50% DMSO (v/v in water) to a concentration of 
20µM and spotted in triplicate on UltraGAPS II coated slides (Corning, New York U.S.A.), 
together with 420 control spots, using the Omnigrid 100 microarray spotter (GeneMachines, 
San Carlos U.S.A.). 
RNA isolation
For fixation of the RNA expression profile, 1 volume bacterial culture was mixed with 2 
volumes RNAse retarding solution16. For each microarray sample 2.5 ml cultivation at an 
OD
590
=1.0 was used. Samples at other optical densities, were  adjusted accordingly, so that 
an equal amount of cells was used for RNA isolation. The samples were concentrated by 
centrifugation and treated with Tris-EDTA buffer, containing 0.5mg/ml lysozyme (Sigma-
Aldrich, Zwijndrecht, The Netherlands) for 3 minutes. Total RNA was extracted with the 
SV Total RNA isolation system (Promega Benelux, Leiden, The Netherlands) according 
to manufacturer’s protocol. Nucleic-acid concentration was adjusted by precipitation and 
spectral analysis was used to determine final nucleic-acid concentration and purity. RNA 
integrity was confirmed with the Bioanalyzer RNA6000 Nano assay (Agilent Technologies, 
Amstelveen, The Netherlands), according to the manufacturer’s protocol.
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cDNA labeling and hybridization reactions
Total RNA from all experimental samples was reverse transcribed to cDNA and labeled 
with Cy3/Cy5 dyes using the Cyscribe Post-Labeling kit (Amersham Biosciences Benelux, 
Roosendaal, The Netherlands) according to manufacturer’s protocol, with one deviation: 
only 2µl random nonamer primer and no oligo-dT primer was used per reaction to reverse 
transcribe 20µg total RNA. The labeled and purified cDNA samples were pooled in Cy3/
Cy5 pairs and volumes were adjusted to 25µl by evaporation under low pressure. 25µl 
hybridization buffer was added, to a final concentration of 25% formamide, 5x SSC and 
0.1% SDS. Samples were applied to the microarray slides and placed in a hybridization 
chamber (GeneMachines, San Carlos, U.S.A.) for 16-20 hours at 42°C in the dark. 
Data acquisition and analysis
The microarrays were scanned with a ScanArray Express microarray scanner (Perkin Elmer, 
Groningen, The Netherlands) and median fluorescence intensities were quantified for each 
spot using ArrayVision software (Imaging Research, Roosendaal, The Netherlands). The 
Figure 2. Open circles ( ) indicate growth curves (OD
590
) of 11 bioreactor cultivations. The center line indicates the 
fitted standard sigmoid function (R2=0.99) and the outer lines indicate 95% prediction interval. Closed circles ( ) 
show the growth data of cultivation C (Figure 4). 
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expression data were natural-log transformed, quantile normalized, and values of replicate 
spots were averaged. These data processing steps were done with the free statistical software 
R (WU Wien, Austria), using an in-house developed script. 
Gene-expression values of the Bvg modulation experiment were calculated by comparing 4 
replicate normal samples to 4 replicate MgSO4-modulated samples. P-values were adjusted 
for multiple testing by calculating the False Discovery Rate (FDR). Fold Ratio (FR)-values 
were expressed as natural log of the normalized MgSO4 / normal signal ratio. The same 
procedure was applied for comparing the normal samples to 4 replicate niacin-modulated 
samples. Observed differential gene expression was considered biologically significant 
when mean FR-values were above 2.0 and FDR values were below 0.10 for both the MgSO4 
and the niacin samples when compared to the normal samples. 
Figure 3. Comparison of virulence activated and repressed genes between the Tohama, GMT-1 and 509 
strains of B. pertussis. Figure 3A shows a Venn diagram of the Bvg activated genes of three strains of B. 
pertussis. Numbers indicate the number of genes that are activated in virulent conditions and repressed in 
a-virulent conditions. Figure 3B shows a Venn diagram of the Bvg repressed genes of three strains of B. 
pertussis. Numbers indicate the number of genes that are repressed in virulent conditions and activated in 
a-virulent conditions. The central areas in both panels show the number of genes that are part of the core 
regulon as proposed by Cummings et al.13. Data for Tohama and GMT-1 strains are adopted from this work. 
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Differential gene-expression levels of the reproducibility experiment (bioreactor cultivation 
A through E) were obtained through comparison with a common reference sample, containing 
equal amounts of RNA from each cultivation. Any genes that showed a FR>2.0 compared to 
the expression levels in the other cultivations were considered deviating.
 
Results
Bacterial growth
The cultivation method using THIJS medium described above resulted in a highly 
reproducible cultivation. Comparison of 11 bioreactor runs shows a high correlation between 
runs (R2=0.99) and low variance (SE=0.055) (Figure 2). 
Figure 4. Comparison of gene expression levels at the end of bioreactor cultivation of B. pertussis. Center line 
indicates optimal correlation. Outer lines indicate 95% confidence interval.  Figure 4a shows a full genome 
comparison of the gene expression levels of Culture A with Culture B.  Closed circles (  ) indicate relative 
gene expression levels. Correlation coefficient R=0.99. Figure 4B shows the full genome comparison of the 
gene expression levels of Culture A with Culture C.  Closed circles (  ) indicate relative gene expression levels. 
Correlation coefficient R=0.95. Figure 4C shows the comparison of the gene expression levels of the Bvg activated 
genes of Culture A with Culture B. Open circles (o) indicate relative gene expression levels. Correlation coefficient 
R=0.99. Figure 4D shows the comparison of the gene expression levels of the Bvg repressed genes of Culture A 
with Culture C. Open circles (o) indicate relative gene expression levels. Correlation coefficient R=0.98.
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Genes involved in virulence
Chemical induction of an a-virulent state, using 50mM MgSO4 or 20mM niacin, and 
subsequent comparison with normal cultivation conditions revealed the genes involved in 
virulence of the B. pertussis 509 strain. These genes were compared with the core regulon 
proposed for the B. pertussis GMT-1 and Tohama strains by Cummings13. Only genes that 
showed an effect in both modulating conditions (MgSO4 and niacin) were considered a hit. 
Any hits that were specific for either condition (Figure 3) were not included. The center of 
the Venn diagrams shown in Figure 3 represents the number of genes of the B. pertussis 509 
strain that overlap with the core regulon proposed by Cummings and co-workers13. A list of 
the genes and their expression levels corresponding with the data in Figure 3 can be found in 
an online supplementary data file at doi:10.1016/j.vaccine.2007.01.015. 
Comparison of RNA expression profiles
Comparison of the overall gene expression levels between cultivations at the harvest point 
may be a relevant indication for the reproducibility. Five bioreactor cultivations (named A 
through E) were analyzed at harvest point with DNA microarrays. Four of these cultivations 
showed a good correlation between gene expression levels (R=0.98-0.99). Two typical 
cultivations are compared in Figure 4A. One cultivation (C) deviated from the others in overall 
expression profile and showed a lower correlation with the other cultivations (R=0.95-0.96), 
Figure 4B). Analysis of the process data revealed that cultivation C was harvested just after 
the main nutrients lactate and glutamate were (nearly) depleted from the medium (0.00 mM 
and 0.66 mM, respectively). The other four cultivations were harvested with 1 – 3 mM of 
both still present in the medium. Cultivation C did not show a deviation in bacterial growth 
(Figure 2) or other process data compared to the other batches. Investigation of the deviating 
genes (FR > 2.0) in cultivation C revealed that most are coding for ribosomal proteins, 
sulphate transport or ABC transporters, indicating decreased protein synthesis, changes in 
metabolism and general cellular activity. A table containing all deviating genes of cultivation 
C is included in the supplementary data file. 
In contrast to the deviating overall gene expression levels, the genes of the core regulon 
correlate well for all cultivations (R=0.98-0.99), including cultivation C (Figure 4C and D). 
This indicates that the limitation of lactate at the point of harvest for cultivation C is not 
likely to result in a risk for product quality. 
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Discussion 
Variation in process performance is a high risk for inconsistency of product quality. 
Identification of the factors that cause process variation will enable their control, which in 
turn will result in more robust and consistent processes. Biological processes such as the 
cultivation of bacteria are usually considered variable and hard to control. If, however, a 
bacterium is given only a limited number of degrees of freedom, it will adopt a predictable 
growth pattern, as demonstrated here. A chemically defined medium, consistent seedlot 
preparation and control of harvest points eliminate most of the variance for (pre)culture 
growth. The THIJS medium that is used for all cultivations15,17 is designed to meet the 
organisms’ nutritional demands at optimal growth conditions and allows little room for 
activation of other (waste) metabolic routes upon starvation or process disturbances, which 
is beneficial for cultivation reproducibility. 
The use of DNA microarrays as a tool to monitor process consistency provides insight in 
the behavior of the organism during growth. Theoretically any disturbance that influences 
product quality should be reflected in the mRNA expression profile, since genes usually 
function in relation with other genes. Therefore, any disturbance or change should be 
reflected by alterations in the expression levels of at least several genes. We observed high 
correlations of both full genome and core regulon expression levels between cultivations 
(Figure 4).  
This is indicative of high comparability at the point of harvest. Depletion of lactate and 
glutamate at the end of the cultivation resulted in a disturbance of the overall expression 
level in one cultivation (C), but the expression levels of the genes of the core regulon were 
not affected. Disturbances that affect the overall expression levels, but not the core regulon 
expression levels are not likely to be critical for product quality, since the virulent (bvg+) 
state is not affected and the proteins important for vaccine efficacy are still expressed.
The genes involved in virulence of the B. pertussis 509 strain show considerable overlap 
with the genes that Cummings13  found to be involved in virulence of the Tohama and GMT-
I strains. Especially the most important and well-known Bvg-activated genes that code for 
protection inducing antigens (i.e. pertussis toxin, pertactin, filamentous haemagglutinin, see 
supplementary data file) seem to be conserved between all strains, while the Bvg-repressed 
genes are more variable. This supports the concept of the core and flexible regulon proposed 
by Cummings13. With these results we now have a set of marker genes for the virulence 
state of the bacteria. Because the Bvg-repressed genes show high variation between strains, 
it is hard to pinpoint the core regulon for virulence-repressed genes. However, for product 
efficacy the Bvg-activated genes are most relevant and evaluation of the virulence state of 
the product can be confined to the expression status of these genes only. 
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The genes that are involved in virulence of the B. pertussis 509 strain code for the most 
likely proteins that can induce an immune response. These results can therefore be a starting 
point for a reverse vaccinology approach to find new vaccine candidates18.  
DNA microarrays can be used for prediction of product quality in a discriminative way, 
while the usual mandatory efficacy tests only provide yes or no answers11. Before PAT can be 
applied on any process, products of poorer quality need to be distinguished from the higher 
quality products, even though both products would meet end-product quality demands. Only 
in this way can processes be optimized and made more robust in order to yield product of 
consistently high quality. Ultimately, mRNA expression data can be correlated to the signal 
of on line process monitoring sensors such as near infrared (nIR) or Raman spectroscopy to 
build a model that can assess process performance and predict product quality on line as is 
desired by the FDA in their PAT initiative. 
Conclusions
Generally, the cultivation of vaccines is considered to have high inherent variance and is 
therefore not as suitable for PAT application as chemical (synthesis) or physical (blending) 
process steps. This paper demonstrates that elimination of the major sources of variance 
leaves a cultivation process step that is highly reproducible. Application of modern techniques 
such as DNA microarrays provides a tool for science-based evaluation of product quality. 
Disturbances in mRNA expression levels of specific genes provide good starting points for 
further research, because the physiological cellular response is visualized. The reproducible 
process and the tools to investigate disturbances and monitor consistency combined with a 
suitable on line monitoring tool (such as near infrared or Raman spectroscopy) would make 
PAT application on this process feasible. The discriminative data on product quality and 
process performance should be correlated to such on line measured data to build process 
models that control the process towards consistent end product quality. Product quality 
would become an inherent trade of the process.
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Abstract
Modern (bio)pharmaceutical process development requires thorough investigation of all 
process parameters that are critical to product quality. The impact of a disturbance of such 
a parameter during processing needs to be known so that a rational decision can be made 
about the release of the product. In cultivation processes the dissolved oxygen concentration 
(DO) is generally accepted as being a critical parameter. In this paper the impact of a 90 
minute period of oxygen limitation during the cultivation of the strictly aerobic Bordetella 
pertussis bacterium is investigated. The cultivation is the most important process step 
for the manufacturing of a vaccine against whooping cough disease. Samples were taken 
immediately before and after oxygen limitation and at the end of cultivation of four oxygen 
limited and three control cultivations. DNA microarray analysis of the full transcriptome of 
the Bordetella pertussis bacterium revealed that a 90 minute period of oxygen limitation has 
a substantial effect on overall gene expression patterns. In total 104 genes were identified 
as a significant hit at any of the sample points, of which 58 were directly related to oxygen 
limitation. The other genes were mainly affected towards the end of cultivation. Of all genes 
involved in oxygen limitation none were identified to show a significant difference between 
the oxygen limited and control cultivations at the end of the batch. This indicates a fully 
reversible effect of oxygen limitation on gene expression. This finding has implications for 
the risk assessment of dissolved oxygen concentration as a critical process parameter.
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Introduction
The manufacturing of vaccines, as well as all other pharmaceutical preparations, has to be 
executed within predefined specifications. When specifications have not been met, the batch or 
run cannot be released and has to be started again. However, sometimes little is known about 
the actual effect of the failure or deviation on product quality. When a certain disturbance 
causes the process to run outside the specifications (out of specs, OOS), the manufacturer has 
no choice but to reject the batch, regardless the actual effect of the disturbance on product 
quality. This means a manufacturer could very well reject a perfectly good batch because the 
process specifications have not been sufficiently supported by scientific evidence.
This undesirable situation has come to exist because the pharmaceutical industry is highly 
regulated and document controlled. In any other process industry the market demand to 
produce products of high quality on time and at low costs would have initiated research for 
better process understanding and process control. In the pharmaceutical industry, however, 
regulatory systems such as GMP have resulted in fixed processes that have to be controlled 
by extensive documentation such as SOP’s, batch records and numerous other protocols. 
One might argue that a document with the correct signatures has become a replacement for 
actual product quality management. 
In response to the continuously increasing paperwork, the American FDA launched the 
Process Analytical Technology (PAT) initiative in 2003 in order to make the pharmaceutical 
industry move away from document control and design processes that can be controlled 
towards a desired end-point quality. The PAT initiative is part of the much broader initiative 
“Pharmaceutical cGMPs for the 21st Century: a risk based approach”  (see http://www.fda.
gov) and has already been adopted by other authorities such as the European EMEA. Recently, 
new guidances released by the harmonization agency ICH (Q8, Q9, Q10) demonstrated 
a worldwide consensus regarding this subject. Generally, the FDA’s definition is adopted 
which states: PAT is a system for designing, analyzing and controlling manufacturing 
through timely measurements of critical quality and performance attributes of raw and in-
process materials and processes, with the goal of ensuring final product quality. 
For each unit operation such a system needs to be developed and therefore, for each unit 
operation the parameters that are critical to process performance or product quality need to 
be known. For a document controlled industry like the pharmaceutical industry, this means 
a completely new way of product analysis and process development. This is especially true 
for the production processes of biologicals, or even vaccines, because these are generally 
considered harder to control and more variable than manufacturing processes for chemical 
drugs. 
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In this paper, we are investigating a PAT application for the cultivation unit operation 
of a production process for a whole cell vaccine against whooping cough, caused by the 
Bordetella pertussis  bacterium. In this batch cultivation process the most critical parameters 
are the starting materials1, because they are the only process input. In a batch process a small 
variation at the start can often result in a much larger variation at the end of the process. 
After the process has been started, only a few parameters can be controlled on line. For a 
typical batch cultivation process these parameters are usually pH, temperature and dissolved 
oxygen concentration. Because each of these parameters can influence bacterial growth and 
product formation, they classify as being critical to product quality and performance. 
For a full PAT application, the failure limits of the critical parameters need to be known. 
This means that for each of the critical parameters the ranges have to be explored that still 
yield good product quality. Within these failure limits a safe range can be selected that is in 
principle not critical to product quality or process performance. In this way specifications 
can be defined that are based on actual process understanding.
Because most processes usually have several critical parameters that can interact with each 
other, the final step is to perform a series of experiments in which all critical parameters 
are varied simultaneously. Such a series of experiments can be designed using basic 
statistical principles. This approach is generally known as experimental design or Design of 
Experiments (DoE)2. By applying DoE the previously defined specifications can be tested 
for unexpected interaction with each other. 
In this study DNA microarrays were used to detect changes in cellular physiology caused 
by a 90 minute period of oxygen limitation and to investigate whether any of the earlier 
reported marker genes are affected, implicating consequences for product quality. By using 
DNA microarrays in such a way general product and process understanding is increased 
as well as general understanding of cellular physiology, because the genes affected by the 
disturbance are revealed. At the same time the risk of a certain critical parameter for product 
quality and performance can be assessed.  The use of DNA microarrays as a tool to increase 
process understanding has become more common in the recent past3,4,5. Previously we have 
demonstrated the suitability of DNA microarrays for the investigation of a bacterial cultivation 
processes1. We reported a set of genes that is important for the quality and performance of 
a whole cell vaccine against whooping cough disease. These marker genes are associated 
with virulence, because it is only the virulent bacterium against which a protective immune 
response can be raised6. Therefore the expression of virulence factors is crucial for vaccine 
performance, especially those that are on the outside of the bacterium or that are excreted 7. 
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It has been hypothesized8,9 that the virulence state of members of the Bordetella genus is 
associated with survival outside the host and adaptation to unfavorable conditions on one 
hand and colonization and infection of the host on the other hand. Bordetella pertussis 
can switch between these states10,11,12, which each have specific proteins that are involved 
in the mechanisms necessary either for survival or colonization. The proteins involved 
in colonization and infection (so called virulence factors) are the targets against which a 
protective immune response is raised in a whole cell vaccine against whooping cough. 
Therefore, changes in the expression of these virulence factors have implications for product 
quality6,13. For a strictly aerobic bacterium, oxygen limitation could be a condition that 
triggers the survival state. This means that the virulence factors are no longer expressed in 
favor of proteins involved in survival outside the host, resulting in an ineffective vaccine.
In this paper disturbance of  the dissolved oxygen concentration during the cultivation of 
Bordetella pertussis is investigated for its impact on expected product quality using DNA 
microarrays. Because the Bordetella family consists of strictly aerobic micro-organisms 14, 
oxygen supply is crucial for bacterial survival. Contrary to what was expected before the 
experiment, oxygen limitation was found to be fully reversible on the gene expression 
level at the end of cultivation after having a large impact immediately after the disturbance. 
This finding has implications on how the risk of oxygen limitation on process and product 
performance should be assessed. It illustrates the importance of investigating a pharmaceutical 
manufacturing process, even for parameters that are considered well understood. True process 
understanding can only come from sound scientific research and careful scrutinization of all 
critical process parameters.
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Materials and Methods
Bacterial cultivation 
Seedlot and starter culture 
Bordetella pertussis strain 509 (NVI, Bilthoven, The Netherlands) used in this study was 
collected in 1963 as a clinical isolate and was used as one of the two strains in the Dutch 
vaccination program until 2005. Cultivation was done using the chemically defined, filter 
sterilized THIJS medium containing lactate and glutamate as main carbon sources15,16.  All 
starter cultures were inoculated from the same working seedlot as described earlier1. The 
working seedlot was prepared using freeze-dried Bordetella pertussis strain 509, obtained 
from the in-house culture collection. The culture was mixed with glycerol (10 % v/v) after 
growth to OD590=1.0, divided in 10 ml aliquots and stored at -140°C. Shakeflask pre-cultures 
for the bioreactor experiments were inoculated at 5 % (v/v) from this seedlot, and cultured 
at 35°C to OD590 =1.0 using an orbital shaker at 200 rpm. 
Bioreactor conditions and operation 
Two fully instrumented bench-top bioreactors (Applikon, Schiedam, The Netherlands) with 
a total volume of 7 liters were used in this study. Bioreactors were fitted with 6-bladed 
Rushton turbines. Cultivations were performed at a working volume of 4L, using an inoculum 
of 5% v/v with OD590=1.0. Temperature, pH and dissolved oxygen (DO) were controlled 
at 34 ºC , 7.2 and 30 %, respectively. A low-drift polarographic electrode (Applikon, 
Schiedam, The Netherlands) measured the dissolved oxygen in the medium, while pH and 
temperature were measured by a glass pH electrode (Mettler Toledo, Tiel, The Netherlands) 
and a Pt100 temperature sensor (Applikon, Schiedam, The Netherlands), respectively. All 
sensors were connected to the bioreactor control system ADI-1040 (Applikon, Schiedam, 
The Netherlands), which was operated using BCSV software (Compex, Ghent, Belgium). 
Oxygen was supplied through the headspace only. Initially, oxygen demand was met by 
50 rpm increments in stirrer speed from 450 rpm to 650 rpm. Further demand was met 
by increasing the oxygen fraction in the air flow with pure oxygen. Total gas flow was 
continuously kept constant at 1 L/min. 
Seven batches were run, i.e. three control experiments (without oxygen disturbance) and 
four oxygen limited experiments, in which the pure oxygen supply was closed for a period 
of 90 minutes, while leaving the air supply intact at 1 L/min. The pure oxygen supply was 
closed when a certain biomass density was reached (OD590=0.4 ± 0.04). At this point the 
stirrer had reached maximum speed and a fraction of pure oxygen was mixed with air and fed 
into the bioreactor headspace to maintain DO setpoint. By closing the pure oxygen supply, 
the bioreactor remained aerated, but oxygen limited. This resulted in a sharp decrease in 
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dissolved oxygen concentration to 0% (Figure 1). The 90 minute period of oxygen limitation 
was considered to start when DO < 1%. When pure oxygen supply was restored, DO 
increased sharply and returned back to its original setpoint within a few minutes. This method 
of oxygen limitation was chosen because it allowed good control of the length of oxygen 
limitation, resulting in reproducible experiments and because it is the only way to isolate the 
effect of oxygen limitation from secondary effects. Complete cut-off of the gas-flow would 
also eliminate carbon dioxide ventilation and cause unwanted side effects. Venting with pure 
nitrogen could result in a complete arrest of cellular function and even cell death and lysis 
because Bordetella pertussis is an obligate aerobic organism. This would make microarray 
analysis impossible and is not a likely situation to occur during manufacturing. 
Sampling 
Samples were taken from the reactor at regular intervals. Biomass concentration was 
measured offline by photospectroscopy at 590 nm using a Vitalab 10 Photospectrometer (Vital 
Scientific, Dieren, The Netherlands) at 590 nm. L-lactate concentrations were determined at 
line using an YSI 2700 analyzer (Yellow Springs Instruments, Yellow Springs, USA). These 
data was used for end-point determination ([lactate] = 2–3 mM). Supernatant of samples 
was stored and later analyzed by 1H NMR (JEOL JNM-ECP 400FT, JEOL, Tokyo, Japan) 
for other nutrient concentrations and also to check for any detectable disturbances in the 
Figure 1. Dissolved oxygen concentration 
profiles of an oxygen limited (dark line) culture 
and a control culture (light line) between 9 
h and 21 h of culture time. The sudden drop 
in the dark profile is caused by the closure of 
the pure oxygen supply into the headspace, 
while the air supply remained intact. After  90 
minutes the pure oxygen supply was restored 
and the dissolved oxygen concentration quickly 
returned to set-point (30%). The dashed line 
indicates 1% dissolved oxygen concentration, 
which is the start of the 90 minutes oxygen 
depletion. The letters A, B and C indicate the 
samples taken immediately before oxygen 
limitation, immediately after oxygen limitation 
and at the end of the batch, respectively.
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metabolism such as the excretion of waste metabolites caused by the oxygen limitation.
Just before interrupting (A) and just before restoring (B) the oxygen flow, samples for mRNA 
analysis were taken. At the end of the batch samples for both protein and mRNA analysis 
were taken (C). The batch was stopped when the residual lactate concentrations was between 
2 and 3 mM. Samples in the control cultures were taken at or near the same culture times as 
the oxygen limited cultures for samples A and B and at the same lactate concentrations for 
sample C (2-3 mM). 
RNA Analysis 
MicroArray design 
Samples were analyzed using a full genome Bordetella pertussis microarray. Based on 
the complete genome sequence of Bordetella pertussis Tohama I17, a set of 3582 70-mer 
oligonucleotides was developed at Operon (Cologne Germany), covering 93% of all open 
reading frames. Oligonucleotide pellets were dissolved in 50% DMSO (v/v in water) to a 
concentration of 20µM and spotted in triplicate on UltraGAPS II coated slides (Corning, New 
York U.S.A.), together with 420 control spots, using the Omnigrid 100 microarray spotter 
(GeneMachines, San Carlos U.S.A.). Prior to use, slides were UV cross-linked, treated with 
sodium borohydride and pre-hybridized according to the manufacturer’s protocol (Corning, 
New York, USA). 
RNA isolation 
For fixation of the RNA expression profile, 1 volume bacterial culture was mixed with 2 
volumes RNAse retarding solution18,19,20. For each microarray sample 2.5 ml bacterial 
suspension at OD590 = 1.0 was used. Samples at other optical densities were adjusted 
accordingly, therefore an equal amount of cells was used for each RNA isolation step. The 
samples were concentrated by centrifugation and treated with Tris-EDTA buffer, containing 
0.5mg/ml lysozyme (Sigma-Aldrich, Zwijndrecht, The Netherlands) for 3 minutes. Total 
RNA was extracted with the SV Total RNA isolation system (Promega Benelux, Leiden, The 
Netherlands) according to manufacturer’s protocol. Nucleic-acid concentration was adjusted 
by precipitation and spectral analysis was used to determine final nucleic-acid concentration 
and purity. RNA integrity was confirmed with the Bioanalyzer RNA6000 Nano assay (Agilent 
Technologies, Amstelveen, The Netherlands), according to the manufacturer’s protocol.
Labeling and Hybridization 
Total RNA from all experimental samples was reverse transcribed to cDNA and labeled with 
Cy3/Cy5 dyes using the Chipshot Indirect Labelling Kit (Promega Benelux, Leiden, The 
Netherlands) according to manufacturer’s protocol, with one deviation: only 2µl random 
nonamer primer and no oligo-dT primer was used per reaction to reverse transcribe 50µg total 
Chapter 3
46
3
RNA. The labeled and purified cDNA samples were pooled in Cy3/Cy5 pairs and volumes 
were adjusted to 25µl by evaporation under low pressure. Hybridization buffer (25µl) was 
added, to a final concentration of 25% formamide, 5x SSC and 0.1% SDS. Samples were 
applied on the microarray slides and incubated in a hybridization chamber (GeneMachines, 
San Carlos, U.S.A.) for 16-20 hours at 42°C in the dark. 
Data acquisition and analysis 
The microarrays were scanned with a ScanArray Express microarray scanner (Perkin Elmer, 
Groningen, The Netherlands) and median fluorescence intensities were quantified for each 
spot using ArrayVision software (Imaging Research, Roosendaal, The Netherlands). The 
expression data were natural-log transformed, quantile normalized, and values of replicate 
spots were averaged. These data processing steps were done with the free statistical software 
R (WU Wien, Austria), using an in-house developed script. 
Differential gene expression levels were obtained through comparison with a common 
reference sample, containing equal amounts of RNA for each sample. P-values were 
calculated using one-way ANOVA statistical analysis and adjusted for multiple testing by 
calculating the False Discovery Rate (FDR). Fold Ratio (FR) values were expressed as 
the natural log of the normalized signal ratio. Observed differential gene expression was 
considered biologically significant when Fold Ratio (FR) > 1.5 and False Discovery Rate 
(FDR) < 0.10. Additional data analysis by principal component analysis (PCA) was done 
using GeneMaths software (Applied Maths, Sint-Martens-Latem, Belgium).
Gene expression shifts between PCA groups (Figure 3) were assessed using Eucledian 
difference in ln-transformed gene expression values to calculate the Mahalanobis distances 
over the set of significantly regulated genes. This corresponds to the distance in the PCA 
plot. P-values were calculated by using these distances in a Hotelling T-test.
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Results
Culture characteristics
All seven cultures showed comparable overall growth characteristics and nutrient 
consumption rates. The control cultures seemed to have a slightly higher biomass yield and 
associated lactate consumption, but they also had a slightly higher lactate concentration at 
the start of the batch. Overall, no significant differences were found between both groups 
in biomass yield from the start of oxygen limitation until the end of the batch (p<0.21), 
i.e. between sample points A and C (Figure 1). The NMR nutrient analysis did not reveal 
any change in excreted (waste) metabolites or other low molecular weight compounds after 
oxygen limitation. 
Microarray results
The complete dataset from the microarray experiment can be found in the supplementary 
data file (Table A). Data from samples taken before oxygen limitation (A), immediately 
after oxygen limitation (B), and at the end of the culture (C) and the samples taken from the 
control cultures at the corresponding time points were averaged between replicates. Genes 
that showed a significant difference between any of the samples were considered a hit and 
are shown in Figure 2 (see on line supplementary datafile Table A for p-values). The 104 
genes identified as hits cluster in 7 groups. Groups I and II consist of 34 genes that were 
respectively only up- or down-regulated immediately after the oxygen limitation period. 
Groups III and IV consist of 41 genes that were respectively up- or down-regulated at the 
end of the cultivation (end of batch effect), but not by the oxygen limitation. Groups V 
and VI consist of 24 genes that were respectively up- or down-regulated immediately after 
oxygen limitation and (to varying extents) at the end of the batch. Group VII consists of 5 
genes that are variably regulated. The genes in the groups I, II, V and VI are the genes that 
are directly affected by oxygen limitation, i.e. these are the genes that showed a significant 
hit between the oxygen limited sample B and the control sample B.  
Genes that have consecutive gene numbers (i.e. are located next to each other on the 
genome) and that were regulated similarly were marked as potential operons, i.e. genes that 
were regulated together, usually to perform a specific cellular task.  Table B in the on line 
supplementary datafile (journal homepage) shows an overview of these potential operons 
and their possible functions. Most prominently, genes involved in mRNA and protein 
synthesis and oxidative phosphorylation are regulated in an operon-like manner as a result 
of the oxygen limitation (groups I, II and VI). Towards the end of the batch, genes involved 
in nutrient transport and metabolism show an effect, most prominently sulphate transport 
(group III). 
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Covariation between samples can be visualized with principal component analysis (PCA). 
Figure 3 shows how the hits from the respective samples are distributed when the first 
principal component is plotted against the second principal component. It is clear that 
sample B (right after oxygen limitation) of the experimental group clusters separately from 
the A samples (before oxygen limitation) and the samples A and B from the control group 
(p<0.0023). Surprisingly, the samples C (end of batch) from the control and the oxygen 
limited group all cluster together, indicating no difference between both groups at the end 
of the batch. 
In order to assess the impact on product quality, the found hits were screened for the presence 
of any of the earlier reported 56 virulence core regulon genes (virulence activated genes or 
vag’s) that can serve as a marker for product quality1. Two virulence genes, bcrH1 and bcrH2, 
were found as significant hit in any one of the samples (see supplementary data table A). 
These are both part of the Type III secretion system operon21, that has recently been identified 
Figure 2. Relative expression levels of all genes that showed a significant 
(FR>1.5, FDR<0.1) result in any of the groups. Sample points A, B and C 
indicate samples taken before oxygen limitation, immediately after oxygen 
limitation and at the end of the cultivation. The control samples were taken 
at the same culture times as the oxygen limited samples for A and B and at 
the same lactate concentration for sample C. The color scale runs from dark 
green to dark red through yellow, where dark green indicates strong down-
regulation and dark red indicates strong up-regulation. 
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to be involved in the excretion of virulence factors in Bordetella pertussis 22. However, neither 
showed an effect in the oxygen limited sample B as compared to the control sample B, but 
these genes were only identified as hit between samples A and C, indicating a change of 
expression towards the end of cultivation. 
Figure 3. Principal component analysis of the hits found with DNA microarrays. This plot shows that the samples 
before oxygen limitation (dark and light circled A) cluster in the center, together with the control samples at the 
time point immediately after oxygen limitation (light circled B). On the left hand side the samples immediate after 
oxygen limitation (dark circled B) of the oxygen limited cultivations are clustered. This cluster is significantly 
different from the center cluster (p<0.0023). All samples taken at the end of cultivation (dark and light circled C) 
cluster together at the right-hand side. This cluster is also significantly different from the center cluster (p<0.013). 
This indicates that the differences between the control cultivations and oxygen limited cultivations observed at 
time point B are reversed at the end of the cultivation, but that there is a shift in gene expression towards the end of 
cultivation that is identical for both control and oxygen limited cultivations.
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Discussion
The experiments described in this paper were performed with the aim to find the effects 
on the end product caused by an oxygen limitation during cultivation in order to assess the 
criticality of oxygen limitation for product quality. Surprisingly, at the end of the cultivation 
no difference could be found between the oxygen limited cultures and the control cultures 
using DNA microarrays, despite the fact that immediately after the oxygen limitation a 
clear effect was observed on the expression levels of numerous genes (Figure 2 and on line 
supplementary data). This means that oxygen limitation has a fully reversible effect on the 
physiology of Bordetella pertussis and is less critical for product quality than previously 
thought. 
The data from the microarrays prove highly valuable, because they give information about 
every single gene of the organism, which allows the observation of changes in pathways or 
cellular functions that with any other technique would remain undiscovered. Also, a process 
disturbance that has such a high impact at the moment it occurs and is undetectable with 
microarrays at the end of the process can be reliably labeled as reversible and istherefore less 
critical than was believed before. In this case, the genes involved in oxygen limitation did 
not show a correlation with the genes of the virulence core regulon. From this the criticality 
of oxygen limitation on product quality can be assessed as limited and reversible.
However, two virulence associated genes were identified as a hit between samples A and 
C. Although two genes are only a small fraction of the reported 56 virulence genes1, this 
is still a worrying finding, because it could indicate that towards the end of a batch the 
virulence of Bordetella pertussis is affected. This notion is consistent with the idea that the 
bvg / virulence system of the Bordetella family is intrinsically evolved to deal with survival 
outside a host in a low-nutrient environment8,9. At the end of a cultivation batch the bacteria 
experience a low-nutrient environment as well. Although the system is not fully functional 
in Bordetella pertussis, it does still react to the same environmental stimuli as the functional 
system in Bordetella bronchoseptica8 and could therefore very well play a critical role in 
product quality at the end of a production batch. 
In conclusion, the results in this paper take us one step further in the investigation of the 
critical process parameters of the cultivation process of Bordetella pertussis. This work 
shows that even a parameter that is generally accepted as being critical in a bioprocess 
appears to have only transient effects on process performance. The specifications for the 
production of a vaccine against whooping cough might be adjusted accordingly, although 
the analysis presented in this paper do not directly link to the clinical performance of the 
product. However as mentioned earlier, a link between the virulence state and product 
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performance has already been established6. The regulatory flexibility necessary to change 
and adjust specifications based on scientific evidence is provided in the FDA’s PAT guidance 
document (http://www.fda.gov/cder/guidance/6419fnl.pdf).
In order to fully comply with the PAT framework, the interaction between oxygen limitation 
and other critical process parameters needs to be evaluated further. Only then can a process 
disturbance be accurately assessed for its risk on product quality. Finally these data and 
possibly additional online data need to be combined in a readily (i.e. on line) available 
database that can be used as cross reference during new manufacturing runs. This allows for 
an on line check on the performance of the running process in respect the already available 
process understanding, allowing the assurance of process performance and product quality 
in real time.
Acknowledgements
The authors gratefully acknowledge Dr. J. Pennings for help with the DNA microarray 
dataprocessing and Dr. B. Zomer for NMR nutrient analyis.  This work was partly funded by 
Senter Novem, The Netherlands, grant number TSGE3067.
Chapter 3
52
3
References
1. Streefland M, van de Waterbeemd B, Happe H, van der Pol LA, Beuvery EC, Tramper J, Martens DE. 2007. 
PAT for vaccines: The first stage of PAT implementation for development of a well-defined whole-cell vaccine 
against whooping cough disease. Vaccine 25(16):2994-3000.
2. Montgomery DC. 1999. Experimental Design for Product and Process Design and Development. The 
Statistician 48(2):159-177.
3. Hirasawa T, Nakakura Y, Yoshikawa K, Ashitani K, Nagahisa K, Furusawa C, Katakura Y, Shimizu H, Shioya 
S. 2006. Comparative analysis of transcriptional responses to saline stress in the laboratory and brewing 
strains of Saccharomyces cerevisiae with DNA microarray. Appl Microbiol Biotechnol 70(3):346-57.
4. Khodursky AB, Peter BJ, Cozzarelli NR, Botstein D, Brown PO, Yanofsky C. 2000. DNA microarray analysis 
of gene expression in response to physiological and genetic changes that affect tryptophan metabolism in 
Escherichia coli. Proc Natl Acad Sci U S A 97(22):12170-5.
5. Seth G, Charaniya S, Wlaschin KF, Hu WS. 2007. In pursuit of a super producer-alternative paths to high 
producing recombinant mammalian cells. Curr Opin Biotechnol 18(6):557-64.
6. Bellalou J, Relyveld EH. 1984. Studies on culture conditions of Bordetella pertussis and relationship to 
immunogenicity of vaccines. Ann.Microbiol.(Paris) 135B(1):101-110.
7. Mills KH. 2001. Immunity to Bordetella pertussis. Microbes.Infect. 3(8):655-677.
8. Cummings CA, Bootsma HJ, Relman DA, Miller JF. 2006. Species- and strain-specific control of a complex, 
flexible regulon by Bordetella BvgAS. J.Bacteriol. 188(5):1775-1785.
9. Nakamura MM, Liew SY, Cummings CA, Brinig MM, Dieterich C, Relman DA. 2006. Growth phase- 
and nutrient limitation-associated transcript abundance regulation in Bordetella pertussis. Infect.Immun. 
74(10):5537-5548.
10. Cotter PA, Jones AM. 2003. Phosphorelay control of virulence gene expression in Bordetella. Trends 
Microbiol. 11(8):367-373.
11. Scarlato V, Prugnola A, Arico B, Rappuoli R. 1990. Positive transcriptional feedback at the bvg locus controls 
expression of virulence factors in Bordetella pertussis. Proc.Natl.Acad.Sci.U.S.A 87(17):6753-6757.
12. Smith AM, Guzman CA, Walker MJ. 2001. The virulence factors of Bordetella pertussis: a matter of control. 
FEMS Microbiol.Rev. 25(3):309-333.
13. Hamstra HJ, Kuipers B, Schijf-Evers D, Loggen HG, Poolman JT. 1995. The purification and protective 
capacity of Bordetella pertussis outer membrane proteins. Vaccine 13(8):747-752.
14. Goodnow RA. 1980. Biology of Bordetella bronchiseptica. Microbiol Rev 44(4):722-38.
15. Thalen M, van den IJssel J, Jiskoot W, Zomer B, Roholl P, de Gooijer C, Beuvery C, Tramper J. 1999. 
Rational medium design for Bordetella pertussis: basic metabolism. J.Biotechnol. 75(2-3):147-159.
16. Thalen M, Venema M, van den IJssel J, Berwald L, Beuvery C, Martens D, Tramper J. 2006. Effect of relevant 
culture parameters on Pertussis Toxin expression by Bordetella pertussis. Biologicals 34(3):213-220.
17. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, Holden MT, Churcher CM, Bentley 
SD, Mungall KL and others. 2003. Comparative analysis of the genome sequences of Bordetella pertussis, 
Bordetella parapertussis and Bordetella bronchiseptica. Nat.Genet. 35(1):32-40.
18. Kasahara T, Miyazaki T, Nitta H, Ono A, Miyagishima T, Nagao T, Urushidani T. 2006. Evaluation of 
methods for duration of preservation of RNA quality in rat liver used for transcriptome analysis. J Toxicol Sci 
31(5):509-19.
19. Mutter, GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker HE, Warrington JA. 2004. Comparison of 
frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 
5(1):88.
Oxygen Supply as Critical Process Parameter for Cultivation of Bordetella pertussis
53
3
20. Ramalho AS, Beck S, Farinha CM, Clarke LA, Heda GD, Steiner B, Sanz J, Gallati S, Amaral MD, Harris A 
and others. 2004. Methods for RNA extraction, cDNA preparation and analysis of CFTR transcripts. J Cyst 
Fibros 3 Suppl 2:11-5.
21. Mattoo S, Yuk MH, Huang LL, Miller JF. 2004. Regulation of type III secretion in Bordetella. Mol.Microbiol. 
52(4):1201-1214.
22. Fennelly NK, Sisti F, Higgins SC, Ross PJ, van der Heide H, Mooi FR, Boyd A, Mills KH. 2008. Bordetella 
pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune 
responses. Infect Immun.

Chapter 4
Gene-expression based quality scores 
indicate optimal harvest point in 
Bordetella pertussis cultivation for 
bacterial vaccine production
Mathieu Streefland1*, Bas van de Waterbeemd1*, Jeroen Pennings2, 
Leo van der Pol1, Coen Beuvery3, Johannes Tramper4, Dirk Martens4
*both authors contributed equally
1Netherlands Vaccine Institute (NVI), Bilthoven, The Netherlands. 
2 National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands
3PAT Consultancy, Vianen, The Netherlands.
4Wageningen University, Wageningen, The Netherlands.
Accepted for publication in Biotechnology and Bioengineering
Supplementary data can be found with the on line published version of this chapter at the journal’s home page
4
Gene-expression based quality scores indicate optimal harvest point in Bordetella pertussis cultivation
57
4
Abstract
Introduction
The evolution of vaccine product quality during batch cultivation of Bordetella pertussis, 
the causative agent of whooping cough, was investigated with the goal to determine the 
optimal harvest point. The process was explored by measuring mRNA expression at frequent 
intervals during cultivation. Because the virulence genes that are important for quality are 
already known for this product, changes in expression levels of these genes are proposed to 
be indicative for product quality. 
Results
A quantitative product quality score is calculated, based on the expression levels of the genes 
that are critical for product quality. Product quality scores were maximal throughout the 
logarithmic growth phase, but dropped significantly at the end of the logarithmic phase and 
the start of the stationary phase, caused by nutrient depletion. The optimal harvest point for 
this batch process was determined, based on rational science-based criteria. 
Conclusions
By measuring the changes in expression levels of genes that are critical for product quality 
during cultivation, the optimal harvest point of Bordetella pertussis cultivation has been 
determined. The product quality score, based on the expression of these genes, allows 
comparison of expected product quality between culture samples or between batches. This 
showed that the decreasing lactate and glutamate concentrations towards the end of the batch 
are critical for product quality. On line measurement of these nutrients allows the cultivation 
process to be harvested at or near the optimal harvest point, increasing process robustness 
and consistency.
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Introduction
Batch cultivation processes are common in biopharmaceutical manufacturing. GMP 
guidelines and other regulations have delayed the evolution to more continuous processing, 
which is much more common in other process industries (i.e. petrochemical industry). 
Batch cultivations have several drawbacks compared to continuous processing. First of 
all, the nutrients and other substrates all need to be present at the start and their starting 
concentration defines the maximal yield at the end of the batch. Moreover, the quality of 
the starting materials is crucial for batch performance. Also much time is lost between 
batches (downtime) and batch processing is relatively labor intensive, because of cleaning 
and handling. Of course the yield can be increased by adopting a fed-batch strategy, but 
the downstream processing usually still involves batch-wise unit operations, which makes 
continuous harvesting impossible. 
Besides the importance of the starting conditions for a batch process, the determination 
of the end-point might be more important for product quality. At the end of a bacterial 
batch cultivation the conditions permitting growth have ceased to exist and the biomass 
will start to die off. This death phase is usually preceded by a stationary phase in which 
enough nutrients are available to sustain basal maintenance metabolism, but not enough to 
sustain growth. These phases are usually marked by profound changes (i.e. in metabolic and 
other pathways) inside the cell1,2,3. For a biopharmaceutical product, the final phase of the 
batch may be critical to the quality of the product. At the end of a bacterial cultivation cells 
usually lyse, which is accompanied by the release of unwanted proteins, DNA or enzymes 
(proteases) that need to be separated from the active pharmaceutical ingredient (API) or can 
degredate the product. In the case of a whole cell product, changes in cellular morphology or 
outer membrane composition can be critical to product performance.
The optimal harvest point of a bacterial batch cultivation should result in the highest 
possible yield of product at the desired level of product quality. However, both could very 
well be in direct competition towards the end of the batch. Product quality even could be a 
variable throughout the batch or could be a constant for most of the batch and only change 
towards the end of the batch. In order to determine the optimal harvest point and to increase 
the understanding of the evolution of product quality during a batch cultivation, the entire 
batch profile needs to be investigated by frequent sampling and analysis of product quality 
and process performance. This paper describes the  investigation of the batch profile of the 
cultivation process step for the manufacturing of a whole cell vaccine against whooping 
cough disease, a severe childhood disease caused by the Bordetella pertussis bacterium
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The manufacturing process of this whole cell vaccine only consists of a cultivation process 
step followed by heat inactivation and concentration to yield the bulk product. For such 
a product it is especially critical to investigate the cultivation process step, because this 
is where the actual product quality is determined (i.e. the potency of the vaccine) and the 
limited downstream processing can change or add little to product quality. The starting 
conditions and materials that yield a robust batch process for Bordetella pertussis cultivation 
have been investigated earlier4. 
The condition and composition of the biomass, more specifically the outer membrane, is 
especially critical for a whole cell vaccine, because it contains the antigens that induce a 
protective immune response after vaccination. Most important antigenic outer membrane 
proteins are, however, known to change with the changing process conditions associated 
with batch processing. Nakamura et al.5  have reported that after the nutrients had been 
completely consumed, substantial changes in gene expression patterns were observed in 
Bordetella pertussis, including many genes of the so called virulence core regulon 6,4. The 
genes of this regulon encode virulence proteins that are involved in host invasion and further 
infection and many of them are known to induce or to play a role in the induction of a 
protective immune response after vaccination7. Their importance is confirmed by the fact 
that immunization studies with non-virulent Bordetella pertussis bacteria showed the loss 
of a protective immune response8. Purified forms of these proteins are commonly used in 
varying combinations in a-cellular vaccines against whooping cough disease.
Previously4, we have demonstrated that microarrays are a suitable tool to identify and 
quantitatively measure the relative expression levels of the virulence core regulon genes. 
This allows discrimination between favorable and unfavorable process conditions by 
assessing the impact of different process conditions on the relative expression levels of these 
marker genes. In this paper this principle is used to determine the optimal harvest point and 
to investigate how the continuously changing conditions of batch processing are reflected in 
the gene expression profile. mRNA expression profiles are measured throughout logarithmic 
growth and plateau phases to increase the understanding of how the bacterium adapts to 
the continuously changing environment of a batch process. Moreover, by measuring the 
expression of the core regulon genes, the impact of these changes on expected product 
quality can be determined. 
The correlation between nutrient availability and expected product quality allows prediction 
and control of the optimal batch end point. At line measurements of nutrient concentrations 
allow harvest at the highest yield without endangering product quality. In fact, observed 
in the light of the recent Process Analytical Technology (PAT) initiative9, we now have a 
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parameter that is critical for product quality and that can be measured during cultivation. The 
at line measurements can be replaced by online monitoring of nutrient concentration with 
spectroscopic techniques, such as near infrared spectroscopy. On line monitoring and control 
of critical process and product attributes with the aim of ensuring final product quality is 
what defines PAT according to the FDA’s guidance on Process Analytical Technology9. 
This paper demonstrates that the overall expression pattern of Bordetella pertussis mRNA 
is relatively constant during cultivation, but towards the end of the logarithmic phase, the 
decreasing availability of nutrients suddenly affects a large number of genes after the key 
nutrients lactate and glutamate drop below a minimal threshold concentration. Among these 
genes are many of the genes involved in virulence, which is an indication that product quality 
is at risk when the bacteria are harvested too late. 
The level of bacterial virulence of culture samples is scored on a scale between optimal 
virulence and complete non-virulence using principal component analysis. This allows us 
to give a virulence-dependent quality score to cultivation samples and especially harvest 
samples. In this way product quality at different sample points can be compared without 
having to use animal potency tests for research activities. Ultimately such a score can be 
used to compare different cultivation end-products with each other or with a golden standard 
reference. In the mean time such a “quality scale” can serve as a powerful research tool 
during process development.
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Materials and Methods
Bacterial strain, media and growth conditions
The Bordetella pertussis 509 strain (Netherlands Vaccine Institute, Bilthoven, The 
Netherlands) used in this study was collected in 1963 as a clinical isolate and used as vaccine 
strain in the combined diphtheria, pertussis, tetanus and polio (DPTPolio) vaccine until 2005. 
All bacterial cultures were grown in chemically defined THIJS medium10,11, which consists 
of basic medium and supplement. Supplement (1%, v/v) was added to the basic medium 
shortly before inoculation. The pH after addition of supplement is 7.1. The preculture was 
inoculated with 10 ml Bordetella pertussis 509 working seedlot (cells at OD590 = 1.00 ± 0.05 
frozen with 10% glycerol, stored at -140° C) and grown in 500 ml shake flasks containing 
200 ml medium at 35° C, on an orbital shaker at 200 RPM. When the starting culture reached 
OD590 = 1.00 ± 0.05, it was used to inoculate a bioreactor. Start density was OD590 = 0.050 
(± 0.005) for all cultivations. 
Bioreactor cultivations
All cultivations were carried out in a fully instrumented 7 L in situ sterilizable bench-top 
bioreactor with six-bladed Rushton turbine (Applikon, Schiedam, The Netherlands). After 
the bioreactor was filled with 4 L THIJS medium and reached set point temperature and 
100% dissolved oxygen (DO), it was inoculated with 200 ml preculture with an optical 
density at 590nm (OD590) of 1.00 ± 0.05. Temperature, DO, pH and stirrer speed were 
controlled at 35 ± 0.1° C, 30 ± 2%, 7.2 ± 0.1 and 450-650 rpm, respectively. A low-drift 
polarographic electrode (Applikon, Schiedam, The Netherlands) measured the dissolved 
oxygen concentration, while pH and temperature were measured by a glass pH electrode 
(Mettler Toledo, Tiel, The Netherlands) and a Pt100 temperature sensor (Applikon, 
Schiedam, The Netherlands), respectively. All sensors were connected to the ADI-1040 
bioreactor control system (Applikon, Schiedam, The Netherlands), which was operated 
using BCSV software (Compex, Ghent, Belgium). DO was first controlled with increments 
of 50 rpm in stirrer speed until the 650 rpm maximum was reached. After this set point was 
reached, DO was controlled by increasing the fraction of oxygen in the headspace. Total gas 
flow was kept constant at 1.0 L/min. Samples were taken at time points indicated in Figure 1 
for OD590 and nutrient concentration measurements. Samples were sterile filtered (0.22 µm) 
and stored at -20° C for nutrient analysis. Growth and nutrient consumption data were fitted 
using Tablecurve 2D software (Systat Software, San Carlos, CA, U.S.A.).
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Nutrient concentration analysis
Lactate and glutamate concentrations were determined with 1H-NMR using a JEOL JNM 
ECP 400 spectrometer operating at 400MHz (JEOL, Tokyo, Japan) equipped with a JEOL 
Stacman auto sampler for 16 samples. Supernatants were analyzed by adding 0.1 ml of 
D2O containing 3-(trimethylsilyl)[D4]proprionic acid sodium salt (TMSP, 0.167 mM) to 
a 0.9 ml sample. The water signal was suppressed by irradiating the signal with standard 
NMR software. The spectra were referenced using the TMSP signal at 0 ppm. Lactate and 
glutamate concentrations were quantified by integration of the relevant signals. NMR was 
also used to check samples for any waste metabolites. 
Microarray design
Samples were analyzed using a full genome Bordetella pertussis microarray. Based on the 
complete genome sequence of the Bordetella pertussis Tohama I strain12, a set of 3582 70-
mer oligo nucleotides was developed at Operon (Cologne Germany), covering 93% of all 
open reading frames. Oligo nucleotide pellets were dissolved in 50% DMSO (v/v in water) 
to a concentration of 20 µM and spotted in triplicate on UltraGAPS II coated slides (Corning, 
New York, NY, U.S.A.), together with 420 control spots, using the Omnigrid 100 microarray 
spotter (GeneMachines, San Carlos, CA, U.S.A.). 
RNA isolation
For fixation of the RNA expression profile, 1 volume bacterial culture was mixed with 2 
volumes RNase retarding solution13,14,15. For each microarray sample 2.5 ml cultivation at 
Figure 1. Fitted growth and nutrient 
consumption curves of the 4 identically 
operated bioreactor cultivations. Right Y-axis 
represents growth (optical density at 590 nm) 
and left Y-axis represents concentrations of 
the primary carbon and nitrogen sources in the 
growth medium (mM). Samples were taken 
at 11 time points (A to K), indicated by grey 
vertical lines, that correspond with samples 
for microarray analysis. Error bars indicate 
standard error (SE).
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OD590 = 1.0 was used. Samples at other optical densities were adjusted accordingly, so that 
an equal amount of cells was used for each sample. The samples were concentrated by 
centrifugation and treated with Tris-EDTA buffer, containing 0.5 mg/ml lysozyme (Sigma-
Aldrich, Zwijndrecht, The Netherlands) for 3 minutes. Total RNA was extracted with the 
SV total RNA isolation system (Promega Benelux, Leiden, The Netherlands) according 
to manufacturer’s protocol. Nucleic acid concentration was adjusted by precipitation and 
spectral analysis was used to determine final nucleic acid concentration and purity. RNA 
integrity was confirmed with the Bioanalyzer RNA6000 Nano assay (Agilent Technologies, 
Amstelveen, The Netherlands), according to the manufacturer’s protocol. 
 
cDNA labeling and hybridization reactions
Total RNA from all experimental samples was reverse transcribed to cDNA and labeled 
with Cy3/Cy5 dyes using the Chipshot Indirect Labeling kit (Promega Benelux, Leiden, 
The Netherlands) according to manufacturer’s protocol, with one deviation: 2 µl random 
nonamer primer and no oligo-dT primer was used per reaction to reverse transcribe the 
total RNA. Experimental samples (Cy5) were pooled with a common reference sample 
(Cy3), containing equal amounts of RNA from all experimental samples in the experiment. 
Volumes of the combined cDNA samples were adjusted to 25 µl and an equal amount of 
hybridization buffer was added, to a final concentration of 25% formamide, 5x SSC and 
0.1% SDS. Samples were applied to the microarray slides and placed in a hybridization 
chamber (GeneMachines, San Carlos, CA, U.S.A.) for 16-20 hours at 42° C in the dark.
Data acquisition and analysis
The microarrays were scanned with a ScanArray Express microarray scanner (Perkin Elmer, 
Groningen, The Netherlands) and median fluorescence intensities were quantified for each 
spot using ArrayVision software (Imaging Research, Roosendaal, The Netherlands). The 
expression data were natural-log transformed, quantile normalized, corrected for the common 
reference dye signal and values of replicate spots were averaged. These data processing 
steps were done with the free statistical software R (WU Wien, Austria), using an in-house 
developed script. P-values were calculated using one-way ANOVA statistical analysis and 
adjusted for multiple testing by calculating the False Discovery Rate (FDR). Maximal 
Fold Ratio (FR) values were expressed as the natural log of the maximal normalized signal 
difference between any of the time points. A FDR of 1.0% was used to select genes whose 
gene expression showed a statistically significant difference. To further select for biologically 
relevant effects, only statistically significant genes with a maximal FR above 0.69 (or 2.00 
without natural-log transformation) were included in the final analysis.
Principal Component Analysis (PCA)16,17 and arrangement of differentially expressed genes 
in expression group clusters was performed with Genemaths 2.01 software (Applied Maths, 
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Sint-Martens-Latem, Belgium). Overall gene expression differences between time point 
groups were assessed by calculating the Euclidian distance between natural log transformed 
gene expression values over the entire set of genes (this corresponds to the distance in a PCA-
plot). P-values were calculated by using these distances in a Hotelling T-test. Functional 
categorization of genes was done using the pathway annotations provided by the KEGG 
database. Pathway abundance in expression groups was estimated by calculating the binomial 
distribution probability. Pathways with P-values below 0.05 and also a representation of at 
least 4 genes in any of the expression groups were considered significantly more abundant 
than expected by chance. 
To calculate product quality scores, only genes from the virulence core regulon4 were 
considered. The results from this study were combined with data from a shake flask study, 
aimed to determine the product quality extremes. This was done by comparing the virulence 
core regulon gene expression pattern during mid-logarithmic growth of 4 shake flasks with 
normal growth conditions to 8 shake flasks with virulence repressing growth conditions 
(addition of MgSO4 or niacin to the growth medium4). Natural log transformed gene 
expression values were adjusted with the median of all samples that were expected to give 
high product quality. PCA analysis was done on the resulting values and the scores of the first 
principal component (PC1) were used together with the expression data to fit a linear model 
containing a weight factor for each virulence core regulon gene. Product quality scores were 
calculated on an arbitrary 0 to 10 scale, with a linear relation to the weighted PC1 scores. 
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Results
Bacterial growth and nutrient consumption
Quadruplicate bioreactor cultivations were sampled at 11 time points, A to K (Figure 1), 
for growth (OD590), lactate concentration (carbon source), glutamate concentration (both 
nitrogen source and carbon source) and microarray analysis (see paragraph 3.2). Logarithmic 
growth was observed from time points A to H. The culture becomes stationary during time 
points I, J and K. This growth arrest coincides with lactate depletion at around time point I, 
followed by glutamate depletion at around time point J (Figure 1). Variance on growth and 
nutrient concentrations was low throughout the experiment, as indicated by the error bars 
in Figure 1.
Microarray gene expression profiles
The RNA samples from time points A to K (Figure 1) were analyzed using full genome 
Bordetella pertussis DNA-microarrays12,4. The overall expression profiles of samples at 
identical time points were compared and showed high correlation for time points A to H (R2 
= 0.990 ± 0.003) and good correlation for time points I to K (R2 = 0.962 ± 0.030). Principal 
Component Analysis16,17 (PCA; Figure 2) was then used to identify the main sources of 
variance in the dataset. The first principal component (PC1) has a 67.9% contribution to total 
gene expression variance. The variance explained by PC1 reveals a significant difference 
between the samples at time points K when compared to samples at A to H (p < 0.000054), 
while time points I and J reveal a transitional phase between these two extremes. This PC1-
shift coincides with the lactate and glutamate shortage and growth arrest shown in Figure 1. 
PC2 has only 8.0% contribution and explains the variance within group A to H by dividing it 
in 2 subgroups: time points A to C and D to H (p < 0.151; not significant). The other principal 
components had minor contributions to total gene expression variance and produced no 
significant shifts between time point groups.
The gene expression data was used to select a total of 705 genes that were significantly 
regulated at any of the 11 time points. These genes were clustered in time point-specific 
patterns, which resulted in 4 distinctive expression groups (figure 3A). Group I consists of 
290 genes that are up regulated after time point H while genes from group II (355 genes) are 
down regulated after this point. Group III contains 52 genes that are up regulated during time 
points D to H. These genes are partly annotated to the sulfur metabolism pathway, sulfate 
and amino acid-related ABC transporters and to the cys and met operons, which are both 
involved in the biosynthesis of the sulfur containing amino acids18. Group IV contains the 
remaining 8 genes, with varying expression patterns. (The supplementary data file (table A1 
to A4) contains a summary of the 4 expression groups, with gene ID’s, annotations, average 
expression values per time point and statistical data.)
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Functional categorization of significantly regulated genes
The genes from expression groups I, II and III in figure 3A were mapped to the biological 
pathway classification provided for Bordetella pertussis by the KEGG database19,20. The 
genes of the virulence core regulon4 were included as an additional pathway. Expression 
group IV was disregarded, due to the inconsistent expression patterns of the 8 genes in this 
group. Mapping of 697 remaining genes in the other expression groups revealed that 25 
pathways were significantly more abundant in at least one of the three groups. Compared 
to random distribution, these 25 pathways contained a significantly higher number of the 
regulated genes, 17 of which are depicted in figure 3B. The other 8 pathways had high 
overlap in gene content or function with the pathways in this figure and are therefore not 
shown. (The supplementary data file (table B) contains a list of all 142 KEGG pathways 
and the p-values associated with increased abundancy.) In addition to several pathways 
involved in translation and energy metabolism, genes of the virulence core regulon were 
significantly more abundant in expression group II (p < 0.00001). After time point H, 33 of 
the 56 virulence core regulon genes (59%) became significantly down regulated, including 
bvgS, bvgA, type 2 fimbriae (fim2), pertactin (prn) and filamentous haemagglutinin (fhaB) 
genes. (The supplementary data (table C) file provides a list that shows which virulence core 
regulon genes were down regulated in this study.)
Figure 2. Principal component analysis (PCA) of overall gene expression variance. All 44 samples (4 per time 
point) are depicted in this figure. PC1 (67.9% of total variance) separates time points with logarithmic growth (A to 
H) from time points with stationary growth (time point K; p < 0.000054). PC2  (8.0% of total variance) separates 
time points A, B and C from D to H as indicated by the dashed line (not significant). 
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Product quality scores
The product quality scores were calculated for each time point, using the weighted gene 
expression values of the virulence core regulon genes in a PCA-derived model. This linear 
model includes all 56 genes of the virulence core regulon, because all these genes were 
previously found to be conserved between three Bordetella pertussis strains4.  Furthermore, 
this model was developed to be applicable in future process development, when other subsets 
of the core regulon might be involved. Figure 4 shows the calculated product quality scores 
Figure 3. A: Clustering of 705 significantly regulated genes. Each row represents the relative expression of a single 
gene throughout the cultivation. Column names (A to K) correspond to the microarray time points in Figure 1. 
Genes are classified into four expression groups (I to IV). The color scale runs from strong down regulation (dark 
green), through no regulation (yellow), to strong up regulation (dark red).
B: Analysis of predominant KEGG pathways in expression groups I, II and III. Bold numbers on the right show the 
total number of genes in each pathway. Bars indicate which percentage of the total pathway size is found within 
each expression group. Grey bars correspond to expression group I, black bars to group II and white bars to group 
III. KEGG pathway ID’s are given between brackets.
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on an arbitrary scale from 0.0 (lowest quality) to 10.0 (highest quality). These product quality 
extremes were derived from a bvg-modulation experiment, where a 10.0 score represents the 
average product quality of cultivations under normal, bvg(+) conditions and a 0.0 score is the 
average product quality obtained under modulated, bvg(-) growth conditions. The majority 
of product quality scores in this study was centered around an average of 10.0 (SD = 0.3) and 
includes all quadruplicate samples from time points A to I. Time point J has a lower average 
quality score of 8.9, as compared to time point A to I (p < 0.075; not significant) and time 
point K has a significantly lower product quality score of 6.2 (p < 0.000094), compared to 
time points A to I. (Table D of the supplementary data file contains all data that was used to 
construct the model for calculation of the product quality scores.) It shows the relationship 
between gene expression data, PCA scores, weight factor of each virulence core regulon 
gene and resulting product quality score.
Figure 4. Product quality scores of 
microarray samples at different time points 
throughout the cultivation process. The 
gene expression of virulence core regulon 
genes was used to calculate product quality 
on an arbitrary scale (y-axis), where 0.0 
corresponds to non-virulent conditions 
(bvg-) that indicate a non-protective 
vaccine and 10.0 corresponds to virulent 
(bvg+) conditions, that indicate optimal 
vaccine potency. White circles represent all 
samples taken during the four cultivations, 
the corresponding time points are globally 
indicated on the x-axis. The samples show 
a clear drift from virulent to less virulent 
conditions, which indicates that product 
quality is at risk towards the end of the 
cultivations (time point K).
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Discussion
The bioreactor cultivation method used for this work, with chemically defined growth 
medium10,11 and other previously described improvements4,21, resulted in a highly reproducible 
process in terms of gene expression, bacterial growth and consumption of nutrients 
(Figure 1). Principal Component Analysis (PCA)16,17 confirmed overall gene expression 
pattern similarity of samples at identical time points and revealed a significant shift of this 
pattern towards the end of the cultivation. The first principal component (PC1) in figure 2 
separate samples taken during logarithmic growth (time points A to H) from samples from 
the stationary phase (time point K; p < 0.0066), through the transitional samples at time 
points I and J. Having established robust starting conditions for the cultivation of Bordetella 
pertussis in previous work4, this PCA trajectory now provides a reliable process fingerprint 
for the selection of an optimal harvest point that balances between good quality and maximal 
yield. 
After inoculation, cells entered logarithmic growth that became stationary upon limitation 
of the primary carbon and nitrogen sources (lactate and glutamate, respectively). This 
nutrient limitation induced a gene expression shift by up regulating biosynthesis-related 
ABC transporter genes (Figure 3, expression group I) and down regulating many genes from 
translation and energy metabolism pathways (Figure 3, expression group II). Interestingly, 
lactate and glutamate limitation also induced significant down regulation of 33 virulence 
core regulon genes22,4, 28 of which were previously found to be growth phase and nutrient 
limitation associated by Nakamura et al.23. (The supplementary data file (table E) shows a 
Venn diagram of the overlap between the genes found in this study and by Nakamura et. al.) 
This observation has implications for the quality of the bacterial suspension in its use for a 
whole cell vaccine. 
The use of full genome DNA microarray technology allows investigation of how an organism 
reacts to the continuously changing environment during batch fermentation processes like 
the one presented in this study24,25. Even though nutrient and biomass concentrations changed 
substantially between time points A and H, the overall gene expression pattern remained 
largely unchanged. The genes in expression group III are an exception, but this group is 
relatively small, and the effect was transient, producing a non-significant in PCA shift and 
did not involve virulence core regulon genes. The gene expression profile in all groups did 
change significantly after time point H, when nutrients became limiting. The resulting list of 
down regulated virulence core regulon genes contains many transcripts encoding virulence 
proteins that are known to be important for a protective immune response against Bordetella 
pertussis, like filamentous haemagglutinin (FHA), pertactin (Prn) and type 2 fimbriae26,27 
(Fim2). (See the supplementary data file (table C) for the full list of all core regulon genes.)
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Differential mRNA expression in prokaryotes is more predictive for changes in protein 
expression than in eukaryotes, because eukaryotes modify their proteins after translation to 
a much higher extent. For this reason, the observed down regulation of 33 virulence core 
regulon genes is likely to be closely reflected in the protein composition of the whole cell 
pertussis vaccine that is made from these bacteria and is therefore useful as an predictor for 
vaccine quality. This hypothesis is supported by other studies, that reported a correlation 
between vaccine potency and virulence protein content28 and a lower protective potency of 
vaccines that were harvested during the stationary growth phase8. 
This proposed link between bacterial virulence and vaccine potency was used to develop a 
statistical PCA-derived model for product quality measurement, which condenses the gene 
expression of all known virulence genes into a single number, the product quality score 
(Figure 4). This score allows benchmarking of a cultivation sample to a linear 0 to 10 scale 
for expected vaccine potency. The presented results show a clear correlation between the 
product quality score and nutrient availability, resulting in a significantly lower product 
quality score towards time point K (p < 0.000094). For process optimization studies, 
such a score is crucial when the effects of small changes in process conditions need to be 
distinguished and assessed for impact on product quality. Especially when the mandatory 
potency test is as crude and unreliable as in this case, the need for a quantitative quality scale 
is obvious, not only for process development, but also for clinical testing, where detailed 
information on the potency of clinical batches can be used to interpret the clinical responses 
more accurately29. 
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Conclusions
To assure maximal quality and potency of the whole-cell vaccine, Bordetella pertussis batch 
fermentations should be harvested during logarithmic growth, before the critical concentration 
of 2 mM of either lactate or glutamate is reached, which corresponds to time point H. In this 
way rational, biologically relevant criteria are used to determine the optimal harvest point 
in respect to both yield and product quality. After determining the starting conditions in 
previous work4, this study now provides a rational, science based harvest point for the batch 
fermentation process of Bordetella pertussis in whole-cell vaccine production. 
DNA microarrays can be a reliable tool for assessing process performance and generating 
process understanding, but are labor intensive and can only be used to test a limited number 
of samples. Implementation of typical Process Analytical Technology (PAT)9 sensors such as 
near infrared spectroscopy (NIRS) during batch fermentation, would generate a continuous, 
multivariate process fingerprint of the inoculation-to-harvest trajectory. On-line monitoring 
of nutrient concentrations for automated detection of the harvest point is also possible 30,31,32. 
Such a science-based PAT approach, in combination with the presented model to measure 
product quality, could result in a process that yields whole-cell vaccines of such intrinsic 
quality and consistency33 that it would change the perspective for the use of the Kendrick 
potency test34,35. Not only is this test cruel for the animals, it is also highly variable and 
gives yes or no answers at best (i.e. protection or no protection)36. With growing scientific 
confidence in the more consistent quality of vaccines produced with PAT controlled processes, 
the need for animal release tests on every single batch will eventually decline9. Additional 
research that validates the correlation between gene expression-based product quality scores 
and the potency of vaccines as measured with mandatory animal tests, could provide the 
scientific basis needed to take the next step in this direction.
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Abstract
An illustration of the operational consistency of the upstream part of a biopharmaceutical 
process is given. For this purpose four batch cultivations of Bordetella pertussis have been 
executed under identical conditions. The batches have been monitored by means of two 
fundamentally different process sensors. First, common single channel measurements such 
as temperature, pH, dissolved oxygen (DO) and flow rates are used and secondly the multi-
channel measurements from the NIR (Near Infrared) analyzer. Because of the fundamental 
differences between the two types of measurements, two models have been developed to 
evaluate the operational consistency. The last sensor studied is a typical representative of 
process analyzers which are described in the PAT (Process Analytical Technology) guidance 
document issued in 2004 by the American Food and Drug Administration (FDA). Data 
from both sensors have been evaluated by a multivariate tool for data acquisition. This 
resulted in two different performance models. Again this approach is characteristic for the 
implementation of PAT for the manufacture of biopharmaceuticals.  
With both performance models, we were able to explore the operational consistency of the 
batches. In addition, the performance models were also able to detect a deviating batch. 
Furthermore, it was shown that both sensor types gave partly overlapping information since 
a deviation in the batch profiles of the logged process variables was accompanied by a 
deviation in the spectral batch profiles.
The performance models are valuable tools in developing advanced monitoring and control 
systems for biopharmaceutical processes. Using such models, advanced knowledge based 
systems can be developed to detect abnormal situations in an early stage and remove the 
cause.
The way of data processing described in this paper is relatively new in the biopharmaceutical 
industry. The NIR analyzer and both performance models presented in this paper are clear 
ingredients for better process understanding and process control, as intended in the FDA’s PAT 
Initiative. This initiative is part of the FDA’s strategy of cGMP (current good manufacturing 
practice) for the 21st Century and aims at introducing innovations in both the manufacturing 
of biopharmaceuticals and the development of new biopharmaceuticals.
This study shows the feasibility of two typical PAT tools for controlling the manufacturing of 
biopharmaceuticals. To the best of our knowledge such feasibility study is not documented 
up to now in the scientific literature.   
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Introduction
The production of most biopharmaceuticals such as Bordetella pertussis vaccine is usually 
performed in a batch wise manner. Batch processes are characterised by a recipe driven 
process. That is, they have a clear starting point, an end-point and non-linear trajectories. 
Biochemical processes as the cultivation of Bordetella pertussis, are driven by the underlying 
biochemical reactions. As a result there exists a dynamic system with a predictable outcome. 
However, cultivation processes are liable to all kinds of variations that can influence the large 
number of simultaneous reactions and processes1. These variations can strongly influence 
the processes in a negative manner, leading to unpredictable behaviour. The approach 
of controlling and monitoring (bio)-pharmaceutical processes to a desired end-point is 
encouraged by regulatory authorities and described in the FDA’s Guidance for Industry on 
Process Analytical Technology (PAT). A full version of the document can be downloaded 
from the FDA’s website www.fda.gov/cder/gmp/gmp2004/guidance/6419fnl.pdf. 
The goal of the FDA’s PAT initiative is to break the barrier that strict regulation has formed 
against flexible processing and to bring the pharmaceutical industry to the current state of 
the art of industrial processing and as already indicated the introduction of innovation in the 
manufacturing and development of biopharmaceuticals. 
While batch production runs are performed according to a recipe, experience learns there can 
be differences between identically operated batches. These differences become apparent in 
the profiles of the logged process variables and in the end product quality. The cause of these 
differences can often be found in variations in the starting materials used for the cultivation, 
operating conditions or manual interventions by the operators during the execution of the 
cultivation step. For the production of biopharmaceuticals such as vaccines, it is therefore 
very important to monitor and control process variations and prevent and reduce unknown or 
abnormal process situations in order to reduce the non-acceptable risks inherent to this more 
‘classical’ way of manufacturing biopharmaceuticals.
To monitor the evolution of a batch process, it is common to take samples during the 
operation of a batch for (bio)-chemical analysis. Furthermore, modern process hardware is 
equipped with single channel sensors such as pressure or temperature sensors. In addition, 
industrial processes are equipped with multi-channel sensors such as spectroscopic process 
analysers. Both sensors are very informative for the current state of the process but they 
are fundamentally different in nature. This results in different, yet complementary types of 
process information. 
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The basic idea behind consistency analysis is that a guaranteed product quality is obtained 
by producing in a consistent manner. It is a priori not always known what the effects of 
variations are on the end-product quality. It is therefore important to work proactively and 
monitor and secure the critical attributes of the production chain. However, before developing 
monitoring and control applications, it is important to understand the variations present in 
the data. 
To understand the variation present in a production process historical process data can be 
collected and analysed. In practice, it is often the case that many operational process changes 
have taken place such that the historical data is not representative for the current manner of 
production. However, although changes have been made, the historical data will give insight 
on the working of the process and will help to identify bottlenecks. Based on such an analysis 
critical attributes can be identified and used for controlling and securing the process. 
The ultimate goal is a well controlled process with a guaranteed end-product quality. This can 
only be realized by monitoring the critical process attributes for the entire production chain. 
It can be expected that if all critical process attributes operate within predefined or statistical 
control limits, a guaranteed good quality product is produced. Besides the determination of 
the critical process attributes and derivation of acceptable limits of operation a first start is to 
study the current way of operating each unit operation on a pilot scale.
The aim of this paper is to illustrate a method for processing of data from both single and 
multi-channel sensors for assessment of process consistency on a pilot scale. The described 
process and process measurements are the first step of an optimization program. The 
experiments are expensive, therefore, prior to performing experiments according to an 
experimental design it should be verified wheter the process can be operated stable around 
a process mean.  
To verify the operational consistency of the cultivation, four batch cultivation runs of 
Bordetella pertussis bacteria have been operated in an identical way. The cultivations are 
carried out in a bioreactor that is equipped with standard process sensors (temperature, DO 
and pH) and a near infrared (NIR) sensor.
The bacterial cultivation of the Bordetella pertussis 
Bordetella pertussis bacteria were cultured on the chemically defined THIJS medium 
Thalen et al.2, which is designed to meet the bacterium’s nutritional demands. Using such 
a chemically defined medium eliminates variation that is commonly caused by undefined 
medium components such as yeast extract. The medium contains two essential nutrients, 
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lactate and glutamate. Glutamate is essential for growth while lactate enhances the growth 
rate.
All bioreactor experiments were carried out in a 7 L in situ sterilizable glass bioreactor 
at a working volume of 4 L. Temperature, dissolved oxygen (DO) concentration, pH and 
stirrer speed were controlled at 34°C, 30%, 7.2 and 450-650 rpm, respectively. Oxygen 
concentration was first controlled with increments of 50 rpm in stirrer speed until 650 rpm 
was reached. Subsequently, DO was controlled by increasing the fraction of oxygen in 
the headspace. After the bioreactors were filled with 4L THIJS medium and had reached 
setpoint temperature and DO=100%, they were inoculated with 200 ml preculture at optical 
density at 590 nm (OD
590
)=1.0±0.05. Samples were taken for OD
590
 and at line nutrient 
concentration measurements (lactate and glutamate) using a YSI 2700 analyzer (Yellow 
Springs Instruments, Yellow Springs, USA). Samples were sterile filtered (0.22 μm) and 
stored at -20°C for later NMR (Nuclear Magnetic Resonance) analysis for confirmation 
of the nutrient concentrations. The bacteria were cultured until a final optical density of 
OD
590
=1.5±0.1 was reached.
Process information from the two different types of sensors
Prior to discussing the mathematical tools for the explorative analysis, it is important to 
realize that in the current analyses there are two distinct types of process data. The first 
type is the commonly known as ‘engineering variables’ or single channel sensors. The 
engineering variables usually consist of physical process information such as dissolved 
oxygen concentration, temperature and pH. The second type of process data is multi-channel 
data from process analyzers such as near-infrared (NIR) spectroscopy. Data obtained from a 
NIR process analyzer is rich in biochemical information and characterised by a high degree 
of collinearity between the variables in the data. 
Within the single channel measurements, there is a distinction in nature of logged process 
variables; first, there are discrete variables such as set-points and valve settings, and second, 
there are the dynamic (continuous) variables such as temperatures or viscosity. 
Extraction of chemical information from NIR spectra requires experience with such a process 
analyzer. NIR spectrometers acquire spectra in the range between 12000 cm-1 and 4000 cm-1. 
NIR-active components such as the substrates, which absorb in this region, are characterized 
by broad overlapping peaks. This implies that there is no clear and unique region for one 
particular component in the medium during the cultivation of the bacterium, but the whole 
spectral fingerprint is important. To be able to relate this complex medium to concentrations 
of the substrates, samples have been analyzed by the analytical reference methods such as 
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the YSI, Nuclear Magnetic Resonance (NMR) and Optical Density (OD
590
). Next, models 
are developed to relate the spectra to the results of the analytical reference methods.
Consistency analysis
Consistency analysis based on single channel measurements 
Using logged process variables, much insight about the process is gained by simply presenting 
these process variables as time series. In this relative simple manner features such as process 
dynamics and process disturbances can be identified. To give an example, the time series 
of the logged process variables are presented in Figure 1. For the three controllers active 
in the bioreactor control system (pH, DO and Temperature) all controller outputs (CO) and 
control actions (acid flow, air flow, etc) are plotted besides the actual measurements of the 
parameters. This does not only provide insight on the performance of a certain controller, but 
also on the output which the controller had to deliver to keep its setpoint. This is valuable 
information specific for each process run. 
However, if the number of batches and logged process variables increases, which is 
often the case in an industrial environment; it becomes difficult to study these high 
dimensional data. A tool often used in industry to study a high dimensional dataset is a 
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Figure 1. Time series for the logged process variables of the four consistency runs. 
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subspace model constructing using principal component analysis, PCA3. The aim of 
a subspace model is to capture the systematic information of a high dimensional dataset 
consisting of collinear data (such as industrial process data) and project it onto a lower 
dimensional space without loss of information. Next, the lower dimensional space is 
explored.
There are many ways to model an industrial batch process using subspace models. The choice 
of the model depends for a large extent on the aim of the experimenter and the availability 
of historical data. In the early nineties the first strategies to study the batch consistency 
were proposed4,5,6. Following the ideas of Nomikos and MacGregor several alternatives were 
suggested to model the data. A detailed overview of possible batch modelling strategies 
can be found in Lee and Vanrolleghem7 and Van Sprang et al.8. In addition, a more detailed 
discussion and applications of these methods in a PAT context can be found in Kourti9, 
Lopes et al.10 and Wold et al.11. 
Consistency analysis of single channel measurements 
As stated earlier, the focus of this study is to determine if the cultivation step is reproducible 
in terms of operational conditions prior to executing designed experimental batch runs. As 
a result there are only four batch runs available. Since there are only four runs available it is 
impossible to make any statements based on statistical arguments. However, by comparing 
the individual trends in a reduced space a fair impression of the operational consistency is 
obtained. 
A series of batch runs can be presented as a three-way array X (I x J x K), where I is the 
number of batches, J the number of process variables and K the number of observations. The 
two often used approaches to model the three-way array are the approaches suggested by 
Nomikos and MacGregor4 and Wold et al.6.
In the approach of Nomikos and MacGregor, the three-way array X is unfolded in the batch 
direction leading to the matrix X (I x JK).  Next, X (I x JK) is modelled using a PCA model 
with R latent variables as shown in equation (1).
X = TPT+E (1)
where the loadings P (JK x R) capture all systematic behavior. The score matrix T (I x R) 
represents the differences and similarities between the batches with respect to this systematic 
behavior and matrix E captures the unmodeled variation. The model of eq (1) is fitted using a 
least-squares approach, hence, by minimizing the sum-of-squared residuals of E.
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In the approach of Wold et al.6, the three-way array X is unfolded in the variable direction 
leading to the matrix X
w
 (KI x J).  Next, X
w
 (KI x J) is modelled using a PCA model with R 
latent variables as shown in equation (2).
X
w
 = T
w
PT
w
 + E
w
, (2)
where the loadings P
w
 (J x R) capture the overall systematic behavior between the variables. 
The score matrix T
w
 (KI x R) captures the dynamic behaviour of the batches in the model 
plane and matrix E
w
 captures the unmodeled variation.
Note that the proposed strategies assume that all batches have time trajectories of equal run 
length. If that is not the case, synchronization strategies such as dynamic time warping must 
be used to align the batches12. The essential difference between (1) and (2) is the way the 
batches are treated. In (1) the behaviour of a batch is summarized in R numbers (one row 
of T), whereas in (2) the behaviour is summarized in K x R numbers (the part of T
w
 related 
to the specific batch). Loosely stated, in (1) each batch is considered as one observation, 
whereas in (2) each time-point in one batch is considered as one observation.
Process data is usually measured in different units. The difference in units can give certain 
process variables an unfair weight of importance in the models. Therefore, prior to modelling 
process data should be standardized (also referred to as pre-processing). The choice of pre-
processing is depending on the aim of the analysis. Sometimes it is desired to give certain 
process variable more or less weight depending on the interest of the analysis. It is important 
to realize that the results of the analysis can be affected by the choice of pre-processing. 
When working with process variables it is common to standardize the data to unit standard 
deviation and mean zero, which is referred to as autoscaling.  
If a relative high number (~ 40) of batches is available for analysis the method as proposed by 
Nomikos and MacGregor4, is well suited to study the batch consistency. Similar batches will 
be clustered together in the model plane and the loadings can be explored for correlations 
between process variables. As stated earlier, the current dataset consists of four batches which 
are assumed to be identical. Using the approach of Nomikos and MacGregor4 with only four 
observations is not very informative since this leads to four points in an R dimensional space. 
Furthermore, there is not enough data to estimate the model parameters properly. Hence the 
approach of Nomikos and MacGregor4 is not used in the current analysis. 
A possible model strategy that can be used for the current dataset is a leave one batch out 
version of the method suggested by Wold6. The principle idea is to leave one batch out of 
the set of available batches and use the three remaining batches to develop a model. Next, 
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the left out batch is projected onto the model and the obtained score trajectories and model 
residuals are used for exploring the operational batch behaviour. This process is repeated 
until all batches are left out once and projected on the model built with the remaining ones. 
Since the batches are operated under identical conditions it is expected that similar profiles 
are found for each batch run. 
In the present study, there are four experimental batches operated under identical conditions 
including the termination of a batch. The batches are denoted as batch 11, batch 12, batch 
13 and batch 15. Each batch has a total of K = 1490 observations and J = 12 logged process 
variables as presented in Figure 1. The data are modelled using the leave one batch out 
approach. Prior to modeling, the data is column mean centered and divided by its standard 
deviation. The number of latent variables is determined using a full-cross validation. In total 
four models are developed. The explained variation per model is presented in Table 1.
Table 1. Percentage explained variation per model using a leave one out strategy for the modelling approach 
suggested in Wold et al.18 
Batch not included
PC 1 percentage
explained 
variation
PC 2 percentage
explained variation
PC 3 percentage
explained variation
Total percentage
explained variation
Batch 15
Batch 11
Batch 12
Batch 13
50.4
49.0
61.4
47.5
15.4
16.1
14.9
16.3
9.4
9.2
7.8
9.9
75.2
74.3
84.1
73.7
Table 1 shows that leaving out batch 12 increases the amount of explained variation with an 
equal number of latent variables compared with the other models. This is an indication that 
the batch 12 has a different behaviour. 
The scores Tlo of the left out batches are found by projecting the observations onto the model 
plane Plo according to:
tTk,lo = xTk,loPlo  (3)
By presenting the new scores tk,lo obtained after projecting the observations for the left out 
batches the batch evolution is easily visualized as can be seen in Figure 2 (a), (b) and (c). 
There, the dynamic behaviour between the four batches is compared. The corresponding 
residuals are found by:
ek,lo = xk,lo - Plotk,lo (4)
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Next, the trajectories of the sum of squared residuals (SSE) are visualized as time series in 
Figure 2 (d).
Figure 2.  Results of monitoring the batch profiles using PCA. The dynamic behaviour for the first latent variable 
(a). The dynamic behaviour of the second latent variable (b). The dynamic behaviour of the third latent variable (c). 
The unmodeled variation (d).
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Figure 2 shows the dynamic behaviour of the four batches presented in the first three latent 
variables. The unmodeled variation is captured in the SSE. The first latent variable in Figure 
2 (a) shows that Batch 11, Batch 13 and Batch 15 follow a similar trend. However, Batch 
12 follows a distinct pattern both in the dynamic behaviour in the first component and in 
distance from the model plane (SSE) Figure 2 (d). The second latent variable in Figure 2 (b) 
shows that the batches suffer from large variations but seem to follow a similar trend except 
for batch 13 that shows a deviating pattern in the first 500 observations during its evolution. 
Further analysis learns that this behaviour corresponds to a deviating pH signal for batch 
13. 
The third latent variable is not very informative. The unmodeled variation captured by the 
SSE shows a higher contribution over time for batch 12. The behaviour of batch 12 was 
unexpected; a more detailed analysis learned that the pH control during the operation of 
Batch 12 was problematic. This is due to the settings of the control system. Apparently, the 
required control action is not sufficient to keep the process under control or a stronger control 
action was required. Furthermore, a high contribution is observed for batch 15 starting from 
observation 1000. Further analysis learned that this behaviour is related to the temperature 
behaviour of this batch.
Consistency analysis using multi-channel data (NIR spectra)
To relate measured NIR spectra to the attributes of interest (lactate, glutamate and the 
optical density) a calibration model is constructed. Because of the nature of NIR spectra (the 
presence of collinearity and overlapping peaks) a multiple regression model is constructed 
usually based on Principal Component Regression (PCR) or Partial Least Squares (PLS). 
During the development of a multivariate calibration model for use within an industrial 
environment a number of challenges are faced. The complexity of the sampling matrix 
and low concentration levels (~1 mmol/l) requires some effort. It is very important to have 
representative samples with the attributes of interest within the sample matrix. Although this 
may seem trivial, it often happens that due to a lack of scrutiny, samples are collected and 
presented for calibration that are not representative for samples under operational conditions. 
In addition, there should also be enough analyte signal in the spectra to create a calibration 
model. The latter is enhanced by spectral data processing strategies13. The choice and type of 
transformation strongly depends on the used sampling interface such as measurement type 
(reflection, transmission) and measurement environment (the sampling matrix).
In some situations, it might be the case that there are no reference measurements available to 
create a calibration model. Then, it is possible to develop models based on process spectra 
only14 and use those directly for monitoring.  
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Assuming having a series of I batch processes that are monitored during their batch evolution 
using spectroscopy, for each observation k a spectrum with J channels is obtained. Next, 
the collected spectra can be arranged in a three-way array X (I x J x K). Depending on the 
situation, there are in principle two choices. 
The first choice is modeling the process spectra using a subspace model in a similar manner 
as discussed in the previous section. That is, the three-way array with collected process 
spectra X (I x J x K) is unfolded in the variable direction resulting in a matrix Xs (KI x J), 
where I is the number of batches, J the number of channels and K the number of observations. 
Next, the data is modeled according to:
Xs = CST  + Es (5)
where C (KI x Rs) captures the relative concentrations in a Rs dimensional space, and S (J 
x Rs) captures the spectral information of the absorbing components and defines the model 
plane in the Rs dimensional space. 
The behaviour of new batches is studied by projecting observations xs,k (J x 1) on the spectral 
model plane S. In this manner ck is obtained. Next, the dynamic behavior of the batches can 
be studied by presenting the quantitative part as time series
The second choice is to incorporate a priori known process information into the model 
parameters. This can be done by putting restrictions on the model parameters during the 
development of the model. A more detailed discussion is given in Ramaker et al.15; van 
Sprang et al16. 
 
An example of the acquired spectra is given in Figure 3. The spectra are obtained with a 
Bruker Optics Matrix F NIR using 5 mm path length and a 1cm-1 resolution.
In Figure 3 the evolution is shown of a batch captured by the NIR analyzer. In this study 
there are three attributes of interest: 1) Lactate, 2) Glutamate and 3) the Optical density. For 
each of the attributes a multivariate calibration model is developed.
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Developing NIR calibration models using PLS  
As stated previously, projection to latent structures (or partial least squares, PLS) is a 
commonly used regression technique in spectroscopy to regress a response variable y (one 
of the attributes of interest) on a set of predictors spectra X (N x J). PLS is a subspace 
regression method which maximizes the covariance between the scores t,y. This is done per 
dimension and finally collected in a matrix T. The matrix X is decomposed in three matrices 
T, P and E. The score matrix T (N x R) is made up of R score vectors. Matrix P (J x R) is 
loading matrix with R loading vectors and matrix E (N x J) consists of the model residuals. 
Vector y is decomposed in a weight matrix q (R x 1) and residual vector f (N x 1).The PLS 
decomposition is given in matrix notation in equation (6) to (8).
Xs = TPT  + E  (6)
  
y = Tq  + f  (7) 
  
T = XW(PT W)-1 (8) 
 
where the matrix W (J x R ) is an orthogonal weight matrix. Using the model parameters W, 
P and q, the response variable y is predicted on-line each time a new observation  (J x 1) is 
measured according to equation 9 and equation 10.
t’
new
 = xT
new
 W(PT W)-1 (9)ˆ
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Figure 3. Raw spectra obtained 
for one batch run (batch 11). 
Spectra move from bottom to top 
during batch evolution.
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y = tT
new
q (10) 
An approximate prediction interval for the individual response at (1- α)×100 confidence 
level is given by
  
y + tv,a/2s(y-y) (11)
where tv, a/2  is the (1-a/2)th quantile of a t-distribution with v degrees of freedom and s(y-y) 
denotes the estimation of the standard error of prediction17.    
The calibration models were based on 52 samples, which are collected during the four 
batch runs. For each sample a spectrum is taken and analyzed accordingly by the analytical 
reference methods discussed in Section 2. The models are developed using an iterative 
approach. First, the spectra are screened to select informative spectral regions. This means 
that noisy regions from the data are removed. This first screening is primarily based on 
visual inspection of the spectra and theoretical knowledge about existing absorption bands. 
Next, the spectra are pre-processed by taking the second derivative spectra to remove 
unwanted variations from the spectra such as scatter effects or baseline shifts/drifts. The 
number of latent factors, or components, is determined by a full cross-validation. During 
this exercise outliers are removed from the data and a re-calibration is started. Then, the 
iterative procedure is stopped. Normally, model development can take several iterations in 
order to optimize the model. In the current study, the number of samples is not enough for 
a full model optimization and model validation but enough to generate models that give a 
reasonable prediction to monitor the dynamics of the attributes. 
Operational consistency based on NIR spectra
The model settings and outcomes are presented in Table 2. From this table, it can be seen that 
the calibration error measured by the Root Mean Square Error of Calibration (RMSEC) for 
lactate and glutamate are approximately 1 mmol/l. Closer inspection of the model residuals 
reveal that the models have more difficulties to predict the lower lactate and glutamate 
(< 2 mmol/l) concentrations. Probably, the absorption signal of lactate and glutamate are 
too low at those concentrations. Normally, the calibration error of the cross validated 
models, expressed as the Root Mean Square Error of Cross Validation (RMSECV)18, are 
approximately an order of 1.5 / 2 higher compared to RMSEC. The results show that this is 
indeed the case. 
ˆ
ˆ ˆ ˆ
ˆ ˆ
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Table 2. Model settings and prediction results. 
Explained 
variables
Latent 
variables
RMSEC
(mmol/l)
RMSECV
(mmol/l)
Selected spectral region
(cm-1)
Lactate
Glutamate
Optical density
7
3
5
1,1
0,9
0.1
1,6
0,8
0.2
5400 - 6300 & 7160 – 9000
5400 - 6300 & 7160 – 9000
7160 – 9000
The batch profiles for lactate, glutamate and the optical density as predicted by the calibrated 
NIR sensor are presented in Figure 4.
Unfortunately, due to a software error it was not possible to collect the full spectral trajectory 
for Batch 15. Therefore, only the results for batch 11, batch 12 and batch 13 are presented. 
The spectral batch profiles of batch 11 and batch 13 shows again a consistent behaviour as 
expected. However, batch 12 shows a clear distinctive pattern for all three predicted quality 
characteristics. The first observation is the deviating behaviour in the early evolution of the 
batch run (observation 0 – 500). From Figure 4(c) it seems that a certain start-up time was 
necessary to reach a similar level as batch 11 and batch 13. Further analysis is necessary 
to search for a cause of this behaviour. Moreover, the relation between the changes in the 
logged process variables and the accompanying changes in the spectral profiles should be 
explored. 
Taking into account the information given in the previous section and, therefore, ignoring 
batch 12, it can be concluded that the two remaining spectral batch profiles follow a similar 
pattern implying a consistent operation.
An additional note should be made for the estimated profiles of the attributes. As can be seen 
from the time series for the predicted attributes, there is a strong correlation between the 
predicted attributes. At this point it is not clear if the models are able to predict the individual 
attributes or a combination of the attributes. That is, is the model predicting a correlation of 
two attributes or are the models able to discriminate between the individual attributes. To 
confirm that the actual attributes are predicted additional experiments are carried out.  
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Sensor fusion: combining single channel sensors with multi-channel 
sensors
Studying the responses of the different types of sensors separately gives complementary 
information about the process. Sometimes it is also revealing to combine the sensors in 
one global analysis; this is called the sensor fusion approach. A few suggestions on how to 
Figure 4. Predicted values for optical density (a), glutamate (b) and the lactate (c) during the batch operation.
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combine the two types of sensors will be discussed shortly. 
Depending on the situation, there are different strategies to follow. If it is not possible 
to develop calibration models for the attributes of interest, a performance model can be 
developed taking into account the different nature of sensors. This can be done by constructing 
a concatenated observation matrix Xobs, 
Xobs =   Xprocess variables    Xspectra  , (12)
where Xprocess variables are the logged process variables and Xspectra the measured NIR spectra. 
By taking into account the nature of the data and a subsequent proper pre-processing of the 
data, a model can be constructed on this concatenated matrix. Using the model in a similar 
way as discussed previously in Section 4.2, an overall view of the batch behaviour will be 
obtained. That is, because of the nature of the used modelling approach, spectral information 
is merged with the engineering variables19,20,21. 
If a distinction has to be made between the absorbing components and engineering data, it is 
possible to summarise the spectra by the predictions of the attributes of interest. That is, if it 
is possible to develop calibration models for the attributes of interest, the predictions can be 
used to develop a new model. This is done by taking the predictions of the Q attributes and 
arrange these in a matrix Acon (K x Q) and simply construct an observation matrix made up 
of the logged process variables Xproces variables and Acon (K x Q).  
Xobs =   Xprocess variables    Acon (13)
Next, a model is developed by applying a similar approach as above (Section 4.2) and the 
operational consistency is evaluated. In addition, if deviations occur it is now much easier 
to assign causes to this deviation. With the current matrix Xobs the individual contribution of 
each of the variables to the observed signal is assigned by means of contribution plots but 
that is beyond the scope of this paper22. 
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Conclusions
In this paper, PAT related data are presented obtained during the execution of the batch-wise 
cultivation of Bordetella pertussis. In addition, well-defined seed material and a completely 
defined medium have been used. These are ideal production conditions to illustrate the use 
of two characteristic tools mentioned in the PAT guidance document for the most critical part 
of the manufacturing of biopharmaceuticals.
The results are presented of multivariate analyses obtained of process data and data obtained 
from the NIR analyzer. The results showed that three of the four cultivations are comparable 
in terms of evolutionary behavior. The NIR data are presented in a quantitative way (optical 
density and the two substrate levels) and showed a somewhat less reproducible picture than 
expected. 
Based upon the information obtained in this paper, the conclusion can be drawn that the 
reproducibility of the cultivation step is high and that both types of PAT tools are very appropriate 
to monitor the upstream part of manufacturing processes of biopharmaceuticals.
We realize that this paper is only the first step in the introduction of the two PAT tools for the 
manufacturing of biopharmaceuticals. Despite the limitations due to the size of the study, 
the data presented are supporting the feasibility of the PAT initiative of the FDA for the 
manufacturing of biopharmaceuticals. 
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Abstract
A licensed pharmaceutical process is required to be executed within the validated ranges 
throughout the lifetime of product manufacturing. Changes to the process, especially for 
processes involving biological products, usually require the manufacturer to demonstrate 
that the safety and efficacy of the product remains unchanged by new or additional clinical 
testing. 
Recent changes in the regulations for pharmaceutical processing allow broader ranges of 
process settings to be submitted for regulatory approval, the so called process design space, 
which means that a manufacturer can optimize his process within the submitted ranges after 
the product has entered the market, which allows flexible processes.
In this paper, the applicability of this concept of the process design space is investigated for 
the cultivation process step for a vaccine against whooping cough disease. An  experimental 
design (DoE) is applied to investigate the ranges of critical process parameters that still 
result in a product that meets specifications. The on-line process data, including near infrared 
spectroscopy, are used to build a descriptive model of the processes used in the experimental 
design. Finally, the data of all processes are integrated in a multivariate batch monitoring 
model that represents the investigated process design space. This paper demonstrates that the 
general principles of PAT and process design space can be applied to an undefined biological 
product such as a whole cell vaccine. The approach chosen for model development described 
here, allows on line monitoring and control of cultivation batches in order to assure in real 
time that a process is running within the process design space. 
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Introduction
“The process design space is the multidimensional combination and interaction of input 
variables (e.g., material attributes) and process parameters that have been demonstrated 
to provide assurance of quality”1. This is the definition of process design space proposed 
by ICH, the International Conference for the Harmonization of Pharmaceutical Regulation. 
The word design indicates the requirement for a rationale behind process development. 
The design of a process that can consistently assure the yield of products with the desired 
quality is one of the key elements of the Process Analytical Technology (PAT) initiative 
introduced by the American Food and Drug Administration (FDA) in 20042. The FDA 
defines PAT as a “system for designing, analyzing and controlling manufacturing through 
timely measurements of critical quality and performance attributes of raw and in-process 
materials and processes, with the goal of ensuring final product quality.”
The development and use of a design space is concisely described in the Annex to the ICH 
Q8 Guideline on Pharmaceutical Development1. Originally, the concept of PAT and design 
space applied only to chemical drugs. However, the principles behind PAT and the design 
space can be readily extended to biopharmaceuticals as is demonstrated in this paper and 
reported earlier by others3. 
Prior to the introduction of the design space concept, process validation relied initially on 
the execution of three consecutive conformity batches that demonstrated process robustness. 
Although this “rule of three” was never mentioned in the official FDA guidance on process 
validation4, it became the standard for (bio)process validation. Amendments to the validation 
guidance eventually resulted in replacement of this rule with the requirement that the 
manufacturer should demonstrate process reproducibility and consistency throughout full 
scale manufacturing.  In all cases, excursions from the validated process must be reported 
as deviation to the regulatory authorities. Thus, manufacturers are bound to execute their 
processes within the validated specifications, unless they revalidate the changed process 
with additional product testing that demonstrates product comparability5. Sometimes even 
additional clinical trials are required. For complex biopharmaceuticals such as classical 
vaccines, this “process is the product” paradigm made it almost impossible to make changes 
to the process without clinical confirmation that the product remains potent, safe and 
otherwise comparable to the original product. 
The design space concept allows manufacturers to move away from fixed processes, permitting 
process variation after sufficient understanding and control of the process and knowledge 
of the impact of process variation on product performance have been demonstrated. In such 
a case, a change of the process settings or trajectory within an approved design space is not 
considered a deviation in the regulatory sense of the word (i.e. it does not require regulatory 
approval). 
One way of demonstrating the understanding of the process and its variation is to investigate 
Exploration and Modelling of the Design Space of a Bacterial Vaccine Culivation Process
101
6
the critical process parameters using Design of Experiments or DoE6. DoE investigates not 
only the impact of the variation of a single, critical parameter, but also any interactions 
that these critical parameters might have with each other. For instance, a process might 
be running fine at high temperature or low pH, but the combination of these two process 
conditions could be unfavorable for product quality. 
The mapping of a process begins with an understanding of the critical product quality 
attributes, for example, in the case of vaccines, the antigens that induce the protective immune 
response. The next step is the identification of those process parameters that influence process 
performance (e.g. yield) or the critical product quality attributes (e.g. antigen expression). 
These parameters can be anything from the quality of (complex) starting materials (such as 
bovine serum or yeast extract) to the pH and temperature during processing. 
Once the critical process and product attributes are known, the failure limits of the process 
can be investigated. These are the limits of critical process parameters at which the critical 
product quality attributes are so compromised that the product will no longer meet its 
specifications or that the process will fail altogether. With existing products, some specific 
limits are well known to the operators that run the process routinely, while others are generally 
known to be common for a broad range of processes. For instance the upper temperature 
limit of a cultivation process step can usually not exceed 40 °C for most organisms, because 
cellular processes are radically changed or even disrupted at high temperatures. The failure 
limits or critical limits for any remaining parameters can be investigated with a series of 
simple experiments, such as we reported for dissolved oxygen concentration7. 
The combination of the failure limits does not, by itself, constitute a design space since it 
provides no means for predictions outside of the actually tested settings. Rather, the knowledge 
gained from the evaluation of failure limits can be used to devise a DoE experimental matrix 
to determine the design space. The results from a DoE experimental matrix can be modelled 
so that predictions can be made for a continuous range of settings and their interactions, based 
on a discrete number of tested settings. Test values for the critical process parameters that 
are known to yield product of specified quality within the process failure limits are selected 
for the matrix. The tested ranges of the critical parameters then provide the boundaries of a 
multidimensional space having the number of its dimensions equal to the number of critical 
parameters in the design. 
Biopharmaceutical products are typically produced in a batch-wise manner, and this gives 
rise to three-way data arrays: batch number vs. processing time vs. process parameters 
(see also Fig. 2). Chemometric methods such as principal component analysis (PCA) and 
partial least squares (PLS) calibration models8 can be used to model the three-way batch 
data in order to provide tools for understanding, fault detection, control, and prediction. The 
resulting dynamic control models can be used to describe a (partial) design space, taking into 
account the evolution of parameters during processing.
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In this paper, we investigate the design space for the cultivation of Bordetella pertussis 
bacteria. This is the key process step in the manufacturing of a whole cell vaccine against 
whooping cough disease. A whole cell vaccine means that the whole bacterial cell is the 
actual product, in contrast to, for instance, sub unit vaccines in which only purified membrane 
proteins are used. The downstream processing of such a vaccine involves only inactivation 
and concentration of the cells without a purification step. Thus, the most critical product 
quality characteristics are already defined at the end of the cultivation process. 
The DoE explores the design space for this process step through variation of the critical 
independent process parameters (within their failure limits) in order to determine what, 
if any, combination of parameter values results in insufficient product quality. The failure 
limits were usually known before the experimentation, this knowledge resting on the fact 
that the Netherlands Vaccine Institute has 40 years of manufacturing experience with this 
product. The purpose of the investigation was to demonstrate that the combination of tested 
ranges for all critical process parameters still results in good product quality. In this case, the 
entire process space under investigation constitutes the design space. 
This approach may be contrasted with that for new products.  In the that case, larger ranges 
of values of the critical process parameters are initially investigated, and the design space 
is determined as a sub-space of the investigated space (sometimes referred to as knowledge 
space, Figure 1). Such an approach is necessary when there is little or no manufacturing 
experience and insufficient knowledge of the process failure limits.
Investigated S pace
Design S pace
Operating S pace
Figure 1. The Design Space as a sub-space of the Investigated Space (also known as the Knowledge Space). The 
Operating Space (where the process is intended to run) can be a large or small part of the Design Space. (Adapted 
from (Harms et al. 2008).
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In order to consistently ensure a predefined quality at the end of the manufacturing process 
(ICH definition of the scope of PAT)1, an additional signal may be needed that can be 
related to process performance or product quality. According to the FDA’s PAT guidance2, 
“Measurements collected from these process analyzers need not be absolute values of the 
attribute of interest”. In this study, near infrared (NIR) spectroscopy is investigated as a 
PAT tool, i.e. an online measurement of critical quality and performance attributes (FDA/
ICH PAT definition), to monitor the cultivation of Bordetella pertussis bacteria. NIR data 
are used to indicate specific attributes of interest (such as biomass concentration) and as a 
“fingerprint” that gives qualitative information on the status and trajectory of the process. 
All data gathered online – NIR as well as conventional cultivation process data (i.e. pH, 
temperature, and gasflow controller outputs) - are combined in a single database using PAT 
compliant software. This database contains all data used to construct the model describing 
the multivariate process design space. 
The design, experimentation and multivariate modelling required to define the design 
space for the cultivation of Bordetella pertussis are described. The resulting process model 
integrates bioreactor control data with online NIR measurements and can be used for on–
line, real time modelling of the cultivation process. This provides real time assurance of 
process performance and an indication of product quality during processing. Ultimately, the 
system will be capable of real time release of the cultivation product for further processing. 
The main goal of this paper is to demonstrate the principles of design space investigation 
for a biopharmaceutical cultivation process. We investigate both the experimental work 
involved, the analytical (PAT) tools used and the data processing and modelling necessary in 
order to devise a model that describes the process design space. It is a first attempt to apply 
the principals of PAT and process design space for an undefined biopharmaceutical product, 
namely a whole cell vaccine. In general, such a product is regarded as the “worst case” in 
terms of how defined and how well characerized the product is. The ability to apply PAT 
principles on this product bodes well for the implementation of PAT on other, more defined 
(bio)pharmaceutical products.
Materials and Methods
Experimental design
An experimental design was executed and data from the design used to mathematically 
model the effects of the process parameters on product quality. A robustness design in which 
the parameter values chosen were at a safe margin from known or expected failure limits 
was employed. The design was a Plackett Burman design in 8 runs to which two times two 
replicate center points were added (two for each of the two reactors). The experimental 
matrix, having 12 runs, is shown in Table 1. Experiment 6 was done twice, owing to a data 
collection problem, once in Reactor A and once in Reactor B.
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The process parameters investigated were: the dissolved oxygen (DO), the pH, the temperature, 
the density of bacteria at the end of the pre-culture phase in the shake-flask (Preculture 
density), the actual density of bacteria at the start of the bioreactor run (Inoculation density), 
and which of the two identical bioreactor systems, A or B, was used in the experiment. 
Table 1.  The DoE matrix for the 12 batch runs used to determine the process design space.
Experiment 
Number
Run 
Order
DO 
(%) pH Temperature (°C)
Preculture 
density
Inoculation 
density Reactor
1 1 10 6.8 37 0.5 0.1 A
2 12 60 6.8 33 0.5 0.025 B
3 2 60 6.8 37 1.5 0.025 A
4 3 30 7.2 35 1 0.05 B
5 4 30 7.2 35 1 0.05 A
6B 10 10 7.8 37 0.5 0.025 B
6A 13 10 7.8 37 0.5 0.025 A
7 5 60 7.8 33 0.5 0.1 A
8 6 30 7.2 35 1 0.05 B
9 7 10 7.8 33 1.5 0.025 A
10 8 60 7.8 37 1.5 0.1 B
11 11 30 7.2 35 1 0.05 A
12 9 10 6.8 33 1.5 0.1 B
Bioreactor Cultivations
Cultivation conditions
All cultivations were carried out in a fully instrumented 7 L in situ, sterilizable bench-top 
bioreactor with a six-bladed Rushton turbine (Applikon, Schiedam, The Netherlands). The 
bioreactor was filled with 4 L of THIJS medium9 and raised to the set point temperature 
and a 100% DO condition. It was then inoculated with preculture from a shake-flask at 
an optical density at 590nm (OD590) of 0.5, 1.0 or 1.5. The volume of preculture used to 
inoculate the bioreactors was adjusted to yield the desired starting density. Temperature, 
DO, pH and stirrer speed were controlled at the different values shown in Table 1. A low-
drift polarographic electrode (Applikon, Schiedam, The Netherlands) was used to measure 
the DO concentration in the liquid. pH and temperature were measured using a glass pH 
electrode (Mettler Toledo, Tiel, The Netherlands) and a Pt100 temperature sensor (Applikon, 
Schiedam, The Netherlands), respectively. All sensors were connected to the bioreactor 
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control system (Applikon, Schiedam, The Netherlands), which was operated using PCS7-
based bioreactor control software (Siemens, Zwijndrecht, Belgium). DO was controlled 
with increments in stirrer speed up to 650 rpm after which it was controlled by increasing 
the fraction of oxygen in the headspace. The fraction of AIR, O2 and N2 were also registered 
in the control system. Total gas flow was kept constant at 1.0 L/min. 
Nutrient concentration analysis
Samples were taken at regular intervals and OD590 and nutrient concentrations were measured. 
Samples were sterile filtered (0.22 µm) and supernatants were stored at -20 °C for further 
nutrient analysis. Lactate and glutamate concentrations were determined by 1H-Nuclear 
Magnetics Resonance (NMR) spectroscopy using a JEOL JNM ECP 400 spectrometer 
operating at 400MHz (JEOL, Tokyo, Japan) and equipped with a JEOL Stacman autosampler 
for 16 samples. Supernatants were analyzed by adding 0.1 ml of D2O containing 3-(trime
thylsilyl)[D4]proprionic acid sodium salt (TSP, 0.167 mM) to a 0.9 ml sample. The water 
signal was suppressed by a standard pulse experiment using presaturation. The spectra 
were referenced using the TSP signal at 0 ppm. Lactate and glutamate concentrations were 
quantified by integration of the relevant signals. NMR was also used to check samples for 
any waste metabolites. 
Data collection and handling
All on line data necessary to build the process model were collected using the SIPAT software. 
Every two minutes this software collected the data from the cultivation system and the NIR 
system (see below) and stored it in a central database. When two bioreactor systems were 
running simultaneously, the SIPAT software collected the data from each system sequentially 
every minute so that each system was still sampled every two minutes. The SIPAT database 
was later used to build the process model.
NIR spectroscopy measurements
An on-line NIR transmission probe (Solvias AG, Basel, Switzerland) with a fixed path 
length of 5 mm, was implemented in both bioreactor vessels. The probe was immersed in the 
liquid with the measurement slit at the height of the stirrer, pointing away from the stirrer. 
Measurements were made every two minutes on both probes using a Bruker Matrix F NIR 
source (Bruker Optics, Ettlingen, Germany). Spectra were taken at a resolution of 4 cm-1 
between 12000 and 4000 cm-1. Each spectrum was an average of 32 scans. 
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Additional samples for PLS calibration of biomass density
Some additional samples were necessary to build a suitable PLS calibration model for 
biomass density. The samples were prepared by cultivating Bordetella pertussis in a glass 
shake-flask according to the standard procedure. At the end of the cultivation (OD590=1.3 – 
1.5), half of the shake-flask was centrifuged and sterile filtered to yield cell-free supernatant. 
Suspension and cell free supernatant were mixed to create samples with optical densities that 
match, the start, half-time and end of the cultivation, but that have nutrient concentrations 
that do not match these cultivation stages. In this way, the correlation between optical density 
and nutrient concentration is disconnected, in order to see if these parameters individually 
correlate to the NIR signal and that they not merely have the same process trend. The samples 
were prepared according to Table 2.
Table 2. Sample preparation matrix for extra samples measured off line using NIR.
                             
Sample Supernatant (ml) Suspension (ml) Lac (μl) Glu (μl) H2O (μl)
1 1 0 0 0 7.2
2 1 0 0 1.8 5.4
3 1 0 0 3.6 3.6
4 1 0 1.8 0 5.4
5 1 0 1.8 1.8 3.6
6 1 0 1.8 3.6 1.8
7 1 0 3.6 0 3.6
8 1 0 3.6 1.8 1.8
9 1 0 3.6 3.6 0
10 0.5 0.5 0 0 7.2
11 0.5 0.5 0 1.8 5.4
12 0.5 0.5 0 3.6 3.6
13 0.5 0.5 1.8 0 5.4
14 0.5 0.5 1.8 1.8 3.6
15 0.5 0.5 1.8 3.6 1.8
16 0.5 0.5 3.6 0 3.6
17 0.5 0.5 3.6 1.8 1.8
18 0.5 0.5 3.6 3.6 0
19 0 1 0 0 7.2
20 0 1 0 1.8 5.4
21 0 1 0 3.6 3.6
22 0 1 1.8 0 5.4
23 0 1 1.8 1.8 3.6
24 0 1 1.8 3.6 1.8
25 0 1 3.6 0 3.6
26 0 1 3.6 1.8 1.8
27 0 1 3.6 3.6 0
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The lactate and glutamate stock solutions were prepared at 4.44 and 2.22 M, respectively. 
The amounts listed in the table above produced concentrations typical for the start, halftime 
or end of a standard cultivation. The half-time samples were prepared by mixing cell-free 
supernatant with cell suspension at a dilution of 1:1. The cell-free supernatant was used as a 
surrogate for the low-OD590 samples.
Samples 1-27 were prepared according to the table and, after thorough mixing, were quickly 
measured using a NIR cuvette bench (Bruker Optics, Ettlingen, Germany). The settings 
were identical to those used for the transmission probe inside the bioreactor. 
Microarray Analysis
RNA isolation
Samples for microarray analysis were taken at the end of each cultivation. For fixation of 
the RNA expression profile, one volume of bacterial culture was mixed with two volumes 
of RNase retarding solution10,11,12. For each microarray sample 2.5 ml cultivation at OD590 = 
1.0 was used. Samples at other optical densities were adjusted accordingly, so that an equal 
amount of cells was used for each sample. The samples were concentrated by centrifugation 
and treated for 3 minutes with Tris-EDTA buffer, containing 0.5 mg/ml lysozyme (Sigma-
Aldrich, Zwijndrecht, The Netherlands). Total RNA was extracted with the SV total RNA 
isolation system (Promega Benelux, Leiden, The Netherlands) according to the manufacturer’s 
protocol. Nucleic acid concentration was adjusted by precipitation. UV spectral analysis 
was used to determine final nucleic acid concentration and purity and RNA integrity was 
confirmed with the Bioanalyzer RNA6000 Nano assay (Agilent Technologies, Amstelveen, 
The Netherlands), according to the manufacturer’s protocol. 
cDNA labeling and hybridization reactions
Total RNA from all experimental samples was reverse transcribed to cDNA and labeled 
with Cy3/Cy5 dyes using the Chipshot Indirect Labeling Kit (Promega Benelux, Leiden, 
The Netherlands) according to manufacturer’s protocol, with one deviation: 2 µl random 
nonamer primer and no oligo-dT primer was used per reaction to reverse transcribe the 
total RNA, because prokaryote mRNA does not have poly-A tails. Experimental samples 
(Cy5) were pooled with a common reference sample (Cy3) having equal amounts of RNA 
from all experimental samples in the experiment. Volumes of the combined cDNA samples 
were adjusted to 25 µl and an equal amount of hybridization buffer was added, to a final 
concentration of 25% formamide, 5x SSC and 0.1% SDS. Samples were applied to the 
microarray slides and placed in a hybridization chamber (GeneMachines, San Carlos, CA, 
U.S.A.) for 16-20 hours at 42° C in the dark.
The microarrays were scanned with a ScanArray Express microarray scanner (Perkin Elmer, 
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Groningen, The Netherlands) and median fluorescence intensities were quantified for each 
spot using ArrayVision software (Imaging Research, Roosendaal, The Netherlands). 
Processing of the expression data
The expression data were natural-log transformed, quantile normalized, corrected for the 
common reference dye signal and the values of replicate spots were averaged. These data 
processing steps were carried out using the free statistical software R, running an in-house 
developed script. 
A product quality score was calculated from the gene expression data as described earlier 
(see Chapter 4). To calculate the product quality score, only genes from the virulence core 
regulon13,14 were considered, since these are the genes that are considered to be critical for 
the function of the vaccine. Based on earlier work, a product quality score of 8 or higher, can 
be considered to represent good quality (see Chapter 4).
Data Analysis and Modelling 
The data available in this study can be categorized as follows (Fig 2): 
•	 XDoE: the setup parameters from the DoE (T, pH, DO, preculture density, inoculation 
density and reactor)
•	 Xproc: the time varying process variables measured throughout the batch evolution (pH, 
DO, T, flow of air, O2, and N2, stirrer speed)
•	 XNIR: the on-line NIR data measured throughout the batch evolution
•	 YprocQ: the process variables related to process evolution measured at-line by taking out 
samples during the cultivation (OD540, glutamate and lactate)
•	 YprodQ: the final product quality variables measured after the completion of the batch, i.e. 
the microarray expression data (product quality score, see paragraph 3.3)
Xproc YprodQ
Variables
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Figure 2. Overview of available data blocks.
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Due to the large number of distinct data sets available for the study, the analysis was split 
up into four sub-steps.
Step 1: Traditional design space analysis
The gene expression data (YprodQ) were transformed into a product quality score and the 
relationship between the design setup parameters (XDoE, Table 1) and the product quality 
score was modeled to detect significant effects. The approach involved  a traditional DoE 
analysis in which the output of the experiments was associated with the input settings. 
Multiple linear regression (MLR) was used to model the relationship between the process 
parameters and the product quality using the MODDE (Umetrics AB, Malmö, Sweden) DoE 
software package. A robust design space should result in a non-significant model in which 
no significant relationship exists between product quality and variation in the process setting 
within the tested range. In that case the process is stable within the design space. 
Step 2: Prediction of process variables from NIR data
The process evolution variables (YprocQ)  OD590, lactate and glutamate are a measure of 
the status of the cultivation and can be used to assess changes in specific growth rate or 
metabolism. However, these parameters are only measured at distinct sample points during 
cultivation. It is of interest to have these variables available on line for more accurate 
monitoring of the status of the cultivation. NIR data was used in an attempt to predict 
these process evolution variables. NIR data values were used as an X data matrix with the 
process evolution variables as the Y data matrix. A PLS regression model was fitted to the 
two datasets. The NIR data were centered before fitting the PLS model, while the process 
evolution data were centered and scaled to unit variance.
Initial modelling revealed a high degree of correlation between the three process evolution 
variables, OD590, lactate and glutamate. Therefore, a prediction model based only on the 
samples taken from the cultivations was not reliable. Additional samples having the three 
evolution variables uncorrelated with each other were therefore prepared as described in 
Table 2. These samples were also subjected to NIR spectroscopy analysis and the data were 
added to that from the cultivations to obtain a reliable prediction model.
Step 3: PCA fingerprints from NIR data
The NIR measurement results in more than 4000 variables, which are not mathematically 
independent and which do not all carry unique information. To use NIR data as a “fingerprint” 
of the status of the process, the spectra are compressed into a small number of independent 
Principal Components that summarize the variation in the large number of initial variables. 
The computational time needed for the calculation was reduced by using one spectrum per 
hour for the calculation of the PCA model for each batch. Finally, all spectra (taken every 2 
minutes) were compressed using this model.
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The “fingerprint” derived from the NIR spectra doesn’t necessarily represent specific physical 
or chemical characteristics of the samples, but may contain more abstract characteristics. It 
is assumed, however, that the NIR fingerprints are similar for all batches, thus that it can be 
used as a non-specific variable for the monitoring of batch evolution, allowing non-biased 
batch-to-batch comparisons. 
Step 4: Building the process control model
The process data registered during batch evolution (denoted Xproc in Figure 2) were modeled 
together with the OD590 predicted from NIR (Step 2)  and the NIR fingerprint variables (Step 
3). Together they constitute a three-dimensional data matrix of batches vs. variables (process 
variables, predicted OD590 data and NIR fingerprint variables) vs. process time.  
The evolution was split up into two phases for each batch. The first phase was represented 
by the part of the cultivation in which Dissolved Oxygen concentration (DO) was controlled 
by increments in stirrer speed and the second in which DO was controlled by increasing the 
fraction of O2 in the headspace. This was done to allow for a different correlation structure 
in the process variables before and after the change in DO control strategy.
The data were modeled as described in Wold et al.8 using the modelling setup denoted 
Observation-Wise Unfolding with subsequent Batch-Wise Unfolding of the scores (OWU-
BWU).
Software 
ArrayVision 8.0 (GE Healthcare, Uppsala, Sweden) was used to quantify microarray 
fluorescence intensities.
R (WU Wien, Austria) was used for statistical analysis of gene expression data. 
MODDE (Umetrics, Umeå, Sweden) version 8 was used for setting up the design and for the 
traditional DoE analysis. 
SIMCA-P+ version 11.5 (Umetrics, Umeå, Sweden) was used for all NIR data analysis as 
well as for building the process control model.
 The SIPAT software (Siemens, Nynove, Belgium) was used for collecting process and NIR 
data during the cultivations and served as the database for extracting data for use in the NIR 
and process models.
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Results and Discussion
Traditional Design Space Analysis
The product quality at the end of each of the 13 runs was determined by calculating the 
product quality score for each batch (see Chapter 4) from the gene expression data (Table 
3). Prior experimentation showed that good quality is represented by a score above 8 (see 
Chapter 4), and thus the scores in Table 3 (all higher than 8.5) should represent good product 
quality. 
Table 3. DoE experiments and their corresponding product quality scores
Experiment number Product Quality Score
01 10,36
02 10,00
03 9,95
04 8,89
05 9,68
06B 9,74
06A 8,57
07 9,67
08 10,07
09 9,51
10 9,91
11 10,58
12 10,53
The quality scores are used instead of the actual animal (Kendrick) tests for product quality 
that are normally required by the authorities for whooping cough vaccine. This test involves 
an intra-cranial challenge of mice previously vaccinated with a human dose of vaccine with 
live Bordetella pertussis bacteria15,16. This test is not only highly variable and very cruel to 
the animals, but also costly and labor intensive17. The product quality scores are therefore 
better suited for building this preliminary process model. 
Using the DoE setup parameters as input (X) variables and the product quality scores as 
output (Y) variables, a traditional DoE analysis was done using MODDE software. No 
significant model could be fitted, (best fit: R2 = 0.38; Q2 = -0.2) indicating that, within the 
ranges of the variables of the DoE setup, variation in the value of the input parameters had 
no effect on the product quality. This indicates that, within the tested ranges, the process is 
robust. The ranges tested in this study can therefore qualify as a design space as intended 
in the ICH Q8 Guideline1. The data collected during these experiments can be used to fit a 
model that describes the process and can later be used as an on-line check of whether a new 
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process is running within the design space. 
Prediction of Process Variables from NIR Data
A raw data plot of the NIR data is shown in Figure 3. The plot shows clear offset differences 
between the spectra, probably due to difference in optical density of the samples. No attempt 
was made to remove this variation as this parameter is probably the main correlate for optical 
density in the NIR signal, which is one of the process evolution variables to be predicted 
from the NIR spectra.
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Figure 3. Raw data plot of NIR spectra of the samples taken out during cultivation.
The very strong signals from water in the spectral regions 7200 – 6500 and 5400 – 4000 cm-1 
saturated the detector and, therefore, models built on the NIR spectra exclude these regions. 
The benefit of these high sensitivity measurements (too high for the water peaks) is that the 
signals in the other regions are stronger. 
A PLS model was built from the NIR spectra (X) and all three process evolution variables: 
OD590, lactate and glutamate (Y). This model provided very good results with a cross-
validated explained variance (Q2Y) of 81-97% for the three parameters. However, the three 
parameters were highly correlated, because OD590 is initially low in a cultivation, while the 
concentration of nutrients is high. As the cultivation proceeds, the OD590 increases while 
concentration of nutrients decrease at the same rate. Thus predictions from this model cannot 
be trusted, because the model is unable to predict samples correctly where this relationship 
between the three variables is not present. Artificial samples were prepared (Table 2) in order 
to break up the correlation between the three process evolution variables. PLS models built 
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only on these samples showed that OD590 could be reasonably predicted, while no significant 
components were found for the prediction models for lactate and glutamate. 
To incorporate any difference between the spectra for the artificial samples prepared from a 
shake-flask cultivation and the samples taken directly from the bioreactor cultivations, a PLS 
model for predicting OD590 that was based on both sets of samples was built (total samples 
number: 85; 58 original cultivation samples and 27 additional samples). The model showed 
very good predictive ability (Q2Y was 96%) and no difference between prediction error of 
the artificial samples and the original cultivation samples was seen (Figure 4). The predicted 
values of OD590 were used in the subsequent analysis of batch evolution together with the 
process variables. This prediction model, based on the NIR signal, can be executed during 
cultivation of future batches, allowing a growth curve to be plotted in real time without the 
need for excessive sampling. However, the prediction of the higher values OD590 still show 
a large prediction error, which means that more samples from more batches need to be 
added to the model in order to increase it’s reliability before it can replace manual sampling 
completely. 
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Figure 4. Plot showing values of OD590 predicted during cross-validation (ordinate) versus measured/prepared 
values (abcissa) of OD590. Circles represent samples from original cultivation, while triangles represent artificial 
samples.
PCA Fingerprints from NIR Data
NIR data can also serve as a fingerprint of the status of the process. For this purpose, a 
Principal Component Analysis (PCA) based model was created from the NIR cultivations 
data. To reduce calculation time, one spectrum per hour was used to construct the model 
(incorporating the entire biological evolution of the batches), resulting in a total of 218 NIR 
Chapter 6
114
6
spectra. The regions containing the water signals were excluded as described above.
A PCA model with five components was created that explained 99.9 % of the variation in 
the data. All NIR spectra (acquired every 2 minutes throughout the cultivations) were then 
compressed into these five components using this model. The five components, used as five 
fingerprint variables (NIR_fp1 to NIR_fp5), together with the process variables are used in 
the subsequent analysis of batch evolution.
Building the Process Control Model
Integrity of process data
Due to an overnight data collection error, the middle part of the process and NIR data for 
Batches 3 and 6B were lost (~ 30-40% of total batch data), which means these data could not 
be used in the model. The data from samples taken from these batches were used, however. 
Process and NIR data for Batches 2, 8, 10, 11 and 12 were not sampled consistently every 
2 minutes throughout batch evolution due to a wrong setting of the NIR sampling method. 
The interval for these batches varied generally between 1 to 5 minutes, which is adequate 
for batch modelling, so the batches could be used. The available data were sufficient to 
build a robust process model. In order to allow all datasets to be processed in a similar way, 
any gaps in the datasets were filled using averaged values in such a way that they did not 
influence the model. 
Modelling of dynamic evolution
Process variables together with predicted OD590 and NIR fingerprint variables were modeled 
using PLS with time as the Y variable, as described by Wold et al. (8). Prior to modelling, 
all variables were investigated individually and trimmed to remove unrepresentative values 
(e.g. spikes caused by air bubbles in the nIR measurement slit). The resulting PLS model 
based on all on-line signals from the bioreactor control system, the predicted biomass and 
the NIR fingerprint variables, describes the evolution of the cultivation batches as a result of 
the settings chosen in the DoE matrix (Table 1). This is called a dynamic evolution model. 
This model consists of two phases, each containing four components, which explain >99% 
of process variance, as shown in Figures 5 and 6. The line graphs show the evolution of the 
loading plots for each batch over time, which the bars (loading plot) indicate the contribution 
of each parameter to the observed variance. A detailed interpretation of these components 
is provided in Appendix 1, while a short summary is given below. Note that it is not critical 
that all components be fully understood for a monitoring model. When, however, this 
model is used for the next level of modelling, the multivariate batch monitoring model, it 
is important that it encompasses “normal” batch evolution, in other words that it describes 
the process design space completely. It should thus distinguish normal or good batches 
from deviating batches. Because of the limited number of batches used in the experimental 
design, this will initially give ambiguous results in parts of the design space that are not 
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fully covered in the experimentation. Data from new cultivations (for instance from regular 
manufacturing) should be added to the process model to make it more reliable over time. 
The model may also be challenged with experimental faulty batches for validation purposes. 
The batch evolution was split into two phases coinciding with a switch in the oxygen control 
strategy (Figure 5 and 6, respectively). At the start of a batch, before inoculation, dissolved 
oxygen (DO) is maintained at set-point using AIR and N2 with a total flow of 1 L/min. After 
inoculation, while maintaining a total flow of 1 L/min oxygen, consumption rises and the 
fraction of nitrogen decreases to zero. Simultaneously, the stirrer speed is gradually increased 
to a maximal set-point value. When both AIR and stirrer speed have reached their maximum 
set-points, the controller switches to a new strategy in which the fraction of oxygen in the 
gas mixture is increased by mixing pure O2 into the airflow, while still maintaining total gas 
flow at 1 L/min. This relationship is seen in the first component for the first phase, where 
PredictedOD, AIR, stirring, and NIR_fp1 are increasing with batch evolution while N2 is 
decreasing. 
The second phase of the process (Figure 6) begins when the stirrer speed is no longer 
increasing and the pure oxygen valve is opened for the first time. This change in control 
strategy is clearly seen in the first component for the second phase, where PredictedOD 
and NIR_fp1 continue to increase, while AIR decreases and O2 is increases. Further, more 
detailed, explanation of the model components is given in Appendix 1.
Multivariate batch monitoring model
For on-line monitoring whether any given process is running inside the process design 
space, a multivariate batch monitoring model is required. The batch monitoring model was 
constructed based on the dynamic evolution model as described in Wold et al.8. This model 
gives a total overview of the difference between the batches. To illustrate this, a PCA model 
with two components was built on the scores from the dynamic evolution model. The scores 
plot of this model is shown in Figure 7. 
This plot is a 2D graphical representation of the process design space as it is described by 
the DoE batches. All batches are condensed into one point and the outer circle represents 
the 95% confidence interval of the (design) space defined by these points. The numbers 
correspond with the batch numbers shown in Table 1. Batches 3 and 6B are not represented 
because of insufficient nIR and process data, as explained earlier.   
All relevant process data, including the predicted OD and the NIR fingerprint variables, are 
condensed in the multivariate batch monitoring model. Figure 7 shows that the design applied 
can be seen to have caused some variation in the process evolution. The batches are similar 
– none fall outside of the Hotellings T2 ellipse that represents a 95% confidence interval. 
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The design is clearly reflected in the plot, as the centre-points of the design (those batches 
run with intermediate values of all six investigated parameters), batches 4, 5, 8 and 11, are 
close together and near the centre of the graph. Furthermore a separation in temperature kan 
be observed, with at the bottom and right part the cultures at 33 °C (squares), in the middle 
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Figure 5. Scores (left) and loadings (right) of Phase 1 of components 1 to 4 (top to bottom) of the dynamic evolution 
model. The outer red lines in the line graphs indicate a 95% confidence interval and the green line the average. 
The other lines each represent the evolution of the score of a cultivation batch over time. The loadings (right) are 
represented as contribution plot in which the contribution of each individual parameter to the variance is shown. 
Error bars indicate the standard deviation over time.
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the cultures run at 35 °C(circles) and at the left and top part the cultures run at 37 °C. Also 
a separation in the rector used can be seen with the runs in reactor A (open symbols) being 
higher in the plot than the runs in Reactor B (closed symbols).
Because all batches were concluded to be of good quality, this plot – including the ellipse at 
Figure 6. Scores (left) and Loadings (right) of Phase 2 of components 1 to 4 (top to bottom) of the dynamic 
evolution model. The outer red lines in the line graphs indicate a 95% confidence interval and the green line the 
average. The other lines each represent the evolution of the score of a cultivation batch over time. The loadings 
(right) are represented as contribution plot in which the contribution of each individual parameter to the variance 
is shown. Error bars indicate the standard deviation over time.
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the 95% confidence interval – can be viewed as a design space. However, the present dataset 
is insufficient to allow release decisions based on this model, because the present model 
does not fully describe the process design space. A batch with a combination of variables 
that is not tested in the DoE setup may fall outside the current design space, but still be of 
good quality or, on the other hand, may fall inside the design space and be of insufficient 
quality. As mentioned above, data from new batches must be added to the model to increase 
its accuracy, especially near the edges of the process design space. 
Conclusions
This report demonstrates how the general principles of PAT and design space can be applied 
to undefined biopharmaceuticals. The complexity of a bacterial cultivation process first 
requires sound scientific investigation of the critical process and product attributes and 
the analyses needed to measure these attributes. Mandatory QC assays may not provide 
the exact scientific information necessary to appraise product quality. A “pass” or “fail” 
result is usually insufficient in this case. The quality of the bacterial suspension at the end 
of cultivation was appraised using a product quality score derived from DNA microarray 
analysis. This provides a quantitative measure of the performance of the run. The already 
available on line data were supplemented with NIR spectroscopy and samples were taken 
Figure 7. Overview of the multivariate batch monitoring model. Batches marked with triangles were run at 37 °C, 
with circles at 35 °C and with squares at 33 °C. Open symbols represent the batches run in Reactor A and closed 
symbols batches run in Reactor B. The numbers denote the batch numbers as denoted in Table 1. 
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frequently to determine nutrient and biomass concentrations. This whole set of data contains 
all relevant information for this process step.
This report shows how this complex data set can be integrated into a single process model 
that descibes the process design space for the cultivation of Bordetella pertussis bacteria for 
the production of a whole cell vaccine against whooping cough disease. The steps that were 
undertaken for the development of this model are described; from experimental design and 
analytical (PAT) methodology to chemometrics and mathematics. The resulting model can 
be used to monitor process evolution on-line and make predictions on the expected product 
quality at the end of cultivation. 
Future application of this approach to all manufacturing process steps will allow the 
development of an overall manufacturing model incorporating the input and output of each 
process step, thus enabling flexible manufacturing at optimal settings. When this is validated, 
any process that has been executed within the process design space is assured to be of the 
specified quality. This means that this process model can make the release decision of the 
product during processing. Of course, to be allowed to replace mandatory QC testing, the 
model must be confirmed through extensive testing using actual process data. The model 
presented in this paper may be considered a starting point for this procedure. It should be 
run in parallel to the normal testing procedures and, when sufficient data is added to the 
model and regular tests have confirmed its reliability and comparability, it can eventually 
replace these tests. The resulting system is then capable of …analyzing, and controlling 
manufacturing through timely measurements (i.e., during processing) of critical quality 
and performance attributes of raw and in-process materials and processes with the goal of 
ensuring final product quality, fulfilling the PAT definition. 
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Appendix 1: Interpretation of the model components
Phase 1
The first component represents a feature that increases throughout the batch evolution. It 
consists of a correlation between main variables AIR, stirring, PredictedOD and the first NIR 
fingerprint (NIR_fp1), which is mainly the offset that also explains OD. These all increase 
while N2 is decreasing. This is a logical correlation since they all follow general trends 
caused by bacterial growth during batch cultivation. Increases in oxygen consumption cause 
the fraction AIR to increase over the fraction pure N2, and combine with an increasing stirrer 
speed and of course increased optical density.
The second component consists mainly of a correlation between temperature and NIR_fp4. 
This is simply a confirmation that temperature is reflected in the NIR spectra. 
The third component shows AIR, DO and O2, together with NIR_fp4 decreasing, while N2, 
pH, Temperature and NIR_fp3 increase. This might just be an effect caused by the different 
DO setpoints in combination with temperatures in each batch. Although dissolved oxygen 
(DO) is stable throughout each batch, between batches there are differences between the N2/
AIR ratios needed to maintain the setpoint. When the setpoint of DO is low, more nitrogen 
and less AIR is needed. This component also picks up an increase in pH that occurs mainly at 
the end of Phase 1. These phenomena maybe be caused by the fact that the oxygen transport 
constant between liquid and gas (kLa) is dependent on temperature. At lower temperatures 
kLa is lower, which means a higher oxygen concentration in the gas phase is needed to 
maintain the setpoint. Also the solubility of CO2 (as H2CO3) is increased which results in a 
reduction in pH.  
The fourth component shows that O2 is negatively correlated with primarily NIR_fp2.  Close 
examination of the scores plot shows that this component reflects a difference between the 
reactors – batches run in Reactor A have low score values and batches run in Reactor B have 
high values. The variables NIR_fp2 and NIR_fp3 reflect some reactor difference (having 
higher values for Reactor A) and since the variable O2 has a small variation between reactors 
– varying between 0 and 0.0005 for Reactor A but between 0 and 0.0015 for Reactor B, this 
component picks up a small negative correlation between the variable O2 and the two NIR 
fingerprint variables.
Phase 2
The first component, again, exhibits a rising trend for all batches. It consists mainly of a 
correlation between PredictedOD and increased NIR_fp1, while AIR decreases and O2 
increases. This indicates an increased oxygen fraction in the gas flow due to the mixing of 
pure oxygen while reducing the AIR to maintain a constant gas flow. This phenomenon is 
accompanied by a strong increase in the optical density and it is reflected in the NIR_fp1.
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The second component shows a diverging pattern with some batches increasing while some 
decrease slightly. The correlation between the factors is relatively weak, except for the NIR 
fingerprints, where NIR_fp1 and NIR_fp2 strongly increase and NIR_fp3 decreases. For 
the other factors, AIR and N2 and PredictedOD increase while all others (O2, pH, Stirrer, 
Temperature) decrease. This complex interaction cannot be readily explained but may be 
the result of several effects due to both bacterial growth and the kLa phenomenon described 
above. 
The third component shows a rather noisy pattern, which is reflected by the larger error 
bars in the loading plot. Predominantly, an increase in DO and Stirrer is accompanied by a 
decrease in N2, pH and temperature. The strong effect of pH is hard to explain, but the others 
are parameters that have been correlated earlier. This seems to be another difficult to explain 
interaction but it may be due to the influence of several effects arising from the different set 
points for all experiments in the design.  
The fourth component shows a slightly less noisy pattern than the third, but it is still largely 
unstructured. It mainly involves a correlation between pH and temperature. This can be 
explained by the aforementioned phenomenon that CO2 (which is produced by the bacteria 
in the fermentor) dissolves better at low temperatures and, since it dissolves as a weak acid 
(H2CO3), reducing the pH . 
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Introduction
This thesis describes the application of Process Analytical Technology (PAT) on the 
bioreactor process step for a whole cell vaccine against whooping cough disease. A whole 
cell vaccine is probably one of the most complex (bio)pharmaceutical products and therefore 
the most challenging for application of PAT. However, the work described in this thesis 
demonstrates that even for such an undefined product, PAT application is feasible and that 
PAT can thus in principle be applied to any (bio)pharmaceutical process. PAT application 
on any pharmaceutical process step can be divided in six steps, which are given below, 
exemplified with the work presented in this thesis:
1.	 Determine	the	critical	product	attributes. This means that a (preferably mechanistic) 
understanding of the function of the product in the human body is acquired. Also the 
specific parts or functional groups responsible for both therapeutic and adverse effects 
should be known (Chapter 2). 
2.	 Develop	assays,	analyses	or	sensors	to	quantitatively	measure	these	critical	product	
attributes. Ideally this information should be available on line as a PAT tool (Chapter 2 
and 4). For  the relatively undefined whole cell vaccine against whooping cough disease, 
potency is routinely determined using a mouse challenge assay1. Such an assay is highly 
variable and gives only a qualitative result regarding product quality (pass or fail). This 
information is not suitable for the development of a PAT application. In this thesis an 
alternative method for the determination of vaccine potency is proposed based on DNA 
microarrays. In this way a quantitative measure for potency is acquired, which allows 
correlation between critical process attributes and critical product attributes.
3.	 Acquire	understanding	of	the	interaction	between	the	process	and	the	the	critical	
product	 attributes. Identification of the critical product attributes (Chapter 2) and 
investigation of the critical process attributes (Chapter 3 and 4) can only be achieved 
with sufficient understanding of the underlying (cellular) mechanisms that define product 
quality. The process parameters that are critical for product formation and their tolerance 
limits need to be known (Chapter 3). This includes both physical (e.g. temperature, shear) 
and chemical (e.g. pH, substrate concentrations) data on the product environment. 
4.	 Incorporate	process	analytical	technology	(PAT). A quantitative determination of all 
process attributes that are critical for product quality needs to be available on line, or at 
least fast enough so that it can be used for process control. This can either be a sensor 
that directly measures critical product attributes or a multivariate (spectroscopic) sensor 
that captures process fingerprints. For the B. pertussis process no sensors that directly 
measure the critical product attributes on line are available, meaning the PAT application 
described in this thesis was based on indirect measurements. The direct measurement of 
product attributes using microarrays was used at the end of the batch to quantify product 
quality. The on-line measured parameters like the oxygen, nitrogen and air flow, agitation 
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Box	1. Six Sigma and Shewhart’s control charts
The buzz-word Six Sigma originates from Motorola in the 1980’s. It is based on statistical process control principles 
that originated much earlier with the work of people like Deming, Shewart, Ishikawa and Taguchi. The term refers 
to the expression of average manufacturing results with respect to the process specification limits. One of the most 
easy ways to illustrate this, is by using Shewhart’s control charts (see figure below). 
Shewhart’s	control	charts.	The chart shows manufacturing outcomes per run. Runs are chronologically plotted 
from left to right. The green line indicates target manufacturing and the red lines the upper and lower specification 
levels (USL/LSL). The upper panel shows a process running at a 2-3 sigma level, comparable to the current 
(bio)pharmaceutical industry. This means that 70-95% of production runs fall inside specification limits. Such a 
process has a significant chance for a faulty production (red circles). The lower panel shows a process running at a 6 
sigma level. This process is called a “world class” process and has only 3.4 faulty runs per 1 million correct ones.
 
These charts show manufacturing outcomes over time and can be used to investigate if a process is still centered 
around the target outcome and how much variance the process has. It also includes the upper and lower specification 
limits. Manufacturing results above the upper or below the lower specification limit have to be rejected or 
reworked. 
The sigma-level of manufacturing is based on these charts. First a Shewart’s control chart is plotted. Than the 
standard deviation (sigma) of the process can be calculated. The number of “sigma’s” that fit between the average 
and the upper or lower specification limits indicates the “sigma level” of the process. Six sigma would mean 
only 2 faulty productions for every 1 billion correct ones. However, a stable process (Fig. 1) is allowed to have a 
systematic variation of 1.5 sigma over time, which means that the process is not always averaged on the center but 
moves 1.5 sigma up and down around the center during the manufacturing lifetime of a product. Therefore, “six 
sigma” is actually “four-point-five sigma”, which means 3.4 faulty productions for every 1 million correct ones. 
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speed and NIR data were used for this process to fingerprint conditions that lead to good 
product quality. (Chapter 5 and 6). Finally, near infrared (NIR) spectroscopy was found 
to be a promising PAT tool for the monitoring of the cultivation of Bordetella pertussis, 
the causative agent of whooping cough disease (Chapter 5). NIR spectroscopy can be 
used on line to quantitatively predict critical process attributes using partial least squares 
(PLS) models or qualitatively by principal component analysis (PCA), which gives a 
process fingerprint.
5.	 Determine	the	process	design	space. The ranges of critical process attributes that allow 
the manufacturing of product with the specified quality should be known, including 
the interaction of these parameters. This results in the determination of the process 
design space2, 3. In this thesis the known critical process attributes (Temperature, pH, 
DO, density of the seed culture and inoculation density) were studied using a design 
of experiments approach (Chapter 6). This study was at the same time used to obtain 
process fingerprints that lead to proper product quality as described in point 4. 
6.	 Develop	 a	 model	 that	 describes	 the	 process	 design	 space. The process data that 
constitute the process design space need to be available on line so that the process 
control system can match information from PAT sensors with the design space data 
to check if the process is running on target (Chapter 6). This control system needs to 
signal if the process starts to run off target. In a next step the process control system 
should automatically adjust the process so that it returns on the target trajectory. In this 
way product quality is ensured during processing, which is one of the PAT principles. 
For the pertussis vaccine process, the NIR data, the regular process data (i.e. pH, DO, 
temperature) and the microarray data were finally integrated in a statistical model that 
describes the process design space for the cultivation of Bordetella pertussis for a whole 
cell vaccine against whooping cough disease (Chapter 6). Although this model is only a 
starting point and needs to be complemented using data from actual manufacturing runs, 
it demonstrates the feasibility of PAT application on a complex product like a whole cell 
vaccine.
Thus by implementing these six steps for the fermentation step of the pertussis vaccine 
production process for the first time an initial PAT application has been developed for a 
complex biopharmaceutical product For other biopharmaceuticals PAT applications have not 
been developed to date. In general, the more complex the product, the harder it is to develop 
a PAT application for such a product. Modern biopharmaceuticals such as monoclonal 
antibodies are already much better defined than, for instance, a whole cell vaccine, but 
they remain complex structures created using complex processes. However, as long as 
the critical product attributes of any product are known, the interaction between process 
parameters and these parameters are mechanistically understood, and a process sensor is 
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available that captures the critical process attributes, PAT application should be feasible for 
any biopharmaceutical product. 
In this chapter the current status of PAT for  biopharmaceutical processes will be disussed 
together with the challenges for developing PAT for different biopharmaceutical products 
and production platforms. This will be done specifically for the bioreactor process step, 
because this is where the product is being formed and therefore this step can be considered 
the most critical process step, both for a whole cell vaccine as well as for a biopharmaceutical 
protein.
Process	quality	in	the	(bio)pharmaceutical	industry
The design of processes in any manufacturing industry requires understanding of engineering 
principles combined with understanding of the mechanism of the product function and 
assembly. For most products this engineering perspective will result in robust processes that 
allow consistent production of high quality products. Sometimes these can even be called 
“world class” processes,  fulfilling the six-sigma principle (see Box 1). This means only 3.4 
faulty productions for every one million correct ones for a stable process. 
The current situation in the pharmaceutical industry is shown on the left panel of Figure 2: a 
sigma level between 2 and 3. A sigma level of 3 means 5% faulty productions. Application 
of PAT is aimed at increasing the industry’s sigma level. A sigma level between 4 and 5 is 
considered to be feasible for (bio)pharmaceutical products.
One of the most cited persons in the field of process quality thinking is William Edwards 
Deming4. He was one of the first to introduce “statistical quality control”, which comprises 
a set of tools to analyze and improve manufacturing processes, such as the process control 
chart (Box 1). Deming started after the Second World War in Japan, where his ideas helped 
this country to become the world leader in the manufacturing of affordable, high quality 
consumer goods throughout the 1960’s and 1970’s. Key principle was to reduce costs and 
increase process efficiency continuously.
Process stability and capability are essential concepts for efficient manufacturing and process 
development. A process is considered stable when mean, variance and distribution of the 
variance of product specifications are constant over time. A process is considered capable 
when it is able to consistently produce output within its specification limits. Both principals 
are illustrated in Figure 1.
Currently the (bio)pharmaceutical industry functions at a level between 2 and 3 sigma5, which 
means that between 70 % and 95 % of all manufacturing falls within specifications, but 5-30% 
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falls outside specification limits (Box 1). The quality of the output of (bio)pharmaceutical 
processes is ensured by extensive testing of the final product in order to prevent release 
of out of spec products. Because this testing takes place on finished products instead of 
during processing, rejection of out of spec products are a considerable cost component of 
(bio)pharmaceutical manufacturing. 
This inefficiency is caused by a combination of a highly regulated industry with poorly 
monitored and controlled processes. Good manufacturing practice (GMP) regulation relies 
on documented quality assurance based on end product testing. Process performance is 
usually not included in the quality system and the quality control (QC) tests that are used 
are not necessarily representative for safety and efficacy of the product in humans. Thus 
product quality is inadequately assured during processing and, as stated earlier, needs to be 
determined on the finished product. In addition to this, a detailed description of the process 
is part of the registration file of the (bio)pharmaceutical product. This means that when a 
A B C
Figure	 1. Process stability and capability. 3D representation of Shewart’s control charts (Box 1). Each curve 
represents average processing and the corresponding variance of a certain time interval (i.e. a group of batches) 
of the total manufacturing lifetime. The arrow indicates the manufacturing life time of the product. A: stable and 
capable process. Average manufacturing remains centred over time and the variance indicates that product quality 
remains well within the specification limits (dotted lines) B: stable but uncapable process. The process remains 
centred over time, however the variance indicates a significant chance that manufacturing output does not meet the 
specification levels. C: unstable and incapable process. The process variance should allow consistent manufacturing 
within the specification levels, however, the average process output shifts over time towards the upper or lower 
specification level (dotted lines) causing manufacturing outside the specification levels and subsequent rejection 
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product is approved for marketing, the validated process specifications in the registration file 
can not be changed.  Usually when new products have just entered full scale manufacturing, 
little is known about the processing capability and stability. Process variance is estimated 
based on a limited number of batches during early manufacturing and fixed upon approval of 
the process. All future manufacturing is bench marked on these batches and excursions from 
the approved process need to be formally reported as deviation to the regulatory authorities. 
For the manufacturing of biopharmaceuticals, this “process is the product” thinking makes 
an approved process essentially fixed. As a consequence, process optimization or changes 
to the process in general need extensive validation and testing in order to assure that the 
product remains unchanged or “essentially similar”. When this can not be assured, new 
clinical tests are usually required, which makes process optimization a costly matter.
Finally, the regulation of the pharmaceutical industry is enforced through timely inspections 
of production facilities and careful evaluation of all documented deviations, (re)validations 
or other test results that support process changes and disturbances. The enormous amounts of 
paperwork that are accumulated for this purpose have reached a point that inspection becomes 
more and more difficult and time consuming for regulators as well as manufacturers. 
The	PAT	Initiative
In an attempt to overcome this, the American Food and Drug Administration (FDA) launched 
the Process Analytical Technology or PAT initiative in 20026. With this initiative, the FDA 
stimulates the use of current scientific knowledge, modern process analytical tools and 
general processing quality principles for design, analysis and optimization of manufacturing 
processes. Or, as formulated by the FDA: PAT is a system for designing, analyzing, and 
controlling manufacturing through timely measurements (i.e., during processing) of critical 
quality and performance attributes of raw and in-process materials and processes with the 
goal of ensuring final product quality. (FDA’s PAT definition). In other words, a system 
that ensures process capability and stability. Also, manufacturers are now allowed to collect 
manufacturing data for research purposes only, without having to show that data upon 
inspection. This means that manufacturers can investigate their processes without having to 
fear that unexpected or unwanted outcomes of the investigations can be used against them 
during inspection. 
In the recent years, the PAT principles have been adopted by the European EMEA and are 
integrated in recent documents from the International Conference of Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The ICH 
Q8, Q9 and Q10 guidances7 have set the standard for pharmaceutical process development, 
manufacturing and quality assurance in the 21st century. 
When manufacturing becomes more and more reliable, consistent processing can be 
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demonstrated (less deviations, less rejects) and product quality becomes an inherent trade 
of the process (real time quality assurance), the need for inspection will decrease. This is of 
course a major benefit for regulators. For manufacturers the main benefits lie in cost reduction 
by more consistent processing (less rejects), processes that are more optimal (higher yields) 
and can be faster optimized and, just as for regulators, a lower regulatory burden. Of course, 
the purchase of a PAT infrastructure and the acquisition of the required level of process 
understanding will remain an upfront investment, which initially will require extra time and 
money and thus can be reason for manufacturers to stick to the quality-by-testing paradigm. 
However, regulations are changing already and the ability to demonstrate scientific process 
understanding and quality assurance during processing will therefore soon require a PAT 
system that monitors “quality-by-design” processes. 
PAT	for	biopharmaceuticals
For chemical drugs the PAT initiative has already resulted in several approved PAT 
applications (i.e. for tablet inspection or granulate drying). For biological processes, 
however, the upstream cultivation or fermentation unit operations, PAT application is 
considered especially difficult. This is mainly because of the difficulties involved in on-line 
measurements of critical product quality attributes of complex biopharmaceutical products. 
Recently, the FDA has opened an invitation for biopharmaceutical companies to work with 
the agency to submit a pilot PAT submission for a biopharmaceutical product8, in an attempt 
to address the industry’s reluctance to adopt PAT principles. 
Biopharmaceuticals or biologicals are generally considered a separate group of 
pharmaceuticals. Especially the ”original” biopharmaceutical products like vaccines that 
consist of whole inactivated viruses or bacteria, or products purified from blood plasma, 
constitute a relatively undefined group of therapeutics as compared to chemically synthesized 
small molecules.  This is reflected in the fact that the American FDA has separate offices for 
approval of new biopharmaceutical products (CBER) and small molecules (CDER). Notably, 
biopharmaceutical products like monoclonal antibodies and recombinant therapeutic proteins 
have been found to be defined enough so that they can be subject to the same approval 
regulation as small molecules. Since a few years, these biological products are governed 
by the Office of Biotechnological Products (OBP), which is part of CDER. This makes 
approval of these products easier and faster, which aids the current developments of the 
pharmaceutical industry, because most of the newly approved biopharmaceutical products 
are monoclonal antibodies or therapeutic proteins9. 
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Looking at the approved biopharmaceutical products of the past 4 years in the US and 
Europe (Table 110-13) reveals that three production platforms are currently predominant: the 
bacterium Escherichia coli, the yeasts Saccharomyces cerevisiae and Pichia pastoris and the 
mammalian Chinese Hamster Ovary (CHO) cell line. Mammalian cells are emerging as the 
new workhorse of biopharmaceutical manufacturing, as is illustrated by the fact that in 2007, 
12 out of the 15 approved biopharmaceutical products were manufactured using mammalian 
or insect cells9. 
Table	1. The number of approved biopharmaceutical products in the US and EU in 2004-2007 and their respective 
production platforms (From Walsh (2005-200810-13)
Year Total	no.	of	products	approved E. coli
S. Cerevisiae / 
P. pastoris CHO
Other	mammalian	
or	insect	cells
Other
production	
platforms
2004 12 2 1 4 3 2
2005 10 4 2 4
2006 13 4 2 3 2 2
2007 15 2 1 8 4
Total 50 12 6 19 9 4
The manufacturing of biopharmaceuticals generally starts with a series of cultivations 
in order to accumulate enough biomass to inoculate a final production bioreactor. The 
bioreactor process step is then followed by a series of purification steps in order to obtain the 
purified product in the desired formulation. These steps do not add to the intrinsic quality 
of the product as it is formed during the cultivation step, but they are aimed at removing 
unwanted compounds in order to prevent side-effects and increase product safety. In general, 
the higher the necessary purification effort, the lower the recovery of the biopharmaceutical 
product. As stated above, the bioreactor process step can be considered the most critical 
process step in biopharmaceutical manufacturing and therefore the most important process 
step for PAT application.  
Available	PAT	tools	for	bioreactor	monitoring
Implementation of PAT means applying the correct sensor(s) to measure the critical product 
and process attributes of the bioreactor process. Depending on the critical attributes that 
need to be monitored during processing, many PAT tools can be applied either on line or off 
line. An excellent overview of the available tools is given by Kansakoski and coworkers14. A 
summary of currently investigated PAT tools for bioreactor analysis is given in Table 2. 
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Table	2 Available PAT tools and their area of application. Information adapted from14-16
PAT	tool Measured	attribute on/at/off	line*
Optical Spectroscopic tools
Near Infrared Spectroscopy
Many biologically important bonds (aliphatic C-H, aromatic 
or alkene C-H, amine N-H and O-H), physical properties 
(particle size, morphology, optical density)
on line
Infrared and RAMAN 
spectroscopy Detailed chemical information of compounds on/at line
Photoacoustic spectroscopy off gas analysis on line
2D fluorescence 
spectroscopy
Many biomolecules and co-factors with fluorescent 
properties at / off line
UV spectroscopy Measures absorption of biomolecules in the UV spectral range on / off line
Real time imaging On line microscopic analysis of the cultured organism on line
Other spectrometric tools
Mass spectrometry
Analysis of metabolome or proteome of the cultivated 
organism, to get information on the metabolic and 
physiologic state, expression of recombinant proteins, growth 
characteristics and harvest point determination
off line
Dielectric spectrometry Analysis of membrane potential to assess the viability of the culture on line
Biomolecular tools
Green Fluorescent Protein Can be used as a marker for product expression and easily measured on line
Biosensors / Biochips
Sensors that are activated upon binding of a molecule to a 
receptor. 
Highly sensitive for specific compounds
at / off line
Transcriptome or proteome
measurements (microarray)
Analysis of the transcriptome of the cultivated organism, 
which gives information on the metabolic and physiologic 
state, expression of recombinant genes and determination of 
optimal harvest point
off line
Other tools
Flow cytometry Analysis of cell morphology and expression of surface proteins and isolating sub-populations of cells at / off line
On line HPLC Analysis of a cell free sample stream, giving information about nutrient and metabolite concentrations during cultivation. On line
Softsensors
Mathematical algorithms that perform calculations on one 
or more on line available parameters to calculate or predict a 
parameter that is not on line measurable
on line
Dynamic modelling and 
prediction
Statistical process models that incorporate a wide range of 
process data from PAT tools to describe the process and make 
predictions on product formation and quality
on line
* On line: real time measurements of the process; at line: off line measurements that are fast enough to be used to 
control the process; off line: off line measurements that can not be used to control the bioreactor process
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The PAT tools described in Table 2 can be used for different types of measurements in 
bioreactor processes. Some allow direct on line measurements of critical attributes or 
directly linked parameters, like on line HPLC17. Others give on line multivariate data that 
needs chemometric processing before interpretation, such as spectroscopic tools16 like as 
near infrared spectroscopy. Off line tools such as DNA microarrays can not directly be 
used for process control, but provide detailed information on the cellular biology of the 
production platform organism. All gathered knowledge and data finally need to be captured 
in a statistical relationship that describes the process and the evolution of critical product 
attributes during the process.
PAT	tools	for	direct	or	indirect	measurement	of	critical	attributes
Direct measurements of critical attributes are preferable, when they are available. For most 
biological products, critical product attributes are measured using labor- and time intensive 
QC tests, such as ELISA, blotting techniques or animal tests. The information from these 
tests can rarely be used on line or at line, although the trend is towards faster, high throughput 
assays18. Recent developments in the biosensor and biochips fields19, 20 show promising 
developments that would make on line measurements of more critical product attributes of 
complex biopharmaceuticals feasible in the near future. As for now, these sensors are usually 
too complex or unreliable to be used in controlling biopharmaceutical manufacturing. 
In many cases derived, indirect parameters of critical attributes can be measured more easily 
than the critical attribute itself. For instance, the direct measurement of the capacitance of 
the cell membrane using dielectric spectrometry can be used as a surrogate for mammalian 
cell culture viability21. A direct measurement of viability involves sampling, staining and 
microscopic observation, which can not be made available on line. A number of robust 
sensors are available at the moment (i.g. Aber®’s capacitance probe). Also, computer 
algorithms (so called soft sensors) are available that predict a non-measurable parameter 
based on its interaction with parameters that can be measured on line. For instance, bacterial 
cell density can be predicted based on the culture’s oxygen consumption rate 22,23. The trend 
to bring measurements on line that were previously only available off- or at line allows a 
new level of feedback control based on these new on line process data. This will enhance the 
controllability of bioreactor processes.
PAT	tools	for	multivariate	analysis	of	critical	process	attributes
Multivariate measurements, like near infrared spectroscopy,  are powerful in the sense that 
they can capture many variables in a single measurement. The difficulty is  that it is usually 
hard to directly link critical attributes to one or more of these variables. Correlation between 
multivariate measurements and critical process and product attributes requires chemometric 
tools such as principal component analysis (PCA) or partial least squares (PLS) calibration 
models (see Chapters 5 and 6) . These techniques search patterns in the multivariate dataset 
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that correlate with the critical attributes of the process or the product. After validation, 
these correlations can be used as an indirect measurement of the critical attributes on 
line. This approach can be used for measurement of critical attributes for which no direct 
on line measurement is available. A number of robust probes for multivariate bioreactor 
monitoring are commercially available (i.g. NIR and Raman probes from several suppliers, 
or the fluorescence BioView® probe from Delta, Denmark). These probes can be readily 
implemented for bioreactor monitoring without technical adjustments to the bioreactor vessel. 
In that respect they form a good starting point for PAT application, because data collection 
can be started immediately, without disturbing the existing process. The collected data can 
then be analyzed (off line) for correlations with critical attributes and subsequently the PCA 
analysis or PLS calibration models can be run on line during manufacturing. However, these 
chemometric analytical tools require the aid of trained chemometricians, especially for the 
modelling of the more difficult non-linear phenomena, which might be a hurdle that prevents 
especially the smaller companies from implementing multivariate tools.
Transcriptome	and	proteome	analysis
Transcriptome or proteome analysis using DNA or antibody microarrays gives complex 
data. Especially for eukaryote organisms or organisms that are not as thoroughly 
investigated as, for instance,  E. coli or S. cerevisiae, interpretation of expression data can 
be difficult. Key is to identify the genes or proteins that are correlated with the critical 
attributes of the product and to use the available scientific knowledge of these specific genes 
and proteins regarding their role and function in cell physiology (see Chapter 2). In this 
way, an understanding is acquired about the interaction between cellular physiology and 
the product during manufacturing. For instance, how cultivation parameters can influence 
glycosylation profiles of complex biopharmaceuticals such as EPO (i.e. the genes and 
enzymes that are involved and how they are regulated). This understanding allows a more 
scientific approach towards process optimization and future process development. Another 
way the measurements of the transcriptome of the production organism can be used is as 
a fingerprint of the physiological (and metabolic) state of the organism. These fingerprints 
can be used to compare overall expression profiles of samples taken during manufacturing 
in order to investigate processing consistency. Of course, these techniques only show part of 
the complex picture of interactions between the several “omics” fields (i.e. transcriptomics, 
proteomics, metabolomics or fluxomics). Regulation of cellular processes can take place 
in may ways, some of which, like siRNA, we are only beginning to understand. Omics 
techniques will generally be less difficult to apply on simpler (prokaryote) organism than 
on, for instance, mammalian cells. The problem of data complexity can be partly overcome 
when only an isolated pathway or group of genes is important for a certain critical product 
attribute. Much like the product marker genes described in Chapter 2, only a limited number 
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of data points are investigated in detail, while the rest of the data can be used only to screen 
for deviating patterns. Of course this approach requires a priori knowledge of which genes 
are important for critical product attributes.
Descriptive	process	modeling
As`stated, key for PAT implementation is to establish a (statistical) relationship between 
processing conditions and the quality of the product. In order to be able to do this, the 
information from the bioreactor control system (i.e. pH, temperature, gas flows, etc) and 
from the additional PAT tools needs to be combined and correlated to information on product 
quality and scientific knowledge24 (see Chapter 6). Such a model can then be used on line 
to monitor the process and check whether product of the specified quality is produced. 
In a second stage, these models should be able to control the process upon deviations or 
disturbances. The complete integration of product- and process understanding, process 
data and product quality with the aim to assure final product quality is what defines a PAT 
system. 
Recently, software has come available that allows both the integration of all available data 
and the development and execution of process control models (Chapter 6 of this thesis). 
With this, the technical realization of full PAT application on a biopharmaceutical cultivation 
process has become feasible. 
Challenges	for	PAT	application	in	bioreactor	processes
A bioprocess is considered more variable than a chemical process (e.g. chemical synthesis) 
or a physical process (e.g. drying). This assumption is based on the current common practice 
and the inherent theoretical complexity of a biological process. This is especially the case for 
the older biopharmaceutical products for which micro organisms and mammalian cells are 
cultured using complex cultivation media. Bovine blood serum, yeast extract, bovine heart 
extract or casein hydrolysates are examples of commonly used complex medium components. 
These components have a highly variable composition of a range of free amino acids, di- 
and tri-peptides and even more complex structures and co-factors. Batch to batch variation 
of a cultivation medium that contains these undefined components can be a major cause for 
bioprocess variation25. Currently, most of the production media are animal component free, 
protein free or even chemically defined, which makes the medium composition easily to 
monitor and control, a crucial prerequisite for PAT application
Another source of variance of a bioreactor process is the condition of the cells that are used 
to inoculate the final bioreactor. These cells usually originate from a frozen cell bank which 
is stored at -70 °C or -140 °C. This Working Cell Bank (WCB, for mammalian cells) or 
Working Seed Lot (WSL, for micro-organisms), is made periodically from a master seed or 
cell bank. The handling procedures to make a WSL or WCB from the master seed lot or cell 
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bank can already influence process variation26,27. 
Going from the WSL or WCB to the actual manufacturing scale bioreactor is another critical 
stage in terms of bioprocess variation. This usually involves a series of cultivations going 
from shake flasks or cultivation plates to small-scale bioreactors before the manufacturing 
scale bioreactor is inoculated. Ideally cells are maintained in logarithmic growth throughout 
this series, in order to maintain short lag times. The lag time is the time the cell needs to 
adjust to a new environment after inoculation28. Therefore, cells show shorter lag times when 
the conditions in the new flask or bioreactor resemble the conditions from the previous 
flask or bioreactor. In practice this means that the cells do not have to adjust their active 
metabolic routes when transferred into a larger vessel. When the new vessel is also at the 
same temperature and pH as the previous vessel, adaptation of the micro-organisms and with 
that the lag times can be reduced to a minimum29,30. The control of these factors can lead to 
reproducible bioreactor cultivations as has been demonstrated in Chapter 2.  
Also, the strains or cell lines selected for production need to be stably transfected and remain 
genetically stable during the entire manufacturing chain from seed to the harvest of the 
large scale manufacturing bioreactor (ICH Q5D7). Furthermore, the cells need to be able to 
manufacture only product in the correct conformation, since it is very difficult to separate 
the correct product from its similar misfolded or differentially glycosylated counterparts 
during purification.  
A good scientific understanding of the cell’s physiology and the means to investigate 
the evolution of cellular physiology during manufacturing are helpful, if not crucial, for 
understanding the relationship between critical process and critical product attributes.
Biopharmaceutical	bioreactor	platforms
As mentioned above, the majority of biopharmaceutical processes involve the cultivation 
of either E. coli, S. cerevisiae or a CHO cell line. Although general bioprocess engineering 
principles may apply on all of these organisms, they have very different and specific demands 
and characteristics that need to be considered in order to develop a process compliant with 
the PAT principles. The choice of the expression system is usually based on the specific 
characteristics of the therapeutic protein that is being expressed31. Proteins that require 
(eukaryote) post-translational modifications such as acetylation, amidation, carboxylation, 
hydroxylation, disulfide bond formation, glycosylation, phosphorylation, proteolytic 
processing or sulphation32 in order to attain their full biological and therapeutic function can, 
for instance, not be effectively produced using the prokaryote E. coli, but require mammalian 
cells. E. coli  is highly suitable for the expression of small proteins or peptides, however9, 33. 
The yeast S. cerevisiae  can serve as an intermediate, in the sense that it is able to perform 
eukaryote post translational modifications. However, the obtained modification pattern does 
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not resemble the human pattern, which may give problems in proteins that are strongly post 
translationally modified34. 
Bacteria
Bacteria have the obvious benefits of fast growth on simple and cheap media and can over 
express large amounts of recombinant proteins. Furthermore, they can be easily transfected to 
yield genetically stable production strains. This makes them commercially very attractive. 
The cultivation of bacteria for biopharmaceutical production generally involves either a batch 
or a fed-batch strategy. A batch cultivation is technologically the most simple cultivation 
strategy, which means it also has, in principle, the least number of critical process attributes. 
For batch cultivation the starting material, i.e. the seed and the medium, is one of the two key 
parameters to be controlled (Chapter 2), because during cultivation only basic parameters 
such as pH, dissolved oxygen and temperature can be controlled, usually at a fixed set point. 
This means that these parameters are only critical for product quality in case of sensor 
failures or process disturbances (Chapter 3). The other key parameter to be controlled is 
the determination of the harvest point. It can be critical to harvest before nutrients become 
limiting and physiological changes in the cell compromise product quality (Chapter 4). Or, 
more commonly, cell lysis starts after the nutrients are depleted, causing massive release of 
DNA and cellular proteins such as proteases, which can hamper product purification or cause 
problems with product degradation. 
In a fed-batch process, a nutrient containing feed is pumped into the bioreactor, allowing 
much higher biomass and product concentrations compared to batch cultivation. It can be 
operated either by supplying ample nutrients in order to ensure the maximum growth rate, or 
by supplying a limiting amount of nutrients and in this way control the growth rate with the 
feed rate35. The latter means that the bacteria are grown under continuous nutrient limiting 
conditions, which may have unwanted side effects on cell viability and subsequently on 
product formation36, 37. The critical attributes to consider for PAT application in a fed-batch 
process are not only seed and medium quality and controlling the physiological parameters 
pH, DO and temperature, but also the feed rate and feed composition. A fed batch cultivation 
usually ends when the desired optical density is reached, or, more practically, when the 
bioreactor vessel is full. The end of the process can therefore be easily monitored. 
 
The high biomass densities that bacterial cultivation can reach, especially using fed batch, 
put high demands on the oxygen supply and mixing of the bioreactor vessel. This means 
that, especially at larger volumes, a bioreactor may suffer from gradients radiating away 
from where oxygen enters the bioreactor (usually near the stirrer). Gradients in pH and 
temperature are common in larger vessels as well. As a result of these gradients, the content 
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of the bioreactor can be inhomogeneous, introducing variance in bacterial physiology and 
the overall gene expression profile38-40. Understanding how gradients affect the product is a 
key aspect of reducing variance within a batch or fed-batch cultivation. 
Because Escherichia coli is probably the most studied organism in molecular biology, it is 
easier to acquire a scientific understanding of the interaction between the process, the cell’s 
physiology and subsequently product formation and quality.  Much research has been done 
already on the optimization of recombinant protein expression in E. coli 41-43. Because E. coli 
can only excrete proteins to a limited extent and mostly not beyond the periplasmatic space44, 
high yield production of recombinant protein in E. coli usually involves the formation of 
inclusion bodies, which are intracellular aggregates of the over expressed protein. These 
aggregates need to be refolded after primary recovery in order to obtain the protein in its 
biologically active form45. This refolding is a very critical parameter for the conformational 
structure and thus the efficacy of the product, which is difficult to control. Thus, in terms of 
PAT the proper control of the refolding of proteins is a challenge for these processes. 
When proteins are accumulated in inclusion bodies, induced expression is more favorable 
than constitutive expression, because the massive expression of the recombinant protein 
and the high concentrations of aggregated proteins inside the cell can interfere with normal 
cellular physiology46. Induction can be achieved either by an increase in culture temperature 
(heat shock) or by the addition of a specific chemical, that triggers the activation of the 
promotor of the recombinant gene47. Controlling the induction of product formation adds 
another critical parameter to the process, however, because the moment of induction and 
the growth environment can influence product expression48. This means that PAT tools need 
to monitor each phase (growth and production) and determine the optimal point for the 
induction of product formation49,50. 
This means that the challenges for PAT applications on bacteria, such as the control of 
process inputs, control of feed rate and composition, knowledge on process gradients and 
control of protein refolding, can technologically be met. The final challenge is to combine 
this technology with the appropriate scientific knowledge to build a PAT application that is 
capable of monitoring all critical process attributes through these PAT sensors and use this 
data for real time quality assurance of the product.
Yeast
S. cerevisiae and other yeasts, like Pichia pastoris, are also fast growing micro oganisms that 
can express large amounts of recombinant protein. Yields are typically somewhat less than an 
E. coli based process, but still commercially very attractive. Most of the PAT challenges for 
the cultivation of E. coli are applicable to yeast cultivation as well51: Yeasts can be cultivated 
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using either a batch or fed batch process and larger scale processes are prone to inhomogenities 
caused by gradients inside the reactor vessel. The more complex metabolism of S. cerevisiae 
and other yeasts makes the control of the feed for a fed batch process more difficult. Yeasts 
are generally able to utilize several carbon sources both aerobically and anaerobically52, 53 
This complex metabolism can cause S. cerevisiae to produce ethanol (usually an anaerobic 
metabolite, which can be toxic at millimolar concentrations) under aerobic conditions when 
excess carbon sources are available. Control of the feed rate and composition are therefore 
more critical and complicated as compared to a bacterial process. 
Yeast can be easily and stably transfected for expression of recombinant proteins. Both 
constitutive and induced expression can be used, depending on the specific product 
characteristics. Recombinant human proteins, such as insulin, glucagon or granulocyte 
macrophage colony stimulation factor (GM-CSF) expressed in S. cerevisiae are among the 
first biopharmaceutical products on the market34. Because of its capability to make some 
post-translational modifications, it is more suitable to produce complex biopharmaceuticals 
than bacteria. However, the pattern of, for instance, N-linked glycosylation is markedly 
different from human glycosylation patterns54 with glycosylation in yeast usually showing a 
high mannose content. Therapeutic proteins with a non-human glycosylation pattern, usually 
have a shorter plasma half-life time than proteins with a human glycosylation pattern. More 
importantly, they can become a target for the immune system with all sorts of unwanted 
side-effects as a result. To overcome this problem, the glycosylation pathways in yeast can 
be “humanized”. For therapeutic proteins with relatively simple glycosylation patterns this 
can already be achieved, which means that yeast will become a more important production 
platform in the future. However, product yield and capping of N-glycans with sialic acid are 
challenges that still need to be resolved. An overview of the work in this field is given by 
Wildt and Gerngross55.  For PAT application, the understanding of how processing conditions 
influence glycosylation profiles is the real challenge. PAT tools can be applied to monitor 
and control the processing conditions that will result in correctly glycosylated, or otherwise 
post translationally modified products.
Mammalian	cells
Mammalian cells, such as the Chinese Hamster Ovary (CHO) cell, grow very slowly 
compared to bacteria or yeast. From a commercial perspective, this means that the platform 
is only interesting for products with a high added value  that can not be produced using 
bacteria or yeast. 
The strategy for cultivation of mammalian cells first depends on the cell’s need for a 
solid surface for anchorage and growth. In order to be able to grow anchorage dependent 
in suspension, a solid surface is suspended in a bioreactor; the so called microcarriers56. 
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Although this technology allows large scale cultivation of animal cells, sub-cultivation 
requires detaching of the cells and subsequent reattachment to the new surface. This is highly 
variable and labour intensive and is more critical than the sub-cultivation of suspension 
cells in terms of process consistency. Most new biopharmaceutical products are therefore 
produced using anchorage independent or suspension cells, such as the CHO cells. Therefore 
we will focus on these cells.
Because of the relatively low density of CHO cell cultures, large bioreactors with a 
working volume between 1 m3 and 20 m3 are used in order to have a high enough yield of 
the therapeutic protein57. The costs of large scale pharmaceutical grade bioreactors and the 
economic risk of a failed batch at even larger scale, prevent the use of even larger bioreactors. 
Manufacturers usually end to building a series of smaller bioreactors to reach the desired 
cultivation volume. 
The complexity of mammalian cells results in many critical cultivation process parameters, 
starting with the medium composition. Even chemically defined media are relatively complex 
and only available for a limited number of cell lines. Furthermore, their genetic complexity 
makes it difficult to generate stable cell lines, as mentioned earlier. Also the selection of high 
producing clones58, 59 and the requirement to demonstrate that the cell line originates from a 
single clone (ICH Q5D guidance7), are challenges for mammalian cells and even this does 
not guarantee a stable and reproducible production platform60. 
Fed batch or perfusion cultivation strategies are also applied in order to increase cell density. 
Wheras a fed-batch only has a feed rate, a perfusion culture has next to a continuous input 
of fresh medium also an outgoing cell free perfusion flow. In addition, often a bleed flow of 
cells and medium is required to maintain the viability of the culture above a certain level. 
The perfusion and bleed flow exactly balance the incoming feed rate, which means that the 
cultivation volume is constant. Furthermore, a steady state is reached after a certain time. Also 
the composition of the feed is different. In fed batch this is usually a concentrated solution of 
essential nutrients, while in perfusion it is usually the same as the cultivation medium.  Both 
strategies introduce difficult to control critical process parameters. For example, the lack of 
understanding of cellular physiology and metabolism, at least when compared to the state 
of the art for E. coli or S. cerevisiae, makes it difficult to develop a feed with the optimal 
composition for fed-batch as well as for perfusion processes. 
The retention of cells in a perfusion process, especially at larger scales or higher cell densities, 
is difficult to control resulting in variable bleed rates and as a consequence variable cell 
densities and viabilities. Furthermore, many cell retention devices are placed outside the 
controlled bioreactor environment, exposing the cells to gradients, which again are difficult 
to control and the effect of which on cell physiology is unknown. 
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Especially for perfusion processes, production times increase considerably and, with that, 
the number of cell divisions during manufacturing. Longer manufacturing times pose 
challenges for the stability of sensors for process monitoring and the sterility of the system. 
In addition, mammalian cell lines are in general less stable than yeasts and bacteria, which 
can have negative consequences for the stability and capability of the process. For example, 
the metabolism of a cell may change after a certain number of cell divisions, which will have 
consequences for the feed composition, for instance. However, stability of the cell line in 
terms of critical product attributes, such as glycosylation patterns of the product, needs to be 
demonstrated for approval of a new product (ICH Q5D7).  Because the knowledge on what 
influences the stability of animal cell lines is limited, this usually means a trial and error 
approach for finding the optimal high producing clone, rather than a targeted search. 
An understanding of the influence of process conditions and nutrient or metabolite 
concentrations on critical product attributes is necessary61 for the application of PAT tools. 
This understanding is beginning to arise, especially for CHO cells, where genetic engineering 
and process optimisations allow the control of product glycosylation patterns62. This means 
that PAT application based on actual understanding of critical parameters of a mammalian 
cell process may be feasible in the near future.
An alternative for the engineering and selection of a stable, high-producing clone is transient 
expression. Transient expression can be achieved by both viral and non-viral gene delivery 
systems63. A recently approved transient expression system for biopharmaceutical products is 
baculovirus transfection of insect cells13 (Cervarix®). This system is also becoming available 
for mammalian cells64. The main benefit of transient expression is the speed at which the 
transfection vectors can be generated and entered into the host cell for gene expression. 
Especially for, for instance, a fast track to clinical testing this method is widely used. 
However, stable transfection is preferable, both from a regulatory as from an engineering 
perspective, because the infection or transfection methods that are applied are very complex 
and hard to controll to ensure final product quality. Despite these challenges,  mammalian 
cells are the only single-cell production platform that is able to express complex proteins 
with a human (like) pattern of glycosylation an other post translational modifications at 
acceptably high levels, which explains their increasing popularity as the workhorse of newly 
approved biopharmaceuticals9, 13. 
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Conclusions
This thesis demonstrates how PAT can be applied on a bacterial cultivation process and how 
the critical process and product attributes of a complex biopharmaceutical can be assessed. For 
other biopharmaceutical production processes, the same principles can be applied, but each 
production platform and each product has its own specific critical attributes. Understanding 
of the interaction between critical process and product attributes is the starting point for any 
PAT application. For the development of a PAT system, the selection of the appropriate PAT 
tools, which are the tools that are able to monitor the critical attributes on line, is depending 
on the specific characteristics of each process and product.
One of the difficulties of bioreactor processes, especially for batch processes such as the 
cultivation of Bordetella pertussis described in this thesis, is that only a few parameters can 
actually be controlled during processing. For a batch cultivation these are usually pH, DO, 
temperature and stirring speed. Because of the lack of control during processing, the other 
critical parameters, such as seed quality, medium quality and composition or sterility, need 
to have been controlled at the start (inoculation) of the process. The only remaining critical 
parameter is the harvest point, which can be determined based on the monitoring of the 
evolution of critical process parameters (such as nutrient concentrations, see Chapter 4). 
In general, each manufacturing platform has its own specific challenges. While bacteria can 
be stably transfected and easily grown to high densities at low costs, the limited range of 
products that are suitable for bacterial expression limits their use. Yeasts have largely the 
same benefits in terms of yield and ease of transfection as bacteria and they can express a 
much broader product range, especially when post translational modification pathways are 
“humanized”. However, medium and feed composition are more complex than for bacteria, 
because of the more complex metabolism, which introduces new critical parameters. 
Mammalian cells are the only suitable platform for high yield production of complex, highly 
glycosylated therapeutic proteins or antibodies. Their complexity, both on the genetic as on 
the metabolic level, introduces complex sources of variance and thus more challenges for 
PAT application.
When there are no means to compensate for variation in process input during processing (i.e. 
the process is fixed), there are two possible strategies. Either the variation in process inputs 
is reflected in process outputs, or, the process input variation is controlled to such an extent 
that process output becomes consistent. This second situation is common practice in current 
biopharmaceutical manufacturing and is described in Chapter 2. Application of PAT on such 
a process means monitoring of critical attributes during the entire process, from the moment 
the medium enters the bioreactor (before inoculation) until the harvest of the product. In this 
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way, process evolution can be captured and compared to the desired evolution trajectory 
or design space. This thesis describes the application of this approach on the cultivation of 
Bordetella pertussis bacteria for a whole cell vaccine against whooping cough disease.
This approach can be viewed as a first level of PAT application, where product quality is 
assured by strict compliance to operating procedures and real time confirmation by the 
process control system if everything is running as expected. The next level of PAT application 
involves a process that is capable of controlling all critical attributes. In other words, a 
variable process that adjusts itself in order to cope with variance in process input. Examples 
for this can be found in other industries. For instance, an oil refinery can cope with the high 
variation in the composition of crude oil, and still produce petrol and even more defined 
products with consistent composition. This is possible because the process adapts based on 
PAT measurements of the input materials. 
For a bioreactor batch cultivation process this is much more difficult to imagine. Maybe it can 
look like a complex fed batch setup in which the medium components are all added depending 
on their specific consumption rates. Or even like a complex array of inducible genes that can 
be controlled by adding specific inducers depending on the evolution of critical process 
attributes. In either way, such an application depends on a sound scientific understanding 
of the mechanisms inside the cell that result in product formation and their interaction with 
processing conditions. It is this understanding that is the true enabler of PAT application 
and the extent of subsequent implementation is largely dependent on technological aspects 
like the availability of the appropriate sensors to measure a critical attribute or the process 
controller that can adjust the process accordingly. Already when the people that operate the 
process understand how processing conditions influence product formation and quality, will 
processing consistency increase. 
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Process	Analytical	Technology	or	PAT	is	an	initiative	launched	by	the	American	Food	and	
Drug	Administration	 (FDA)	 in	 2003	 and	 has	 been	 adopted	 by	 the	 European	Medicines	
Agency	(EMEA)	and	the	International	Conference	for	Harmonization	(ICH)	as	well.	By	this	
initiative,	the	regulators	want	to	overcome	manufacturing	rigidity	caused	by	the	regulations	
that govern the pharmaceutical industry and move to more flexible processing. This can 
be achieved by providing scientific evidence of the ranges of processing conditions and -
parameters	(critical	process	attributes)	that	will	result	in	the	manufacture	of	products	with	the	
desired specifications (critical product attributes). The interaction between critical process 
and product attributes needs to be understood. These scientifically supported manufacturing 
ranges	constitute	the	so	called	process	design	space.		
In	addition	to	this,	on	line	measurements	(using	PAT	tools	and	sensors)	need	to	monitor	the	
process in order to assure that the process runs within the specified ranges of critical process 
attributes,	 thus	within	the	process	design	space.	By	applying	this	principle,	 the	assurance	
of	product	quality	can	 rely	 less	on	 the	mandatory	end	product	 testing	 (as	 is	now	usually	
the	case)	and	more	on	the	actual	process	data.	When	all	what	is	critical	is	measured	during	
the	process	and	the	tolerance	of	these	critical	attributes	is	known	and	understood,	quality	
assurance	can	actually	become	part	of	the	process	itself.	
The increased scientific understanding allows more flexibility in manufacturing, because 
deviations	from	the	target	process	can	be	assessed	for	their	impact	on	product	quality,	rather	
than	rejection	of	the	batch	or	only	accepting	it	after	testing	of	the	end	product.	Also	process	
optimizations	 and	 subsequent	 changes	 of	 the	 process	 target	 settings	 within	 the	 process	
design	space	are	no	longer	subject	to	regulatory	approval	when	the	process	design	space	has	
previously	been	approved	for	registration.
FDA’s	original	PAT	guidance	document	was	intended	for	small	pharmaceutical	molecules.	
Larger	molecules	(i.e.	therapeutic	proteins	or	antibodies)	or	vaccines	(i.e.	inactivated	viruses	
or bacteria, or parts of them) are more complex and therefore application of PAT is considered 
more difficult. Especially the cultivation process step that is usually part of the processes for 
the manufacture of these biological products is a complex unit operation. It involves the 
growth of cells or micro organisms that express the protein of interest using a bioreactor 
system.	In	 the	case	of	whole	cell	vaccines,	 it	 is	 the	cultivated	pathogen	that	 is	 the	actual	
product. These processes and their underlying mechanisms are much more complex than 
the	processes	for	small	pharmaceutical	molecule,	where	chemical	synthesis	is	the	product	
forming	unit	operation.	
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In this thesis the application of PAT on a complex biological product, a whole cell vaccine 
against	whooping	cough	disease,	is	investigated.	A	whole	cell	vaccine	means	that	the	product	
consists	of	 inactivated	whole	cells	of	 the	pathogen,	 in	 this	case	 the	bacterium	Bordetella 
pertussis.	The	vaccine	functions	by	inducing	a	protective	immune	response	against	proteins	
on	the	outer	membrane	that	are	presented	to	the	patient’s	immune	system.	The	composition	
of	 the	 outer	membrane	 of	 the	 bacterium	 can	 therefore	 be	 considered	 crucial	 for	 vaccine	
efficacy and product quality. Many of the outer membrane proteins are involved in bacterial 
virulence.	They	 play	 a	 role	 in	 the	 attachement	 to	 human	 epithelial	 cells	 and	 subsequent	
colonization	and	infection.	
In	order	to	be	able	to	asses	the	outer	membrane	composition,	a	DNA	microarray	analysis	was	
developed	to	measure	mRNA	levels	of	all	the	genes	of	the	bacterial	cells	during	cultivation.	
By measuring mRNA expression levels on samples taken during processing, understanding 
was built on how process conditions influence growth and outer membrane composition 
and what this means for the expected quality of the final vaccine. Fifty-six conserved 
marker genes were identified to be activated when Bordetela pertussis	 enters	 its	virulent	
state.	These	include	all	genes	that	code	for	outer	membrane	proteins	involved	in	inducing	
a protective immune response. The expression levels of these marker genes could then be 
used	 to	calculate	a	quantitative	product	quality	 score.	This	 score	 is	a	weighed	 indication	
of	Bordetella pertussis’ virulent state and can thus be expected to indicate product quality 
during	cultivation.
In	this	way	the	response	of	the	bacteria	to	changes	during	normal	and	disturbed	processing	
could be quantified. For instance, the response of the cells and the expected effect on product 
quality after a period of oxygen depletion or the depletion of nutrients at the end of the 
process were determined. Oxygen limitation was shown to be reversible in overall gene 
expression levels and did not affect the virulence marker genes at the end of cultivation. Also 
by	determining	the	product	quality	score	at	many	time	points	during	cultivation,	the	optimal	
point	of	harvest	was	determined.	The	optimal	harvest	point	proved	to	be	dependent	on	the	
concentrations	of	the	nutrients	lactate	and	glutamate.	
Because	 the	DNA	microarray	 analysis	 is	 an	off	 line	measurement,	 it	 can	not	 be	used	 as	
PAT tool. In fact, it is difficult to measure the entire composition of the outer membrane 
by	an	on	line	PAT	sensor.	To	overcome	this,	on	line	near	infrared	(NIR)	spectroscopy	was	
implemented. NIR can be used in two ways. First to measure fingerprints of the entire process 
by	determining	the	variance	between	many	spectra	taken	during	processing,	which	allows	
batch-to-batch comparison. Second to measure specific process parameters on line that were 
previously	only	available	off	line,	such	as	optical	density	or	nutrient	concentrations.	
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Finally, in order to determine the process design space, an experimental design (DoE) was 
followed.	The	ranges	of	process	conditions	that	allow	the	cultivation	of	Bordetella pertussis 
with the desired outer membrane composition were explored, which was confirmed at 
the	end	of	each	batch	using	DNA	microarrays.	During	these	cultivations	all	process	data,	
including	NIR,	were	collected	in	a	central	database.	These	data	were	subsequently	processed	
to build a statistical model that encompasses all the explored ranges and thus describing the 
process	design	space.	This	model	can	be	used	to	check	if	new	production	runs	fall	inside	the	
explored process design space, so that they can be expected to lead to the desired product 
quality.	 This	 approach	 demonstrates	 how	 quality	 assurance	 can	 be	 built	 into	 a	 bacterial	
cultivation process for vaccine manufacturing, thus fulfilling the PAT principles.
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Process	 Analytical	 Technology	 oftewel	 PAT	 is	 een	 initiatief	 dat	 in	 2003	 door	 de	
Amerikaanse	Food	and	Drug	Administration	 (FDA)	 is	gestart.	 Inmiddels	 is	het	ook	door	
Europese	regelgevers	overgenomen	en	is	het	opgenomen	in	richtlijnen	van	de	International	
Conference	of	Harmonization	(ICH).	Door	dit	initiatief	probeert	de	regelgever	de	starheid	
van (bio)farmaceutische processen te doorbreken en meer flexibiliteit toe te staan. De starheid 
wordt	veroorzaakt	door	de	strenge	regelgeving	die	voor	deze	 industrie	van	 toepassing	 is.	
Meer flexibiliteit kan alleen worden toegestaan als er voldoende wetenschappelijk bewijs 
is	 dat	 kritieke	 procescondities	 binnen	 een	 bepaald	 bereik	 resulteren	 in	 een	 product	 van	
voldoende	 kwaliteit.	De	 invloed	 van	 procesparameters	 op	 (de	 vorming	 van)	 het	 product	
tijdens	het	proces	dient	hierbij	volledig	bekend	 te	zijn.	Het	gecombineerde	onderbouwde	
bereik	van	alle	procesparameters	samen	vormt	als	het	ware	een	multi-dimensionale	ruimte,	
waarbinnen	het	proces	altijd	een	product	van	de	gewenste	kwaliteit	oplevert.	Deze	ruimte	
wordt	de	process design space	genoemd.		
Daarnaast	 dienen	 on	 line	metingen	 tijdens	 het	 proces	 (met	 zogenaamde	 PAT	 tools	 en	 –
sensoren)	het	proces	goed	te	volgen	zodat	kan	worden	gecontroleerd	of	het	proces	nog	binnen	
het gespecificeerde bereik van de respectievelijke kritische procesparameters verloopt. Deze 
toepassing	leidt	ertoe	dat	al	tijdens	het	proces	uitspraken	over	de	kwaliteit	van	het	product	
kunnen	worden	gedaan.	Immers,	wanneer	de	PAT	tools	hebben	aangetoond	dat	het	proces	
het	gewenste	verloop	heeft	gehad	en	in	ieder	geval	binnen	de	design space	is	gebleven,	is	de	
productkwaliteit geborgd. Hierdoor hoeft men minder op het testen van het product na afloop 
van	het	proces	te	vertrouwen,	hetgeen	nu	de	verplichting	is,	maar	kan	men	meer	van	de	on	
line	procesdata	uitgaan.	 Indien	alle	kritische	parameters	daadwerkelijk	 tijdens	het	proces	
kunnen	worden	gemeten	en	de	tolerantie	op	deze	parameters	in	termen	van	productkwaliteit	
bekend	is,	dan	wordt	kwaliteitsborging	als	het	ware	onderdeel	van	het	proces	zelf.	
Het	 verhoogde	wetenschappelijk	 inzicht	 in	 de	 interacties	 tussen	 product	 en	 proces	 staan	
meer flexibiliteit in de uitvoering van het proces toe, doordat afwijkingen in het proces 
kunnen	 worden	 ingeschat	 op	 hun	 effect	 op	 de	 kwaliteit	 van	 het	 product.	 Met	 andere	
woorden,	 of	 ze	 binnen	 of	 buiten	 de	design space	 vallen.	Wanneer	 het	 proces	 binnen	 de	
design space	blijft,	hoeft	het	product	niet	te	worden	afgekeurd	of	de	test	op	het	eindproduct	
te	worden	afgewacht.	Daarnaast	zijn	veranderingen	van	het	proces	binnen	de	design space	
als	 uitkomst	van	optimalisatie	 studies	ook	 toegestaan.	Deze	hoeven	niet	 ter	 goedkeuring	
aan	de	regelgever	te	worden	voorgelegd,	wanneer	de	hele	design space	al	eerder	door	de	
regelgever	is	goedgekeurd.
De	 originele	 PAT	 richtlijn	 van	 de	 FDA	 was	 eigenlijk	 alleen	 bedoeld	 voor	 kleine,	
chemische	farmaceutische	moleculen.	Grotere	moleculen	(zoals	therapeutische	eiwitten	of	
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antilichamen)	of	vaccins	(vaak	geinactiveerde	bacteriën	of	virussen,	of	onderdelen	daarvan)	
zijn veel complexer. Daarom kan toepassing van PAT op de productieprocessen voor deze 
biofarmaceutica	als	ingewikkelder	worden	beschouwd.	Met	name	de	cultivatie	stap,	waarbij	
dierlijke cellen, gisten of bacteriën worden opgekweekt, is een zeer complexe stap. Het is 
meestal	de	 eerste	 stap	 in	 een	biofarmaceutisch	productieproces	 en	het	 is	de	 stap	waarbij	
het	eigenlijke	product	wordt	gevormd.	Of,	in	het	geval	van	vaccins,	waarbij	het	gekweekte	
pathogeen zelf het product is. Deze processtap is veel complexer dan de chemische synthese 
die	de	product-vormende	stap	voor	kleine	chemische	geneesmiddelen	vormt.	
In dit proefschrift worden de mogelijkheden voor toepassing van PAT op een complex 
biofarmaceuticum,	een	cellulair	vaccin	tegen	kinkhoest,	onderzocht.	Een	cellulair	bacterieel	
vaccin	 betekent	 dat	 het	 product	 uit	 geïnactiveerde	 cellen	 van	 het	 pathogeen	 bestaat,	 in	
dit	 geval	 de	 bacterie	Bordetella pertussis.	De	werking	 van	 een	 dergelijk	 klassiek	 vaccin	
is	 gebaseerd	 op	 het	 opwekken	 van	 een	 immuunrespons	 tegen	 de	 afgedode	 bacteriën	 die	
bescherming	biedt	 tegen	 infectie	met	 levende	bacteriën.	Met	name	de	buitenkant	van	de	
bacteriële	 cel	wordt	herkend	door	het	 immuun	 systeem	en	de	 immunologische	afweer	 is	
dan	 ook	 gericht	 tegen	 structuren	 op	 de	 buitenkant	 van	 de	 cel.	 De	 samenstelling	 van	 de	
buitenmembraan	is	dus	van	groot	belang	voor	de	effectiviteit	van	het	vaccin.	Veel	van	de	
eiwitten	op	de	buitenmembraan	zijn	betrokken	bij	de	virulentie	van	de	bacterie.	Ze	spelen	
bijvoorbeeld	een	rol	bij	de	hechting	van	de	cel	aan	een	gastheercel	en	het	verder	koloniseren	
en	infecteren	van	de	keelholte.	
Om	 uitspraken	 over	 de	 samenstelling	 van	 de	 buitenmembraan	 te	 kunnen	 doen	 werden	
de expressie niveaus van alle genen van de bacteriële cel tijdens het cultivatieproces 
gemeten	met	DNA	microarrays.	Uit	deze	metingen	volgde	informatie	over	het	effect	van	
procescondities op de expressie van de verschillende genen, waaronder de genen die voor 
de	 buitenmembraan-eiwitten	 coderen.	 Op	 deze	 manier	 kon	 het	 effect	 van	 veranderende	
procescondities	op	de	verwachte	kwaliteit	van	het	product	worden	ingeschat.	Uiteindelijk	
werden	56	marker	genen	gevonden	die	allen	geactiveerd	worden	als	Bordetella pertussis	
virulent	wordt.	Hierbij	zaten	alle	genen	die	coderen	voor	(buitenmembraan)eiwitten	waarvan	
bekend	 is	dat	ze	betrokken	zijn	bij	het	 induceren	van	een	beschermende	 immuunrespons	
na vaccinatie. Het expressie niveau van deze genen werd omgerekend naar een gewogen 
kwantitatieve	score	voor	productkwaliteit	waarmee	de	verwachte	productkwaliteit	 tijdens	
het	kweekproces	kon	worden	aangegeven.	
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Met	 deze	 score	 kon	 het	 effect	 van	 veranderingen	 tijdens	 het	 proces	 en	 als	 gevolg	 van	
procesverstoringen	 worden	 gemeten.	 Bijvoorbeeld	 het	 effect	 van	 een	 verstoring	 van	 de	
zuurstofvoorziening	en	het	effect	van	lage	concentraties	van	nutriënten	aan	het	einde	van	
de	kweek	zijn	onderzocht.	Zuurstof	 limitatie	bleek	een	 reversibel	 effect	 te	hebben	op	de	
expressie van alle genen en beïnvloedde de expressie van de virulentie genen aan het einde 
van	de	kweek	niet.	Door	 tijdens	een	groot	aantal	 tijdspunten	 tijdens	het	kweekproces	de	
productkwaliteitsscore	 te	 bepalen	 kon	 het	 optimale	 oogstmoment	 worden	 bepaald.	 Dit	
optimale	oogstmoment	bleek	sterk	afhankelijk	van	de	concentraties	van	de	nutrienten	lactaat	
en	glutamaat	aan	het	einde	van	het	kweekproces.	
De	 DNA	 microarrays	 zijn	 een	 bewerkelijke	 off	 line	 analyse	 en	 kunnen	 daarom	 niet	
gebruikt	worden	 als	 PAT	 tool	 voor	 online	metingen	 aan	 het	 proces.	Echter,	 er	 zijn	 geen	
sensoren	beschikbaar	 die	 tijdens	het	 proces	metingen	kunnen	doen	 aan	de	 samenstelling	
van	 de	 buitenmembraan.	Om	dit	 probleem	op	 te	 lossen	 is	 on	 line	 nabij	 infrarood	 (NIR)	
spectroscopie	toegepast.	Deze	sensor	kan	op	twee	manieren	worden	gebruikt.	Enerzijds	om	
een	zogenaamde	vingerafdruk	van	het	gehele	proces	te	maken	door	de	variatie	tussen	spectra,	
genomen	gedurende	de	gehele	batch,	te	bepalen.	Hiermee	kunnen	verschillende	batches	met	
elkaar worden vergeleken. Anderzijds door specifieke kritische procesparameters te meten, 
die	voorheen	alleen	off	line	beschikbaar	waren,		zoals	nutriënt	concentraties	of	de	optische	
dichtheid	van	de	cultuur.	
Uiteindelijk werd een experiment ontworpen volgens de DoE methode waarbij de 
process design space	voor	de	kweek	van	Bordetella pertussis	 in	kaart	werd	gebracht.	De	
verschillende	kritische	procesparameters	werden	over	een	bepaald	bereik	getest	waarbinnen	
goede	productkwaliteit	kon	worden	verwacht.	In	een	DoE	ontwerp	worden	alle	parameters	
tegelijkertijd	gevarieerd	waardoor	de	interactie	tussen	de	parameters	ook	zichtbaar	wordt.	
De	 productkwaliteit	 werd	 aan	 het	 eind	 van	 elke	 cultivatie	 bepaald	 met	 de	 microarray	
analyse.	Alle	procesgegevens	van	deze	kweken,	inclusief	de	NIR	metingen,	werden	in	een	
centrale	databank	opgeslagen.	Vervolgens	werden	deze	gegevens	gebruikt	om	een	statistisch	
model	te	construeren	dat	het	verkende	bereik	van	alle	kritische	procesparameters	omvat.	Dit	
model	beschrijft	de	process design space.	Het	model	kan	gebruikt	worden	tijdens	nieuwe	
kweekprocessen	 om	 te	 controleren	 of	 het	 proces	 binnen	 de	 design space	 valt	 en	 of	 de	
bacteriën	dus	de	gewenste	samenstelling	van	de	buitenmembraan	hebben.	Hiermee	is	voor	
een complex biologisch proces voor vaccinproductie aangetoond hoe kwaliteitsbewaking 
onderdeel	van	het	proces	zelf	kan	worden	en	dat	dus	kan	worden	voldaan	aan	de	principes	
van	PAT.
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Het	laatste	en	veelal	meestgelezen	hoofdstuk	van	een	proefschrift	is	natuurlijk	opgedragen	aan	
alle	mensen	die	dank	zijn	verschuldigd	voor	hun	hulp,	steun,	kritiek,	humor,	relativering	of	
onvoorwaardelijke	liefde.	Het	zijn	deze	mensen	die	dit	boekje	mogelijk	hebben	gemaakt.
Allereerst	 mijn	 (co)promotoren.	 Hans,	 dank	 voor	 je	 immer	 terechte	 commentaar,	 je	
complimenten	 en	 bemoedigende	 woorden.	 Het	 is	 een	 eer	 en	 genoegen	 om	 jouw	 laatste	
promovendus	te	zijn	in	een	lange	reeks	die	bij	RIVM/NVI	en	Proceskunde	zijn	gepromoveerd.	
Dirk, dank voor je onaflatende en altijd constructieve kritiek. Waar ik dacht dat het wel goed 
genoeg	was,	vond	 jij	 altijd	punten	waar	verbetering	mogelijk	was.	Met	name	 tijdens	het	
schrijven	van	het	laatste	hoofdstuk	wisselden	we	dagelijks	nieuwe	versies	uit,	waarvan	elke	
steeds	beter	dan	de	vorige	was.	Leo,	dank	voor	de	ruimte	en	vrijheid	die	je	me	in	de	laatste	
fase	van	mijn	promotie	hebt	gegeven.	Nooit	heb	je	bezwaar	gemaakt	tegen	de	uren	die	in	dit	
proefschrift	zitten,	ook	nadat	het	PaRel	project	was	afgelopen.	Je	bent	een	“PAT	believer”	
geworden	en	verschillende	elementen	uit	dit	proefschrift	zijn	al	geïntegreerd	in	de	manier	
van	werken	binnen	PO.	Tenslotte	Coen,	geestelijk	vader	van	het	PaRel	project	en	een	echte	
mentor	tijdens	de	promotie.	Na	de	hectiek	van	het	eerste	jaar,	heeft	het	PaRel	project	bij	alle	
partners	 tot	geweldige	 resultaten	geleid.	 Jouw	visie,	enthousiastme	en	onvoorwaardelijke	
steun	zijn	een	heel	belangrijke	motivatie	voor	mij	geweest.	Het	is	geweldig	om	iemand	te	
hebben die in je gelooft. We zullen elkaar in de toekomst zeker nog vaak ’s avonds bellen. 
Dan	mijn	twee	paranimfen	Bas	en	Paul:	de	ruggegraat	van	het	PaRel	team.	Ik	neem	mijn	
hoed	af	en	buig	diep	voor	jullie	inzet	tijdens	het	project.	Paul,	jij	was	er	vanaf	het	begin	bij.	
De	discussies	met	Siemens	over	de	samenhang	met	het	BIOCS	project	en	het	 incasseren	
van	vertraging	op	vertraging	staan	mij	nog	helder	voor	de	geest.	Je	bent	tegen	wil	en	dank	
expert	 in	 PCS7	 geworden	 en	 altijd	 bereid	 om	 het	 gecrashte	 systeem	weer	 op	 te	 lappen.	
’s Nachts aanenten was ook nooit een probleem, zelfs toen je daarvoor op de fiets uit Vianen 
moest komen met een lekke band op de koop toe. We zijn samen opgegroeid met het PAT 
gedachtengoed	en	ik	ken	niemand	die	de	technische	consequenties	van	het	ontwerpen	van	
een	PAT	applicatie	beter	overziet	dan	jij.	Bas,	ik	zie	je	nog	zitten	tijdens	je	sollicitatie	gesprek,	
waarbij met Gino een discussie loskwam over je onderkomen in Carol’s Paradise. Je bent 
een	zeldzame	combinatie	van	gezelligheid	en	gedrevenheid	en	zonder	jouw	bijdrage	met	de	
microarrays	had	hier	slechts	een	heel	mager	proefschrift	gelegen.	Het	is	voor	mij	nog	steeds	
verbazingwekkend om te zien hoe jij van een onwaarschijnlijke chaoot in een ongelooflijke 
perfectionist verandert als het op experimenteren aankomt. Ik kan je alleen zeggen dat zo’n 
promotie	een	hell	of	a	job	is,	maar	ik	weet	zeker	dat	jij	het	ook	kan.	Ga	ervoor	de	komende	
jaren	en	ik	zal	je	helpen	waar	ik	kan.	Noblesse	oblige.
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Dan	waren	er	nog	mijn	studenten	die	veel	werk	voor	me	hebben	verzet.	Paloma,	jij	was	de	
eerste	en	dat	was	voor	mij	wel	een	vuurdoop	vanwege	je	geweldige	temperament.	Hester,	
jij	bewees	dat	vrouwen	gewoon	beter	in	het	lab	zijn	dan	mannen.	Bedankt	voor	het	leggen	
van	de	basis	voor	mijn	proefschrift	in	hoofdstuk	2.	Joeri,	jij	was	met	afstand	de	gezelligste	
student, maar dat ging zeker niet ten koste van je inzet. We zullen zeker nog afspreken voor 
een	biertje.	Ruud	“de	Roller”,	met	afstand	de	meest	onzichtbare	student,	bedankt	voor	 je	
werk	aan	de	kweek	pH.	Jun,	thanks	for	giving	me	insight	in	the	Chinese	culture	and	for	your	
wonderfully warm personality. Don’t become too attached to Holland, else you cannot “Go 
back	China”	anymore.	Good	luck	with	your	thesis.	
Verder	zijn	er	mensen	die	hun	heil	elders	zoeken.	Gino,	dank	voor	je	enhousiasme	en	gevoel	
voor	humor.	Je	haast	Spartaanse	huishouden	in	Bilthoven	heeft	plaatsgemaakt	voor	warm	
familieleven.	Ik	weet	binnenkort	hoe	goed	dit	bevalt.	Heel	veel	succes	in	het	Gentse.	Zita,	ik	
hoop	dat	je	herstel	blijvend	is	en	wens	je	alle	goeds	toe	in	Portugal.	Onze	samenwerking	was	
soms	stroef,	maar	van	wrijving	komt	glans.	Jij,	en	ik	wil	hier	Ton	ook	zeker	niet	vergeten,	
hebt	een	geweldige	bijdrage	aan	het	project	geleverd.	Jeroen,	je	was	ook	altijd	een	gezellige	
collega	op	het	 lab.	Marcel,	eerst	als	collega,	 later	als	afdelingshoofd,	maar	met	name	als	
de	 ontwikkelaar	 van	 het	THIJS	medium,	waar	 al	 het	 kweekwerk	 in	 dit	 proefschrift	mee	
is	 uitgevoerd.	En	natuurlijk	 Jan…	Je	kon	gelukkig	niet	 lang	ontkennen	dat	 het	NVI	 een	
heerlijke	plek	is	om	je	kweekjes	te	draaien.	En	voor	bakkie	doen!
Ook	alle	andere	mensen	van	de	unit	O&O	van	het	NVI	en	dan	speciaal	de	afdeling	(L)PO,	
wil	 ik	 hierbij	 bedanken.	Met	 name	Gideon	 voor	 zijn	 steun	 voor	 het	 PaRel	 project	 in	 de	
beginfase,	Bert	voor	het	analyseren	van	al	mijn	saaie	samples	en	Claire	voor	je	aanstekelijke	
enthousiastme; fijn dat je in mijn commissie wilde plaatsnemen. Karin, dank voor je hulp en 
advies bij de “papieren” kant van het PaRel project. En natuurlijk Wilma voor de geweldige 
layout	van	dit	boekje.	Jij	hebt	me	echt	uren	frustratie	en	computerleed	bespaard	en	het	is	
dankzij jou een prachtig proefschrift geworden. Alle andere collega’s ontzettend bedankt 
voor de goede sfeer en de vele gezellige momenten in het lab of de koffiekamer. 
Buiten	O&O	wil	ik	met	name	Marvin	en	Gerhan	bedanken	voor	de	samenwerking	in	het	
begin	van	het	project.	De	vergaderingen	bij	Applikon	en	Siemens	staan	mij	nog	levendig	voor	
de	geest.	Deze	bedrijven	bleken	geweldige	projectpartners	en	de	samenwerking	als	geheel	is	
met	de	nodige	ups	en	downs	al	met	al	toch	altijd	zeer	prettig	geweest.	Arthur,	ik	herinner	me	
de	avondsessie	bij	Applikon	nog	goed	waarbij	we	de	subsidieaanvraag	hebben	afgemaakt	
en	uiteindelijk	al	de	hele	basis	voor	het	PaRel	project	hebben	gelegd.	Jaap,	bedankt	voor	de	
samenwerking,	met	name	tijdens	de	vele	stuurgroep	vergaderingen	waarbij	we	steevast	over	
de	uitputting	van	de	subsidie	moesten	steggelen.		Ingrid,	je	bent	tijdens	dit	project	uitgegroeid	
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tot	een	ware	PAT	discipel	en	je	bent	in	staat	de	evidente	voordelen	op	een	geweldige	manier	
uit	te	dragen.	Ik	zal	de	manier	waarop	je	het	abstracte	PAT	principe	kan	overbrengen	nooit	
vergeten.	Veel	succes	in	je	nieuwe	job.	Leo,	een	verkoper	zal	ik	nooit	worden,	maar	ik	heb	
wel	geleerd	van	de	manier	waarop	jij	tegen	zaken	aankijkt.	Elsa	en	Alexander,	bedankt	voor	
het	uiteindelijk	afmaken	van	de	BIOCS	software	library	waardoor	wij	verder	konden	met	
onze	experimenten.	Hans	voor	de	goede	samenwerking	en	je	geweldig	nuchtere	en	zakelijke	
manier	van	redeneren,	ik	vond	het	ook	erg	leuk	je	in	Beijing	te	treffen;	veel	plezier	en	succes	
in	China.	Erik	als	geweldige	opvolger	van	Hans.	Nog	bedankt	dat	je	me	op	sleeptouw	hebt	
genomen	 tijdens	 de	 IFPAC.	 Jan	 voor	 de	 ondersteuning	 van	 bij	 het	 debuggen	 van	 PCS7	
en Kjell idem voor SIPAT. Geniet van je prachtige dochter. En verder alle andere mensen 
bij	Siemens	en	Applikon	die	ik	ben	vergeten,	maar	die	er	wel	voor	gezorgd	hebben	dat	de	
experimenten	uit	de	laatse	hoofdstukken	van	dit	proefschrift	konden	worden	uitgevoerd.	
En dan was er nog mijn tweede werkplek, de vakgroep proceskunde in Wageningen. Ik was 
er	bijna	nooit,	maar	ik	vond	het	altijd	leuk	om	er	te	zijn.	Met	name	als	er	iets	te	vieren	viel	of	
als	er	een	reisje	in	het	verschiet	lag,	was	ik	er	graag	bij.	De	eerste	echte	kennismaking	was	
de	brainstormsessie	eind	2005,	waarbij	Hedy	actief	beleid	voerde	om	het	alcoholgebruik	op	
te	voeren.	Franske	werkte	ook	goed	mee.	Joost,	ik	heb	jou	daar	als	partner	in	crime	ontmoet	
en	 onze	 sterke	 voorliefde	 voor	 nog	 een	 laatste	 biertje	 heeft	 onze	 reputatie	 bestendigd	 in	
Kopenhagen. Lades was duidelijk the place to be, alhoewel niet iedereen dat met ons eens 
was. Packo, Marieke, Koen, Eduard, Dorinde, Annette, Floor en vele anderen heb ik leren 
kennen	op	die	reis.	In	Japan	werd	de	afwezigheid	van	Joost	ruimschoots	gecompenseerd,	
door Klaske, Sina, Maria en eenmalig René,  thanks for the wonderful evenings in Japanese 
restaurants bars and disco’s. Oh, en de presentaties waren natuurlijk ook zeer leerzaam. 
Verder	wil	ik	ook	alle	andere	mensen	van	de	vakgroep	bedanken	voor	de	geweldige	sfeer	die	
ik	mocht	proeven	tijdens	de	gelegenheden	dat	ik	met	jullie	mee	mocht.	
Aan	het	begin	van	mijn	promotie	had	ik	nog	wel	eens	wat	vrije	tijd	en	die	breng	ik	graag	door	
met	mijn	vrienden.	Mijn	oude	studiegenoten	waarmee	naar	hartelust	verhalen	van	“vroeger”	
kunnen worden opgehaald gaven altijd weer nieuwe energie. Thijs, Werner, Valesca, Erik, 
Marieke,	Joke,	ik	heb	jullie	leren	kennen	in	de	mooiste	tijd	van	mijn	leven,	en	dat	krijg	ik	bij	
jullie	altijd	weer	een	beetje	terug.	Ook	alle	anderen	die	ik	bij	gelegenheid	nog	wel	eens	tref	
met	een	biertje	in	de	hand,	bedankt	voor	alle	gezelligheid.	
“Vroeger”	gaat	eigenlijk	ook	al	op	voor	mijn	lieve	vrienden	uit	Ridderkerk.	Raymond,	Bas,	
Marjolein,	Femke,	Matthijs,	Jolanda,	Martijn,	Sietske,	Jan	en	An,	onze	vakanties	in	mei	zijn	
elk	jaar	weer	geweldig	en	geven	het	gevoel	een	maand	weg	te	zijn	geweest.	Als	er	iets	is	dat	
we	samen	goed	kunnen	dan	is	het	wel	lachen.	Het	is	altijd	een	feest	om	bij	jullie	te	zijn.	
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Wim en Sjanie, dank voor jullie belangstelling en bemoedigende woorden. Jullie zijn 
geweldige	schoonouders	en	sinds	kort	ook	opa	en	oma.	Geniet	van	deze	bijzondere	tijden.
Pap	en	mam,	met	dit	boekje	haal	 ik	mijn	 laatste	schooldiploma.	Al	zou	 ik	verder	willen,	
het	kan	niet	meer;	dit	 is	het	hoogst	haalbare.	Dankzij	 jullie	steun	kon	ik	de	eerste	doctor	
in	de	familie	worden.	Jullie	hebben,	soms	terecht,	soms	niet,	weleens	getwijfeld	aan	mijn	
inzet, met name op het VWO en de studie in Leiden, maar nooit aan mij; jullie wisten dat ik 
het	kon.	Dank	jullie	wel	voor	alles;	alle	zorgen	en	alle	keren	dat	jullie	trots	waren.	Ik	weet	
zeker dat jullie een fantastische opa en oma voor Bouke worden. We gaan een geweldige 
tijd	tegemoet!
En	dan	als	laatste,	maar	nooit	als	minste,	mijn	lieve	Mariska.	Teerbeminde.	Een	brok	in	de	
keel,	zelfs	tijdens	het	typen,	als	ik	denk	aan	wat	jij	voor	mij	betekent.	Je	bent	er	altijd	als	het	
slecht	met	me	gaat.	Je	danst	met	me	mee	als	het	goed	met	me	gaat.	Love	is	you.	Love	is	me.	
Love	is	knowing	we	can	be.	Moeder	van	mijn	zoon.	Liefde	van	mijn	leven.	Ik	hou	van	je.	
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